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ABSTRACT
A NOVEL NEEDLELESS LIQUID JET INJECTION DEVICE METHODOLOGY FOR IMPROVING
CARDIAC GENE THERAPY: AN INVESTIGATION OF DELIVERY PARAMETERS AND THEIR
ASSOCIATED HOST RESPONSES IN ISCHEMIC HEART FAILURE
Anthony S. Fargnoli
Charles R. Bridges

Heart disease remains the leading cause of mortality and morbidity worldwide,
with 22 million new patients diagnosed annually. Essentially, all present therapies have
significant cost burden to the healthcare system, yet fail to increase survival rates. The
heart transplant, which is the gold standard for patients suffering from disease, will never
meet clinical demand due to the shortage of viable donors. Therefore, the investigation
of novel treatments is a significant unmet need in the health system with vast
opportunity. Since the decoding of the human genome, the rapid expansion of the
biotechnology field has ushered in new tools for therapeutic development. These new
therapies can be tailored to act at the cellular level to address the root cause of disease
progression or in other cases replace/repair those affected by disease.
One key employed strategy is the genetic reprogramming of cells to increase
contractility via gene therapy, which has advanced to Phase IIb Clinical Trials for
advanced heart failure patients. It has been argued that the most significant barrier
preventing FDA approval are resolving problems with safe, efficient myocardial delivery,
whereby direct injection in the infarct and remote tissue areas is not clinically feasible.
Briefly, widely accepted intracoronary (IC) infusion via catheterization is limited by poor
transfer across intact endothelial barriers, while direct needle injection is essentially a
dead end approach due to injury, inefficient transfer, and high incidence of the immune
response. Here, we aim to: (1) Improve direct cardiac gene delivery through the
v

development of a novel liquid jet device approach (2) Compare the new method against
traditional IM injection with two different vector constructions and evaluate outcome (3)
Evaluate the host response resulting from both modes of direct cardiac injection, then
advance a drug/gene combination with controlled release nanoparticle formulations.
We plan to execute as follows. Briefly, animals will be assigned to one of the 6
resultant groups: 2 delivery methods x 2 AAV vector constructs = 4 treatment groups +2
Saline delivery control groups. Then each animal will be assessed for quantitative gene
transfer, cardiac function and various immunohistochemistry assays to assess
inflammation and adaptive immune responses. Separately, a forward thinking drug/gene
therapy concept will be advanced with controlled release polymer formulations.
The work presented in this dissertation represents the advancement in the field
of cardiac gene delivery techniques toward improving outcomes in future pre-clinical and
clinical studies. The evaluation of synergistic relationships between route selection,
vector configuration and their respective impact on the host response will improve
delivery science.
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CHAPTER 1
Introduction: Heart Disease and Emerging Gene Therapy Applications
th

Adapted From: Gene and Cell Therapy 4 Edition, Taylor and Francis Publishing Group, Chapter
8: Katz MG, Fargnoli AS, Williams RD, Bridges CR “Cell and Gene Therapies for Cardiovascular
Disease”.

1.1 Heart Disease Burden and Treatment Options
An estimated 83.6 million American adults suffer from numerous cardiovascular
diseases (CVD). Mortality data show that CVD accounted for 31.9% of all deaths in
2010, or 1 in every 3 deaths in the United States. That is 4.4 times more than the deaths
attributable to cancer. The total direct and indirect cost of CVD in the USA for 2010 is
estimated to be $315.4 billion. By comparison, the estimated cost of all cancers and
benign neoplasms was $201.5 billion [1]. These data clearly show that cardiovascular
diseases are still the leading cause of mortality and morbidity in the US and developed
countries. In the United States, coronary artery disease is the underlying cause of CVD
in 65-75% of cases [2]. Following the initial myocardial insult after a period of time, the
unfortunate fate for the majority of chronic heart disease patients is full blown heart
failure despite significant accumulated, yet ineffective clinical interventions. Heart failure
(HF) imposes a significant burden on the global healthcare system with annual costs
alone exceeding $32 billion. The incidence and death rate is appalling, with 22 million
additional patients diagnosed per year with 50% mortality within 5 years. In many of
these patients, HF develops as a consequence of post infarction remodeling and
associated progressive dilatation extending to remote areas distant from the original
infarct [2].
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Although cardiac transplantation is the gold standard for the treatment of endstage heart disease, up to 30% of patients unfortunately die waiting for a matched donor
heart. Even more disturbing, as many as 60,000 patients per year could benefit from
such therapy [3,4]. The most frequently used technology at present for these patients is
mechanical pump-based assist devices, which have been quite useful both as a bridge
to transplantation [5,6], and as destination therapy using both left ventricular assist
devices (LVAD) [7,8] and the total artificial heart [9]. Despite significant improvements
mitigating some of the limitations of LVAD, most notably thromboembolic events, it
appears that mechanical cardiac assist technology will face increasing scrutiny given its
cost to benefit ratio. Thus, given the shortcomings of the best available therapies, there
is a significant unmet need for newer, more efficacious and more cost-effective therapies
for severely afflicted patients.
There are two major emerging alternative treatment paradigms to improve long
term outcomes in both early and late stage heart disease, namely replacement (i.e. cell
therapy) or genetic reprogramming of native cells with gene treatments. The focus in
late stage management is improving contractility, whereby the opportunity to arrest
infarct expansion and global LV remodeling has past. Therefore, the transfer of
therapeutic genes for the treatment has emerged as the more attractive strategy given
its impact on directly enhancing contractility within the myocytes. Extensive pre-clinical
studies have provided solid proof of concept data indicating gene therapy’s clinical
potential, whereby the expression of selected transgenes in the myocardium enhances
contractility, restores global function, and in some cases completely reverses chronic
HF. Although promising, as this body of research will explore, a number of problems
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must be addressed in order to achieve more successful outcomes and avoid the
deleterious events the field has experienced in the early 2000’s.

1.2 Cardiac Gene Therapy Applications Strategies
Currently, there are primarily two strategies described for cardiovascular gene
therapy manipulation (Figure 1.1).

Figure 1.1 Cardiac Gene Manipulation Strategies
The most commonly applied strategy features overexpression of a target gene,
which may involve either replacement of a missing or dysfunctional gene as in X-linked
recessive disorders such as the heart failure associated with or Becker’s
cardiomyopathy, an autosomal recessive gene defect such as those associated with
alpha sarcoglycan deficiency in the limb girdle muscular dystrophies. More commonly,
heart failure may not have a defined genetic basis (ischemic cardiomyopathy) yet certain
genes are consistently downregulated (e.g., SERCA2a). The second group of strategies
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relates to inactivation of dominant negative gene function involved in disease etiology or
progression (other names: gene silencing or gene blockade) [10,11,12].
1.2.1 Overexpression of target gene
A gene’s physiological function y may be impaired or downregulated as a result
of a mutation or a pathological process. Therefore, the restoration of function through
exogenous delivery to replace the deficient gene seems quite logical. In this case, fulllength or partial cDNA encoding the deficient gene is delivered to the target tissues
using a vector system capable of expressing the therapeutic protein [10]. Several steps
in the gene overexpression process may be modulated, including the transcription, RNA
splicing, translation, and posttranslational modification of a protein.
1.2.2 Specific gene blockade
1.2.2A Antisense oligodeoxynucleotides (ODN)
ODN are used as inhibitors of specific gene expression without any change in
function of other genes. Single stranded ODN may be delivered either by direct
administration (as a pharmacological agent) or by transfection with a vector encoding the
ODN. The ODN binds to the target mRNA transcript and prevents translation. This
mechanism of action is based on the presence of two forms of ODN: the RNase Hdependent ODN, which induce the degradation of mRNA, and the steric-blocker ODH,
which physically blocks the progression of mRNA translation. Concerning cardiac
applications, the antisense ODH approach has been tested to prevent restenosis after
balloon angioplasty [13]. Treatment with antisense ODN directed against VEGF
receptors could prevent VEGF-mediated arteriogenesis [14]. Systemic delivery of an
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antisense ODN induces silencing of miR-208a in the myocytes, thus improving cardiac
function and survival in hypertensive-induced heart failure (HF) in rats [15].
1.2.2B Decoy-based gene therapy
Synthetic double-stranded (ds) DNA with high affinity may be introduced into
target cells as a “decoy” or alternatively described as a cis-regulatory element, which
binds to a sequence-specific DNA factor and changes gene transcription. Transfection of
dsODN will result in the attenuation of the cis-trans interaction of cell surface receptors,
and remove the trans-factor from the endogenous cis-element resulting in inhibition of
gene expression [12]. dsODN containing binding sequences (decoy) for transcriptional
factors involved in the activation of pathogenic genes. Transfection of the decoy ODN
prevents the binding and trans-activation of the genes regulated by the target
transcriptional factor [10].
The decoy strategy is very attractive for several reasons: the synthesis of the
sequence specific decoy is relatively simple and can be targeted to specific tissues, the
knowledge of the exact molecular structure of the target transcription factor is
unnecessary; it has been shown to be more effective than antisense technology [12].
Some restrictions of this method however are: short half-life, lower uptake efficiency and
degradation by endocytosis and nucleases. Using mice and monkey models it was found
that E2F decoy transfection prevented intimal hyperplasia in cardiac allografts [16]. In a
report of Yamasaki et al, the successful in vivo transfer of NFkappaB decoy ODN to
inhibit vascular stenosis in balloon-injured porcine coronary arteries was demonstrated
[17].
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1.2.2C Short interfering RNA (siRNA)
Gene silencing via siRNA technology is a novel strategy with great therapeutic
potential. siRNA is a short dsRNA molecule that induces sequence specific
posttranscriptional gene modification. This mechanism is called RNA interference
(RNAi). Recently, this strategy was used for the treatment of HF and the results showed
that the restoration of cardiac function was most likely through the reduction of
hypertrophy [18]. Once transfected into a cell, the siRNA incorporates into the nuclease
complex, where they then interrupt translation of targeted genes. Successful left
ventricular intracavitary delivery of DNA/siRNA complexes by means of sonoporation
was demonstrated in murine hearts [19]. The incorporation of siRNA into terminally
differentiated adult rat cardiac myocytes using adenovirus has also been reported [20].
1.2.2D Ribozymes
Another strategy used to inhibit the disease process at the transcriptional level is
the use of ribozymes. Ribozyme gene therapy aims to turn off a mutated gene in a cell
by targeting the mRNA transcripts copied from the gene. Therefore, protein synthesis by
the target RNA may be specifically inhibited by ribozymes. This process involves three
steps: (1) Delivery of RNA strands engineered to function as ribozymes (2) Specific
binding of the ribozyme RNA to mRNA encoded by the mutated gene and (3) Cleavage
of the target mRNA, preventing it from being translated into a protein. Several studies
have used ribozymes to limit neointimal hyperplasia with smooth muscle cell proliferation
in response to balloon angioplasty. Ribozymes against c-myb mRNA [21] and
transforming growth factor [22] prevented development of restenosis.
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1.3 Heart Failure Gene Targets
Gene therapy targets generally aim to: increase contractility, attenuate adverse
remodeling and inhibit apoptosis. A schematic demonstrating the therapeutic aim and
their associated specific targets is presented in (Figure 1.2).

Figure 1.2 Cardiac Gene Therapy Targets for Heart Failure
1.3.1 The calcium cycling proteins
Ca2+cycling has been found to be critically dysregulated in chronic HF and,
provides an important role in excitation-contraction coupling. Depicted in (Figure 1.3) is
the excitation contraction complex in the myocyte including all elements.
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Figure 1.3 Calcium Handling Targets in Myocardium
To understand the Ca2+ handling defects in heart failure, we need to briefly
describe the processes occurring in cardiac excitation–contraction coupling. During the
cardiac action potential, Ca2+ enters the cell through depolarization-activated Ca2+
channels as an inward Ca2+ current, which contributes to the action potential plateau.
Ca2+ entry triggers Ca2+ release from the sarcoplasmic reticulum (SR). This allows Ca2+
to bind to the myofilament protein troponin C, which then switches on the contractile
process. For relaxation to occur there is a decline in intracellular Ca2+ concentration,
allowing Ca2+ to dissociate from troponin. This requires Ca2+ transport out of the cytosol
by pathways involving SR Ca2+ -ATPase, sarcolemmal Na+ / Ca2+ exchange,
sarcolemmal Ca2+ -ATPase or mitochondrial Ca2+.
1.3.1A SERCA2a
Deficient SR Ca2+ uptake during myocyte relaxation has been identified in failing
hearts from both humans and animals, and is associated with a decrease in the
expression and activity of sarcoplasmic reticulum calcium ATPase (SERCA2a). This
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protein is a Ca2+-ATP-dependent pump of the sarcoplasmic reticulum that has a critical
role in Ca2+ regulation, known as SERCA2a. The overexpression of SERCA2a has been
demonstrated to increase contractility and normalize calcium cycling in failing human
cardiomyocytes [23]. A number of animal studies with a variety of models of HF has
demonstrated that overexpression of SERCA2a has a positive inotropic effect, improves
oxygen utilization, attenuates the progression of HF and prolongs survival. SERCA2a
gene transfer was found to substantially decrease incidence of ventricular arrhythmias
and reduce infarct size in a model of ischemia/reperfusion [24]. A lentiviral vectormediated SERCA2a intracoronary delivery after myocardial infarction in rats resulted in
favorable molecular remodeling with improving systolic and diastolic function six months
later [34]. An improvement in left ventricular diameter, fractional shortening, and Ejection
Fraction was also demonstrated in a tachycardia-induced HF model [25].
A first-in-human clinical trial Calcium upregulation by percutaneous
administration of gene therapy in cardiac disease’ (CUPID) involving gene transfer of
SERCA2a cDNA via a rAAV1 vector in patients with advanced HF has been undertaken
in a randomized, double-blind, placebo-controlled study; although the results were
somewhat difficult to interpret due to the absence of a clear dose-response. At 12
months, SERCA2a treated patients in the highest dose cohort demonstrated a
consistent trend in clinical symptomatic improvement and in functional capacity [26].
1.3.1B S100A1
In cardiomyocytes, S100A1 plays an important role in increasing SERCA2a
activity. This effect is achieved through diminishing diastolic SR Ca2+ leak, augmenting
the systolic open probability of the ryanodine receptors, leading to an overall gain in SR
Ca2+ cycling. Also, S100A1 regulates SERCA2A-Phospholamban function, resulting in a
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balanced enhancement of SR Ca2+ release and uptake. S100A1 is downregulated
during the development of HF [27]. Thus, in theory, S100A1 may be a promising factor in
the treatment of HF. In a rat model of HF, significant cardiac recovery was demonstrated
after 8 weeks in AAV6/S100A1 treated animals [28]. A study in a postinfarction pig
model after 14 weeks revealed improvement in dP/dt and ejection fraction, and also
restoration of high-energy phosphate homeostasis in failing myocardium [29].
1.3.1C Phospholamban (PLN)
PLN regulates the homeostasis of SR Ca2+ mediating slower cytosolic Ca2+
decay in cardiomyocytes, which translates into diastolic relaxation. Phosphorylation of
PLN suppresses its inhibitory effect. AAV-mediated overexpression of a mutant
(“pseudophosphorylated”) form of PLN improved LV function and mitigated adverse
remodeling in post-MI rats [30]. Silencing of PLN expression after tachycardia-induced
HF in sheep increased ejection fraction and decreased LV end-diastolic area [107].A
study in a volume-overload HF proved that adenovirus encoding antisense PLN
preserved LV contractility and normalized LV mechanoenergetics [31].
1.3.2 The β-adrenergic signaling cascade
The β-adrenergic receptor (βAR) signaling system plays an important role in the
control of cardiac function, mediating the inotropic, chronotropic and lusitropic responses
to the sympathetic neurotransmitters [32,33]. Therefore it represents an attractive
molecular target to improve heart function. Two important components of the βAR
system include the β-receptors and the regulatory G protein-coupled receptor kinases
(GRKs). Dysregulation of the βAR pathway, including downregulation, uncoupling of
second-messenger systems, and upregulation of βAR kinase (βARK1, GRK2), has been
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shown to be a hallmark of HF. βARs are regulated by GRK2, a member of a G proteincoupled receptor kinase family that phosphorylates and inactivate these receptors [34].
βARKct, a competitive inhibitor of GRK2, has the potential to resolve βAR
downregulation and desensitization associated with HF [34,35]. Thus, inhibiting the
activity of GRK2 or lowering its expression appears to offer a novel means to enhance
cardiac function.
1.3.2A The βARKct Peptide
In a rabbit model of HF induced by myocardial infarction it was first demonstrated
that the βARKct transgene improved heart function and delayed development of HF [36].
Inhibition of myocardial βARK1 via Ad/βARKct delivery before creation of acute coronary
ischemia, may represent a new strategy for cardiac protection [37]. Long-term βARKct
expression in the rat is by reversed LV remodeling and a normalization of the
neurohumoral status of chronic HF animals [38]. The high level of βARKct expression in
pressure-overload heart hypertrophy can preserve adenyl cyclase activity and βAR
density and also improve cardiac function and cell morphology [39]. Based on the above
results and earlier results derived from transgenic animal models, it appears that delivery
of βARKct could be beneficial in the setting of IHD and HF.
1.3.3 Other Ischemic Heart disease targets
Current gene therapy research efforts in IHD include: stimulation of
angiogenesis; limitations of reperfusion injury through the use of antioxidant therapy and
endothelial nitric oxide synthase; and cardioprotection by using anti-apoptotic proteins
[40]. These are summarized in (Figure 1.4). Nevertheless much of the previous
research was devoted to the study of angiogenesis.
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Figure 1.4 Other Targets for Ischemic Heart Disease
One major focus of gene therapy for ischemic heart disease is
neovascularization of fibrous post-infarct or poorly-perfused (hibernating) myocardium.
Therapeutic angiogenesis can be achieved by gene transfer of vascular endothelial
growth factor (VEGF), hepatocyte growth factor, fibroblast growth factor, and hypoxiainduced factor 1α. VEGF has five isoforms which act on tyrosine kinase receptors, FLK1 and FT1. This protein factor has been shown to stimulate endothelial cell proliferation,
migration and vascular permeability and to affects fibroblast and smooth muscle growth
[40,41,42]. Preclinical gene therapy studies with VEGF in various large animal models of
myocardial ischemia have demonstrated stimulation of angiogenesis and improvement
in fractional shortening [43], reduction of infarct size and peri-infarct fibrosis [44]. In
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addition, it has been noted that there is an appearance of apoptosis-resistant
cardiomyocytes in the border zone [45] and improvement of myocardial viability [46].

1.4 Therapeutic Vectors
Choosing the right vector for cardiovascular applications is one of the most
challenging aspects. The availability of vectors for gene transfer has improved
significantly over time. The ideal vector would have the following characteristics: it
must be cardiotrophic, result in long-term expression, minimize the risk of cellular
immune response, have a large coding capacity and have high transduction efficiency
[41]. The main challenges to the vector are as follows: (i) Escaping the neutralizing
effects of specific antibodies and non-specific adsorption to other blood components (ii)
overcoming the endothelial barrier and penetrating the vascular wall for diffusion through
the extracellular matrix; and (iii) Uptake into the cell at the level of the plasma membrane
and efficient trafficking to the nucleus and (iv) synthesis by the host of the complimentary
DNA strand for single stranded delivery vectors followed by transcription and translation
of the transgene [47]. A number of different vectors have been used to achieve
myocardial gene transfer, modified or selected to enhance the probability of overcoming
each of these challenges. All vectors can be classified into two main categories, the nonviral and recombinant viral.
1.4.1 Non-viral vectors
Non-viral vectors are grouped as plasmid DNA, liposome-DNA complexes
(lipoplexes), and polymer-DNA complexes (polyplexes). Oligonucleotides are also
considered non-viral vectors [48]. In 1990, Lin and associates injected plasmid DNA into
the left ventricle and demonstrated that the lacZ gene could be introduced and
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expressed in cardiac myocytes [49]. Although non-viral vectors have the major
advantage of production in relatively large quantities at low cost while at the same time
possess fewer toxic or immunological problems, their transfer efficiency is generally poor
independent of delivery route [50,51]. Nevertheless, a large number of human cardiac
clinical trials are based on plasmid-mediated gene transfer investigating angiogenesis in
myocardial ischemia [52-54]. A major advantage of this approach is that it avoids many
of the biosafety concerns associated with viral vectors. However, the level of transgene
expression and the efficiency of gene transfer (percent of target cells expressing the
transgene) are low and expression is restricted to the zone of the injection site. DNA
complexes are relatively more efficient [55].
There is however a major discrepancy between the data obtained in vivo and in
vitro. In addition, these complexes are unstable and thus quickly removed by
phagocytes when delivered, especially through intravascular delivery systems. An
additional shortcoming of these vectors (e.g. oligonucleotides) is their short biological
half-life due to intracellular degradation and non-specific binding [56]. The
demonstration of plasmid gene transfer opened a new era of cardiovascular
pharmacotherapy. Despite numerous efforts to enhance efficiency through modification,
direct myocardial plasmid injection basically remains a proof of concept tool only [57].
1.4.2 Viral vectors
Successful cardiac gene therapy applications demand both efficient myocardial
transduction initially and long-term transgene expression. Many authors strongly believe
that only viral vectors appear to meet these demands in terms of performance [58,59].
Compared to non-viral vectors, viruses have an evolutionary advantage in their
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interactions with the cellular surface receptors, directly leading to more efficient
intracellular trafficking of packaged DNA to the nucleus. Furthermore, their protein
capsid protects the message from degradation in lysosomes [47,57,60,61]. Some viral
vectors are able to integrate into the host genome, whereas others remain episomal.
Integrating viruses result in persistent transgene expression while viruses in episomal
form lead to long term expression in predominantly non-dividing tissues (e.g., adult
myocardium) but only transient expression in rapidly dividing tissues (e.g., the
hematopoietic system). It should be noted that for some disorders, short -term
expression in a relatively small proportion of cells would be sufficient or even desirable
(e.g., angiogenesis post myocardial infarction) whereas other pathologies might require
long-term expression (e.g., autosomal recessive cardiomyopathy).
1.4.2A Lentiviruses
These vectors were initially developed for HIV therapy. Lentiviral vectors can
infect non-dividing cells, cause long-term expression and do not typically induce an
inflammatory or immune response. The major limitation is the risk for mutagenesis and
oncogenesis [58]. The new generation of lentiviruses, containing a mRNA and a nuclear
import sequence have been used for successful myocardial transduction, although
expression is usually short-term [62,63]. Fleury et al. in a study with rat cardiomyocytes
in vivo succeeded in obtaining persistent GFP transfer for up to 10 weeks [64]. In
another study the transduction efficiency of lentiviral vector-mediated SERCA2 gene
transfer was about 40% and the positive physiological effect persisted six months later
[65].
1.4.2B Adenoviruses
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Adenoviral vectors have historically been the most frequently used transfer
system in experimental and clinical studies. This is attributed to the vector’s known
advantages such as: the ability to transduce non-dividing cells, ease of manufacture in
very high titers, the possibility to achieve high levels of transgene expression and a large
transgene cloning capacity. However, their use is limited clinically due to transient gene
expression, and their inability to integrate the genome into the cellular chromosomal
DNA. In addition, adenoviral vector particles are highly immunogenic and cause
inflammatory and toxic reactions in the host. This is due to the fact that the adenovirus
stimulates both the innate and adaptive immune systems. Using a rat model, it was
confirmed that adenovirus was several orders of magnitude more efficient in transducing
myocytes than plasmid DNA expressing the same construct [66,67]. Later, it was shown
that the direct intramyocardial injection of replication-deficient adenovirus can program
gene expression in large animal in vivo. However, the authors noted a robust T cellmediated immune response against the vector and limited distribution of the reporter
gene [68].
Simultaneously, several groups confirmed the possibility to achieve significant
cardiac gene expression after catheter-mediated delivery of adenovirus encoding
phospholamban and the β2-adrenergic receptor [68,69]. Using adenovirus to deliver
selected transgenes, enhanced cardiac performance several weeks after gene transfer
has been demonstrated [70]. Despite sophisticated modifications in an attempt to
attenuate the host immune response to the adenovirus, the risk is too high to advocate
the use of this delivery vector for clinical cardiovascular applications.
1.4.2C Adeno-associated viruses

16

Adeno-associated virus (AAV) is a small (20 nm), non-enveloped virus that
belongs to the dependovirus genus of the parvovirus family. AAVs have a singlestranded DNA genome. The viral genome is approximately 4.7 kb in length, and is
composed of two major open-reading frames which encode Rep (replication) and Cap
(capsid) proteins [71]. For an infection to occur, AAV requires co-infection with a helper
virus such as adenovirus. This allows the viral genome to replicate episomally, and
leads to synthesis of the AAV proteins. AAV is one of the smallest viruses, with a capsid
mean diameter of 22 nm. The first AAV2 infectious clone was created in 1982 by
Samulski and colleagues [72]. Several years later, it was established that AAVs can
express foreign genes in mammalian cells [73]. One of the major advantages of AAV
vectors is that in multiple animal models and humans, it has been demonstrated that
after reaching a steady state level, AAV expression may last for years with an absence
of a significant immune response to the transgene [74]. Moreover, AAV vectors can be
engineered to provide a wide range of cell type tropism with the ability to transduce both
dividing and non-dividing cells. Due to their biological properties and advantages over
other viral vector systems, AAV has gained great popularity in the last decade in many
clinical trials. Seventy five clinical trials using AAV have been initiated over the past 15
years [60] with ~10% indicated for cardiovascular diseases [75].
The process of AAV endocytosis and intracellular trafficking is complex and
cannot be underscored in understanding problems with clinical outcomes. Despite the
availability and diversity of AAV vectors, several biological barriers appear to limit the
effectiveness of AAV mediated gene therapy [76,77]. Understanding the fundamental
basis of these barriers has led to the establishment of methods to improve the efficiency
of rAAV-mediated gene delivery [61,77]. Clarification of the processes by which a virus
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first enters and traffics through a cell helps to understand the life cycle of the virus and
its ability to act inside the cardiac muscle. The transport activity of AAV is mainly
determined by selective receptor-mediated vesicle transcytosis [78]. This intracellular
route does not appear to alter the properties of the AAV. The entry of AAV vectors into
the cell involves several steps illustrated in (Figure 1.5).

Figure 1.5 Viral Vector Mediated Gene Transfer

(1) Binding to the membrane receptor/co-receptor, or attachment factors; (2)
Endocytosis of the virus by the host cell occurs in distinct membrane compartments,
called clathrin-coated pits, which can be internalized to form clathrin-coated vesicles.
Clathrin-independent endocytosis involves the uptake in caveolae, membrane lipid rafts
and microdomains; (3) Following endocytosis the AAV vectors are compartmentalized
into early endosomes. This is the distribution station in the endocytic pathway; (4) Early
endosomes then mature into late endosomes that are degraded by fusion with the
lysosome later, secretory vesicles, and the material that will be recycled back to the
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plasma membrane; (5) Some separate viruses can escape lysosomal degradation via
acidification of the endosome and it is a necessary prerequisite for the release of the
AAV; (6) These AAVs particles are then trafficked into the nucleus, where viral
uncoating leads to single-stranded DNA release. The single stranded DNA is then
converted to double stranded DNA, and finally to concatamers and or integrated into the
host genome.
AAV transport can be blocked by neutralizing antibodies, temperature, and
physical and chemical inhibitors through a time and dose-dependent process. In vivo
studies have noted that several serotypes of AAV are able to cross vascular
endothelium with different efficiencies [79]. It is known that AAV2 has a relatively poor
tropism for vascular cells, although reasonable levels of transduction have been
achieved in cardiac myocytes [80]. Local delivery AAV2 led to transduction of underlying
vascular smooth muscle cells and sequestration of AAV in the extracellular matrix
around endothelial cells thus preventing cell binding and entry. The potential of AAV6
vector for cardiac gene therapy was achieved through the use of VEGF to increase
vascular permeability [81].

1.5 Conclusions
The growth in CVD gene therapy applications has been dramatic in recent times
given successes in other disorders. However, physicians and translational scientists still
must address key safety and efficacy problems associated with viral vector mediated
gene transfer. The adeno-associated virus platform to date offers the best means to
achieve safe and long term gene expression as indicated now with over 3 years of safety
data from the Phase I/IIb CUPID trials. Despite this promise, the level of interest in
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regenerative cell therapy applications will continue to grow unless the problems of
efficient delivery and avoidance of undesirable immune responses can be achieved.
Next generation viral and non-viral vector applications are being co-developed alongside
smart device based delivery systems to increase cardiac specificity and limit off target
effects. The remaining chapters of this body of work are dedicated to advancing cardiac
gene therapy through the development of a novel, cardiac specific delivery system. This
body of research essentially asserts that delivery strategy selection and execution drives
outcome with any given high risk/reward gene therapeutic.
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CHAPTER 2
Cardiac Gene Therapy Delivery Systems: Present and Future Applications
Adapted From: Katz MG, Swain JD, Tomasulo CE, Sumaroka M, Fargnoli AS, Bridges CR.
Current Strategies for Myocardial Gene Delivery. J Molecular Cell Cardiol. 2011 May: 50(5)76676.

2.1 Introduction
An important prerequisite for introducing cardiac gene therapy into clinical
practice is the development of simple and efficient gene delivery techniques. During the
last two decades, we have witnessed the development of several experimental gene
delivery strategies with potential therapeutic value for the transition from the preclinical
phase to clinical trials. Yet, efforts at gene transfer will require solutions to several
problems. These problems include delivery of the vector to the target tissue, improved
safety and efficacy, prevention of complications, creation of new delivery devices and
techniques, and improved geographical specificity of gene delivery to areas of
therapeutic interest while simultaneously minimizing systemic spillover.
Although cardiac tissue-specific promoters may mitigate collateral organ gene
expression, only a true cardiac specific gene delivery method can diminish the
biodistribution of vector capsids to extra cardiac organs. Extra cardiac exposure results
in unsafe levels of exposure to antigen presenting cells. Antigen presenting cells
provide another mechanism to increase the potential for a T-cell mediated immune
response to the vector capsid. Ideally, the most optimal gene-delivery system should be
combined with an appropriate vector. Recombinant AAV vectors have rapidly evolved
as tools for cardiac gene therapy. For numerous target diseases, they offer advantages
over other viral vector systems. Multiple AAV serotypes have been isolated in recent
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years. Among all AAV serotypes, AAV2 vectors have been successfully used in several
experimental approaches such as protection from ischemia/reperfusion injury, inotropic
therapy and beneficial effects on neoangiogenesis. Recent reports demonstrate that
serotypse 6 and 9 facilitate relatively stable cardiac gene expression and are superior to
others in the heart, likely due to enhanced cellular internalization and nuclear uncoating
in cardiomyocytes. Successful solutions to these and other challenges will undoubtedly
help to achieve transmural, homogeneous, high-density cardiac gene transfer [1, 2].
There are many published methods to transduce myocardium; yet, most of these
approaches have shown inefficient transduction and thus failed to demonstrate effective
therapy when applied to disease involving the whole heart [3]. Existing methods of gene
delivery can be classified by the site of injection, interventional approach and the
physiology of the cardiac circulation (Figure 2.1)

Figure 2.1 Diagram of Cardiac Gene Delivery Techniques by Route
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In this chapter, we describe both the most common and innovative gene delivery
methods and attempt to outline future developments in this dynamic field.

2.2 Direct Cardiac Gene Delivery
Direct gene delivery methods have been utilized for at least two decades and
some authors continue to reference and utilize them in their preclinical cardiac gene
therapy studies. Numerous methods have also successfully been translated for use in
clinical trials. The most relevant of them are usually classified as either an open
technique, that is to include the surgical opening of the chest or a closed technique, i.e.,
transcutaneous or minimally invasive. A minimally invasive application is desirable and
can also be achieved via a subdiaphragmatic or thoracoscopic approach. (Figure 2.2)
depicts the three major approaches and their results which are described in detail in the
following subsections.

Figure 2.2 Direct Myocardial Gene Delivery: Left, (A) Pericardial; Center, (B) Catheter
Based Endocardial; Right, (C) Intramyocardial Sites
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2.2.1 Intrapericardial Injection
The rationale underlying intrapericardial gene delivery is related to the advantage
of the anatomical connection between the pericardium and the myocardium, and the
accessibility of the pericardial sac for percutaneous vector delivery [4] (Figure 2.2A).
Zhang et al. made a percutaneous puncture of the pericardium at the left costoxiphoid
angle of the anterior chest with injection of Ad.CMV.lacZ. After three days, significant
lacZ expression was observed in the epicardium, myocardium, and endocardium of
neonatal mice. The authors concluded that intrapericardial injection is an efficient
technique to achieve transmural gene expression. Unfortunately, these results appear to
be age-specific and are far less efficient in adult (rather than neonatal) animals.
Furthermore, the group later found that at two months the expression only persisted in
atrial tissue and not in ventricles, the presumed target area to address the majority of
cardiomyopathic diseases. Additionally, this method was associated with high levels of
hepatic transduction [5].
Fromes et al. performed intrapericardial injections with a transdiaphragmatic
approach, using adenovirus encoding β-galactosidase in rats. The staining observed
was exclusively restricted to the pericardial cell layers; however, injecting a mixture of
proteolytic enzymes with the virus led to an increase of transgene expression to 40% of
the myocardium at day seven. As expected when using an adenoviral vector, the
expression decreased to 0.5 % at day 28. The authors also found positive βgalactosidase activity in distant organs [6]. March et al. used a hollow, helical-tipped
penetrating catheter for vector delivery in the canine myocardium. The catheter was
introduced percutaneously and advanced into the pericardial space through the apex of
the right ventricle. All of the animals tolerated the procedure without incident,
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demonstrating the feasibility of localized cardiac gene delivery via a catheter-based
pericardial approach [7]. The administration of Ad2.CMV.LacZ into the pericardial sac
produced extensive transfection of the visceral and parietal pericardium and doxycycline
pretreatment increased this effect [8].
2.2.2 Endocardial Injection
The feasibility of fluoroscopy-guided, percutaneous endocardial vector injection
was demonstrated by Gwon et al. in the porcine heart [9] (Figure 2.2B). Sanborn et al.
used the same approach with a coaxial catheter for endocardial delivery of adenovirus
encoding VEGF in the porcine myocardium. Regional VEGF expression was found to be
significantly greater in targeted zones as compared with non-targeted zones [10].
Several authors believe that the electromechanical mapping-guided approach allows for
better deployment of the tip of the catheter around areas of ischemia [11-13]. However,
this system and the equipment needed to execute the procedure are quite complex and
expensive.
In a porcine model, Grossman et al. compared endomyocardial and epicardial
microsphere injection, finding that endomyocardial injection performed with the Stiletto
system was associated with 43% microsphere retention, compared with 15% after
epicardial injection. Reduction of injectate volume (10 µL) resulted in significantly
improved retention compared to 100 µL injection, a typical volume used in clinical trials.
These authors also found evidence of significant viral transfection in the liver and spleen
after injection of adenovirus encoding β-galactosidase [14]. The study of Naimark et al.
highlights the importance of enhancing the biocompatibility of the catheter for
endocardial and epicardial gene delivery [15]. Despite the ease of implementation
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advantage of catheter-based endocardial and epicardial injection, there is an increased
potential for complications associated with ventricular perforation, cardiac tamponade,
endocardial thrombosis and intramyocardial hematoma, especially in patients with
chronic ischemia who have thinned and scarred myocardium [9].
While there has been demonstration of the feasibility of percutaneous
endocardial gene transfer and gene expression, many questions still exist regarding this
approach [10]. For instance, in patients with ischemic cardiomyopathy, should
vector/transgene administration be targeted to ischemic areas alone or to “border zone”
to stimulate collateral flow? What quantity represents the ideal dose and how many
injections are necessary, especially given that the patients have multiple areas of
ischemia?
2.2.3 Intramyocardial Injection
The majority of successful preclinical studies have involved direct administration
of vector. This technique allows for the application of a high concentration of vector
directly at the target site. Several groups have demonstrated the feasibility of delivering
transgenes to the heart via direct intramyocardial injection of plasmid DNA [16-19]
(Figure 2.2C). Although these studies have been encouraging because plasmid DNA
may be expressed for up to six months by cardiomyocytes adjacent to the area of
injection, estimates of the number of myocytes that can be transfected in vivo have been
as low as 60 to 100 cells per injection [16]. This low efficiency has made it difficult to
measure the physiological effects of gene expression in myocytes, making it unlikely that
clinically significant effects will result [20]. The low transduction efficiency of plasmid
DNA vectors leads to the search for improved gene transfer efficiency with direct
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injection of an adenovirus vector. Hearts transfected with an adenovirus vector
containing the β-galactosidase gene showed significantly increased β-galactosidase
enzymatic activity compared with hearts injected with β-galactosidase plasmid.
Unfortunately, the gene expression persisted for only one week after injection and it
included acute inflammatory response, which the authors considered to be related to the
injury produced by direct injection as well as a cellular immune response against the
adenovirus itself [20].
The studies of French et al. [21] demonstrated for the first time, in a porcine
model, a number of important points relevant to this technique: 1) direct intramyocardial
injection of replication-deficient adenovirus is 140,000 times more efficient than injection
of an equal number of genome copies of recombinant plasmid DNA and can program
recombinant gene expression in the cardiomyocytes of a large animal species; 2) the
impact of this procedure on cardiac function appears to be negligible; 3) the amount of
recombinant protein produced increases with the amount of virus; 4) the expression of
recombinant genes following intramyocardial injection is similar in the left and right
ventricles; 5) the percentage of cardiomyocytes expressing β-galactosidase in the
needle track adjacent to the injection, but rarely are lacZ positive cells detected farther
than 5 mm from the injection site [21].
In a canine study using adenovirus encoding chloramphenicol acetyl transferase,
peak gene expression was noted at two days and decreased by an order of magnitude
14 days after direct single myocardial administration. In this study, there was not
significant transduction of distant organs and no documented changes in global or
regional LV function [22]. However, the feasibility of adenovirus-mediated gene transfer
has been limited by the cellular immune response which causes myocardial
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inflammation and results in transient recombinant gene expression [23].
Svensson et al. showed that stable β-galactosidase expression can be achieved
without evidence of myocardial inflammation or myocyte necrosis after substituting rAAV
for adenovirus vector-mediated gene transfer [24]. Furthermore, in an landmark study,
Tomiyasu et al., succeeded in augmenting cardiac function in cardiomyopathic hamsters
with heart failure by transfecting cardiac muscle with the β2-AR gene after direct
intramuscular injection. Echocardiographic examination revealed that stroke volume and
cardiac output were significantly elevated at two to four days after β2-AR gene transfer
[25].
Rengo et al studied myocardial gene transfer to post-myocardial infarct rats with
intramyocardial direct injection. In order to stop beating of the heart (for 2.5 min),
adenosine was injected and both ascending aorta and pulmonary artery were clamped.
A volume of 4x1011 total particles of rAAV6-βARKct was injected in the LV free wall. The
investigators found robust transgene expression in the LV at 12 weeks after delivery. A
significant finding was that βARKct (gene of interest) significantly improved cardiac
contractility and reversed LV remodeling in this heart failure model [26].
In summary, the direct gene delivery approach was the first among others that
helped establish the therapeutic efficacy of cardiac gene therapy. Furthermore, the use
of this method in some experimental models resulted in successful therapeutic
myocardial angiogenesis, and focal treatment of cardiac arrhythmias through effects on
cellular electrophysiology; thus, making this platform widely used. Finally, this approach
has been successfully utilized in Phase І/ІІ clinical trials demonstrating its potential
therapeutic relevance.

34

2.3. Transvascular Gene Delivery
There are many potential therapeutic targets that are inaccessible directly in vivo
and, hence, require the transvascular administration of gene delivery vectors. A few
candidate therapeutic applications include essential hypertension and pulmonary
hypertension. Effective therapy in these diseases will likely require a gene delivery
method capable of globally transducing the myocardium and selected other tissues and
organs [36-38]. This paradigm is particularly valid in heart failure gene therapy where
most authors agree that gene transfer should be as diffuse and homogeneous as
possible [39,40].

Figure 2.3 Catheter Based Antegrade Catheter Infusion Delivery Approaches: (A) Left,
Selective (B) Right, Non-Selective
2.3.1. Selective Coronary Catheterization with Antegrade Intracoronary Delivery
To date, one of the most preferred gene delivery methods involves catheterbased, percutaneous infusion of vector into the coronary arteries (Figure 2.3A). The
benefits of this technique include its minimal invasiveness, the possibility of transgene
delivery to all four myocardial chambers, and the delivery of vector genomes using
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endovascular coronary catheterization—a procedure for which there is established
clinical experience. Early reports using simple antegrade intracoronary delivery achieved
very limited myocardial transduction efficiency [22,39,41,42]. The variability in
transduction was due to a number of factors that included differences between animal
species, biocompatibility of catheter and vector, different pharmacological agents used
to permeabilize the vasculature, and vector-related variables such as vector serotype
and titer [4].
Using intracoronary perfusion in explanted hearts, Donahue et al. reported highly
effective gene transfer to the heart and identified critical parameters influencing the
efficiency of intracoronary gene transfer. These included exposure time, high coronary
flow rate and perfusion pressure, the use of crystalloid solution as opposed to whole
blood, virus concentration, and temperature [37]. Several authors believe that aside from
these factors, a major deficiency in intracoronary gene transfer is the short residence
time of vector within the coronary circulation [39,43,44]. Attempts to resolve this
shortcoming have resulted in a number of strategies. Logeart et al showed that brief
interruption of coronary flow is required to obtain significant myocyte transduction during
single-pass delivery in the isolated rat heart model [42].
In other experiments, this laboratory obtained similar results in vivo, when
adenoviruses were delivered downstream of an occluded artery and when occlusion was
maintained for 30 seconds following adenovirus injection [42]. This procedure raises
questions as to the potential role of ischemia in enhancing gene transfer by increasing
microvascular permeability. The authors also demonstrated that selective catheterization
of the coronary venous sinus, which was transiently occluded and retroperfused with
saline during their procedures, increased the pressure inside post-capillary venules,
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which in turn improved gene transfer by increasing vector residence time in coronary
vessels [39].
Hayase et al. used the technique of antegrade intracoronary gene delivery with
concomitant coronary venous blockade. The myocardium was preconditioned with one
minute of occlusion of the left anterior descending and circumflex arteries. Quantitative
β-galactosidase analysis showed that gene expression was improved after selective
coronary venous blockade [40]. Donahue et al. found that decreasing perfusate Ca2+
concentration or pre-treating with serotonin or bradykinin significantly decreased the
exposure time necessary to achieve widespread transfection [45]. To prolong viral
exposure time, Ding et al. pharmacologically induced transient cardiac arrest, while
occluding the aorta and obstructed venous return to the heart. Cardiac arrest of two
minutes allowed for transfection of 18% of cells, whereas an extended time to five
minutes resulted in a cardiac transfection of about 43% of cells [43].
Increasing perfusion pressure and flow augments myocardial expression perhaps
by increasing the fenestration width between capillary endothelial cells, permitting better
viral transendothelial transfer and enhancing virus-myocyte interaction [46, 47]. Emani et
al used an apparatus consisting of a constant flow infusion pump with pressure
transducer and examined the effects of altering intracoronary flow rate, while obtaining a
seal between the catheter and the coronary lumen. The results indicate that efficient
cardiac transgene expression is dependent upon the infusion flow rate and requires an
intraluminal seal. Excessive flow rate is associated with myocardial injury [48].
2.3.2 Nonselective (indirect) Intracoronary Delivery
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Hajjar et al observed that adenovirus infusion into the left ventricle during brief
aortic clamping results in efficient adenoviral gene transfer, perhaps due to the resulting
high perfusion pressure inside the coronary vessels (Figure 2.3B). Later, to achieve
diffuse cardiac gene transfer in vivo, the authors developed a catheter-based technique
in rodents. In this approach, a catheter was inserted in the LV apex and advanced
beyond the aortic valve. A high concentration of an adenoviral preparation was then
injected through the catheter while the aorta and pulmonary artery were cross-clamped,
distal to the catheter tip for a period of 10 to 40 seconds.
This method achieves grossly homogeneous transduction of cardiac myocytes
throughout the left and right ventricles. By cross-clamping both the pulmonary artery and
the aorta, the left ventricular end-diastolic pressure does not increase because blood
return to the left ventricle is minimal. This method relies on the creation of a
transcoronary myocardial perfusion gradient for vector delivery. This allows perfusion of
the virus at relatively low downstream pressure, and the endocardium can be efficiently
transfected. It is noteworthy, according to the authors, that aortic occlusion during aortic
valvuloplasty is well tolerated in ill patients for periods of time comparable to those
required for gene transfer in animal models [36,49].
Maurice et al used a similar technique in the leporine model, whereby a catheter
was placed into the LV chamber through the apex of the heart. The adenovirus solution
was injected while the aorta was cross-clamped for 40 seconds. After six days, the
authors found global myocardial β-galactosidase expression in both ventricles. However,
three weeks later, β2-AR over-expression was minimal [50]. This method shunts the
virus down the coronary arteries, and global transgene expression is possible; yet, there
is a risk of systemic ischemia and acute LV overload during the aortic cross-clamping,
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and time must be limited [51]. This data was supported by Parsa et al., who showed in a
rabbit model with cross-clamping of the aorta, a significant decrease in dP/dtmax, which
they explained, indicates a negative effect on cardiac contractility after aortic occlusion
with elevation of afterload [46]. Kaspar et al. also used aortic and pulmonary artery
cross-clamping for indirect coronary delivery of AAV encoding GFP. Gene expression
was evaluated at four time points up to one year after vector delivery, revealing 20-32%
transmural gene expression in the left ventricle [52]. Eckhart et al. showed that in vivo
myocardial gene delivery in rabbits using this LV/cross-clamp delivery method of either
the β2AR transgene or a gene encoding βARKct can enhance cardiac function in normal
hearts as well as failing hearts [53]. Variations of this method may include clamping of
the aorta without pulmonary artery occlusion, occluding the distal rather than ascending
aorta, and the use of hypothermia to prolong cross-clamp times [4].
2.3.3. Selective Coronary Sinus or Coronary Venous Catheterization with
Retrograde Delivery
The feasibility and efficacy of percutaneous retrograde gene delivery by selective
pressure-regulated retroinfusion of the coronary veins has been demonstrated by
Boekstegers et al using a constructed apparatus, consisting of a pump unit,
extracorporeal circuit, and retroinfusion catheter and suction device. The authors
demonstrated advantages of retrograde delivery compared to antegrade and confirmed
the results from several groups that blocking the venous outflow and coronary ischemia
can significantly increase viral transfection of the myocardium [44, 54]. These authors
believe that selective coronary retroinfusion prolongs adhesion time of the vector and
increases endothelial permeability.
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This finding has led to an important advance in this field of delivery, although this
method does not reduce transduction of extra cardiac organs like the liver and lung [55].
Also, Hou et al. showed that a single retrograde coronary venous administration resulted
in efficient regional myocyte transfection of human Del-1 and GFP. The authors believe
that the coronary venous approach offers minimal washout and allows for controlled
dwell times for longer exposure [56]. Kaye at al developed the V-Focus delivery system
for a minimally invasive percutaneous procedure, which was designed to isolate the
coronary circulation from the systemic. This system includes percutaneous intervention
catheters, extracorporeal pump-oxygenator circuit, infusion pump and monitors.
According to the authors, this system achieves superior myocardial gene
expression in contrast to intracoronary delivery and is associated with lower systemic
expression [57, 58]. Although the authors represent this method as a “closed loop”
recirculation, careful analysis of the authors’ reported quantitative PCR results indicates
that the vector genome concentration was 26 times higher in the liver than in the heart
and thus isolation of the heart was not achieved as claimed [59].
In summary transvascular gene delivery provides the ability to obtain
homogenous and efficient cardiac gene expression accomplished with rapid dilution of
vector in circulating blood with significant extra cardiac expression. Surgical
manipulations included temporary aortic/pulmonary clamping or coronary arterial/venous
occlusion but both have significant clinical limitations and would require more
translational research, preferably in large animals, prior to considering clinical
application.
2.3.4 Ex vivo Gene Delivery
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Even though there is a shortage of donor organs, over 2,000 heart transplants
are performed annually in the United States. Ex vivo, myocardial gene delivery to the
donor heart before reimplantation is an active area of investigation. Such an approach is
clinically relevant in the setting of clinical heart transplantation and in surgical treatment
of heart failure. Strategies to improve cardiac allograft function could potentially increase
the longevity of current allografts, modulate the host immune response for prevention of
allograft rejection, treat ischemia-reperfusion injury and make available additional
marginal organs for transplantation that are currently not utilized [64]. Multiple studies
have demonstrated the ability to transfect cardiac allografts with intracoronary,
intramuscular, and transported delivery of vectors prior to transplantation [60,65-67].
Because gene delivery is carried out in the donor heart, total body virus exposure is
limited in the recipient, thus making it clinically favorable [68]. Using intracoronary
perfusion in explanted hearts, Donahue et al. reported highly effective gene transfer to
the heart [37].
In the study of Griscelli et al., recombinant adenoviruses encoding βgalactosidase were injected into the coronary vessels of the harvested non-beating
hearts of piglets at a dose 1010-1011 pfu. The hearts were maintained in contact with
the vector-containing solution for one hour at 40C and the coronary vascular bed was
then washed out by injecting 100 ml of cardioplegia solution and the last virus titer in the
coronary sinus effluent was three logs below that of the infused viral solution. Gene
transfer to allografts was evaluated four days after heterotopic reimplantation. In four out
of 11 animals, transgene expression was detected in all cardiac areas, PCR analysis
revealed minimal collateral organ transfection [60], and gene expression was not
enhanced by the exclusion of blood [47]. Shah et al. performed ex vivo perfusion of
41

cardiac allografts with adenovirus encoding transgenes that enhance β-AR signaling
[69]. The group demonstrated that five days after heterotopic transplantation, left
ventricular systolic and diastolic performance was significantly increased in transfected
grafts compared with controls. Further, Svensson et al. showed that 15 minutes of
perfusion with AAV.CMV.lacZ was sufficient to result in transduction of 40% of
cardiomyocytes after four weeks [24].
2.3.5 CPB and Cardioplegic Arrest
Another possible application of gene therapy is its use during operations with
extracorporeal circulation or cardiopulmonary bypass (CPB), which has become a
routine cardiac procedure. In fact, in 2009 more than one million cardiac procedures that
depend upon CPB were performed worldwide. Potentially widespread clinical application
would involve intracoronary (antegrade or retrograde) gene transfer in the setting of CPB
and cardioplegic arrest. The ability to augment myocardial performance with gene
transfer could potentially reduce the need for long-term inotropic or mechanical support
in the post-bypass setting, avoiding the complications associated with these
interventions [64].
High-risk patients undergoing revascularization or valve replacement with
coexisting severely reduced ventricular function and inherited forms of cardiomyopathy
might particularly benefit from concomitant gene therapy. Bridges et al. and Davidson et
al. first hypothesized that cardiopulmonary bypass may facilitate cardiac-selective gene
transfer using recombinant replication-deficient adenovirus [70,71]. The absence of a
significant influence of cold temperatures on transgene expression in an in vivo model
with CPB was described by Jones et al. [72]. They also demonstrated the presence of
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crystalloid cardioplegia compared with blood cardioplegia within the coronary circulation
had no effect on transgene expression and hypothesized that endothelial contact with
cardioplegia and the associated relative ischemia likely increased endothelial
permeability [73]. Ikeda et al. evaluated the feasibility of restoring δ-sarcoglycan
deficiency in cardiomyopathic hamsters after injection of a cardioplegia solution
containing an adenoviral vector encoding δ-sarcoglycan into the aortic root [74]. At one
and three weeks after transfection, immunostaining showed extensive restoration of
deficient membrane proteins with significantly less progression of LV dysfunction
compared with controls. Davidson et al. demonstrated the feasibility of myocardial gene
delivery during CPB with cold, hyperkalemic cardioplegic arrest in the porcine model
[71]. (Figure 2.4A).
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Figure 2.4 Advanced Cardiopulmonary Bypass Based Gene Delivery Systems:
(A) Top, Single pass delivery (B) Bottom, Closed Loop Recirculation Delivery
with MCARD

Unlike previous studies that utilized a single-pass perfusion technique, Bridges et al.
were the first to create an isolated “closed loop” recirculating model of vector-mediated
cardiac gene delivery in the large animal heart using cardiopulmonary bypass with an
antegrade delivery approach, allowing for vector recirculation for 20 minutes [70]. Later,
they used CPB with high-pressure retrograde coronary sinus infusion with multiple-pass
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recirculation of vector through the heart and washed out of the cardiac circuit prior to
weaning from CPB, which limited extracardiac gene expression (Figure 2.4B). They
were able to show an increase of several orders of magnitude in cardiac marker gene
activities compared with controls. Furthermore, there was minimal gene expression in
the liver and other collateral organs [75]. These results validate this surgical technique
as a potentially clinically translatable approach for cardiac gene therapy in carefully
selected patients.
In summary, despite the allure of ex-vivo and CPB-mediated gene delivery
approaches, it should be noted that one cannot exclude possible attendant morbidity.
Morbidity may be related to technique-associated complications as well as the additional
CPB time required. Finally, these methods have not been translated to clinical trials,
and the only evidence we have that they are effective is founded on the basis of data
derived from experimental studies. Therefore, it is difficult to judge objectively about the
likely clinical efficacy of these gene delivery platforms.

2.4 Cardiac Gene Delivery in Clinical Trials
A significant proportion of patients with myocardial ischemia and congestive
heart failure remain refractory to pharmacological therapies and unsuitable for
percutaneous or surgical interventions. Trials involving gene therapy in patients with
ischemic heart disease have been undertaken to stimulate angiogenesis. Rosengart et
al reported a Phase І clinical trial involving 21 patients with clinically significant coronary
artery disease that utilized adenovirus encoding human VEGF 121 cDNA with a goal to
induce therapeutic angiogenesis. The vector construct was administered by direct
myocardial injection into an area of reversible ischemia either as an adjunct to coronary
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artery bypass grafting or as sole therapy via a mini-thoracotomy. In both groups,
coronary angiography and stress sestamibi scans suggested improvement in angina
class patients after therapy [80,32,33].
Percutaneous catheter-based myocardial gene transfer of naked plasmid DNA
encoding phVEGF-2 was tested in human subjects by Vale et al. [81]. After the
completion of electromechanical mapping, the injection catheter was introduced
percutaneously via a femoral arteriotomy across the aortic valve into the LV and the
needle was advanced 4 to 6 mm intramuscular to administer six injections of plasmid
DNA into the ischemic myocardium. All patients experienced reduced angina, reduced
nitroglycerin usage and improved myocardial perfusion by SPECT-sestamibi scanning.
Also, results of single intracoronary administration of Ad5-FGF4 show evidence of
favorable anti-ischemic effects in patients with stable angina pectoris [82]. In this study
the transgene was infused over a period of 90 seconds through subselective catheters
into all major patent coronary arteries that could be engaged. Nevertheless, it should be
noted that these Phase I studies have not measured the amount of recombinant protein
produced; hence, it has not been possible to make accurate, quantitative determinations
of the relative efficiency of gene transfer, and a placebo-induced therapeutic effect
cannot be excluded.
Hajjar et al and Jaski et al performed the first-in-human Phase I/II clinical trial
with single intracoronary infusion of AAV1.SERCA2a in advanced heart failure. Standard
percutaneous catheter engagement technique with the coronary arteries was performed.
This usually involves delivering two-thirds of the dose to the anterolateral and one-third
to the posterolateral myocardium, based on the coronary anatomy. Of the nine patients,
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several demonstrated symptomatic, functional and biomarker improvements from
baseline to month six. The Phase II results largely showed similar results [83,84].

2.5 Conclusions
Gene delivery technology and science has improved expeditiously as demanded by the
growing pipeline of therapies for various cardiovascular diseases. Translational
problems have surfaced through clinical implementation and are associated with dosing
at sufficient levels to achieve therapeutic benefit while remaining within safety limits.
The ideal method for a particular cardiac gene therapy application maximizes
therapeutic expression with the least required dose and delivery efficiency at the
cardiovascular tissue is paramount. Despite significant advancements, there is still great
room for improvement to increase both safety and efficacy through developing more
advanced systems alongside the clinical science. Minimally invasive catheter based
systems remain at the forefront due to their ease of use in the clinic, but must address
problems associated with compromised vessels. As reviewed in this chapter, advanced
catheterizations systems including pharmacologic agents to increase vector distribution
from the primary infusion site have been implemented. It is expected this trend will
continue given that 80% or more of advanced patients present with moderate to severe
coronary artery disease. Higher risk surgical mediated delivery methods featuring
cardiopulmonary bypass at present are the only known means to achieve the highest
possible transduction through the vascular anatomy, but at the cost of complexity.
Furthermore these systems would be only reserved for a limited number of patients
undergoing cardiac surgery for a separate indication.
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Chapter 3 will describe the rationale for a unique contribution to the direct
myocardial delivery repoitore, which is currently limited to standard IM injection. Direct
injection methodology are primarily reserved for local, peri-infarct area but could also be
implemented for other therapies provided the risk/reward and clinical strategy are
feasible.
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CHAPTER 3
Research Program Overview & Strategy
3.1 Specific Aims and Hypotheses
Despite a well characterized gene transfer vector in AAV, high levels of transfer
in larger species have been problematic both due to scale (i.e. 100 times greater
myocardial mass) and more restrictive anatomical barrier factors. Transfer problems in
general are not realized in murine models, since successful AAV mediated gene transfer
can be achieved with a simple tail vein injection. As summarized in detail in Chapter 2,
cardiac gene delivery systems basically fall into two major categories:
1. Transvascular Based Infusion Methods (i.e. access and transfer of AAV through
capillary network vessels into myocardium)
2. Direct Myocardial Injection Methods (i.e. AAV directed right into myocytes through
mechanical means)
By physician standards, either of these categories can be considered minimally
invasive with recent advances in image guided catheterization. Also as outlined in
previous studies, each specific technique within its respective category has its own
advantages and disadvantages. Transvascular methods, particularly antegrade
intracoronary infusion, are still the mode of choice given for AAV products since they are
routinely utilized in the clinic by interventional cardiologists. These following
requirements however have not been met completely with current transvascular
techniques:
(1) Limit or stop leakage of AAV in the system and demonstrate greater gene transfer in
the heart versus collateral organs
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(2) Provide a solution for patients pre-screened with antibodies to AAV
(3) Allow for global myocardial gene transfer with the highest possible efficiency within
safety limits (e.g. not damage delicate vessels).
In response to the problems with other transvascular methods described in (1) (2) and
(3), our lab has developed the most sophisticated transvascular gene delivery system,
molecular cardiac surgery with recirculating delivery (MCARD). (Figure 3.1)

Figure 3.1 MCARD, Advanced Dual Perfusion Transvascular
Delivery Featuring Complete Cardiac Isolation
MCARD was inspired from the need to address these demands from larger
organisms: higher cardiac specific transduction efficiency and to reduce systemic
exposure. MCARD is a dual perfusion system featuring complete cardiac isolation in
situ, which recirculates a high concentration of AAV (i.e. cardiac circuit is bloodless) with
complete protection from the system circulation. It offers the unique ability to deliver
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AAV through the much more favorable dimensions of coronary venous system, while
also not working against the beating heart (e.g. CPB arrests the heart). When
comparing the MCARD vs. standard intracoronary infusion delivery methods with the
same vector dose, greater than 400 fold higher expression was found in the MCARD
animals with no immune response [16,17]. Despite unprecedented transduction
performance and the ability to minimize the risk for collateral expression, it is clear that
the cost of invasiveness of this system relative to catheter based approaches will limit
MCARD as an option for many patients unless substantial risk/benefit is demonstrated.
This type of delivery method would most likely be indicated for Class III-IV heart failure
patients receiving adjunctive therapy.
On the other hand, the direct methods by and large are seemingly confined to
needle based systems. Due to the simple ease of use, needle injection into heart
muscle was the first method performed at the large animal and human scale for gene
therapy. Once the heart is exposed via thoracotomy or accessed via catheterization,
control and selection over the desired injection sites is attainable.
Despite this advantage, it is well known now that several critical disadvantages
with AAV needle injections have resulted in a clear bias in favor of vessel infusion
techniques. The problems of scale and immunogenicity have seemingly placed a dead
end with using this approach for a clinical application. With regard to scale, this is
evidenced by the fact that 4-5 injections were found sufficient to achieve beneficial
therapeutic expression levels in small animal models (heart weight = 3-6 g) versus
greater than 200 to achieve a substantially reduced expression profile in larger species
(heart weight = 350 – 600 g). Limitations in volume injection per site, the number of
available sites to inject, and adverse immune reactions have been documented by
various investigators [18]. Furthermore there is an often overlooked problem of
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inadvertent systemic leakage most likely attributable to myocardial wall perforation
during the injection process.
Given the limitations of the most advanced transvascular and needle injection
methods, there is a need for a direct viral vector cardiac specific delivery system
that would offer greater myocardial gene transfer per injection. Understanding the
immune consequences as a function of delivery and vector selection has not been
explored in detail. The scope of this work seeks to expand both the methodology
and delivery science of direct myocardial injection.
Global Hypothesis: We hypothesize that liquid jet injection technology can offer an
alternative delivery platform with superior cardiac specificity competitive with
intracoronary infusion and superior to needle injection. In addition, evaluating the role of
delivery profiles in the context of the host response with regard to delivery and vector
selection can improve outcome. Specifically, this work will test four hypotheses that are
described in detail below. The overall goal of the work is to obtain a better
understanding of how to address both the problem of scale and immunogenicity
associated with direct intracardiac injections, especially within the ischemic disease
setting since this is the intended clinical application.
Specific Hypothesis #1: The mechanical liquid jet device approach can be optimized
for a cardiac gene therapy application to maximize cardiac gene transfer as measured
per myocardial cross sectional area, while reducing unwanted systemic exposure as
measured by collateral liver.
Specific Aim 1: Define and optimize engineering parameters for the liquid jet
injection device for the cardiac application in an acute rodent model and ex vivo
large animal setting to define a safe, yet effective operating transfer ranges.
Optimization is defined as in vivo tolerance whereby significant cardiac damage is
58

avoided, yet sufficient myocardial transfer is achieved suitably. This aim will be
achieved with ex vivo testing, quantitative fluid mechanics evaluation of the jet, and
limited non-survival animals.
Specific Hypothesis #2: The mechanical liquid jet device approach will result in
increased myocardial retention, cardiac specificity (i.e. heart transfer to collateral organ
exposure), and wider range delivery area versus IM injection, while in the range of the
best intracoronary delivery approach in a rodent model.
Specific Aim 2: Perform a two phase therapeutic delivery study to the beating
heart in an acute rodent model to evaluate the liquid jet approach against
traditional methods in practice. The methods to evaluate against are: A. Standard
IM Injection B. Non-selective Intracavitary Infusion C. Intracoronary Infusion
featuring Occlusion. The first phase of the study will evaluate immediate retention
following 10 minutes of delivery in a non-survival model followed by a repetitive second
phase study using AAV9.GFP marker therapy in the normal heart.
Specific Hypothesis #3: Liquid jet injection will achieve efficacious therapeutic AAV9
mediated S100A1 gene therapy over standard IM injection, while minimizing collateral
organ exposure and minimizing the immune host responses. It is argued that a
disperse, more homogenous expression pattern with the same magnitude range as IM
delivery will yield greater efficacy.
Specific Aim 3: Perform a chronic ischemic infarction 10 week model study to
evaluate delivery of a single dose 1.2 x 1011 Vgp of ssAAV9.S100A1 vector
featuring a head to head format comparing liquid jet vs. IM injection. Outcome
assessment will be a comprehensive, compiled data set of: (1) AAV9.S100A1 genome
copy detection (2) Quantitative proteomic S100A1 (3) CD38 Histological marker of
Immune activation in cardiac tissue (4) Serological markers of global inflammation via
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cytokine panel. In this aim there will be 4 assigned groups: A. IM Injection with Saline
B. Liquid Jet injection with Saline C. IM injection ssAAV9.S100A1 and D. Liquid Jet
injection ssAAV9.S100A1
Specific Hypothesis #4: Altering therapeutic vector and delivery strategy can
significantly alter outcome and in vivo performance.
Specific Aim 4: Two key testing parameters that may significantly alter host
responses are offered: A. Using self-complementary double stranded vector
equivalent B. Co-delivery of anti-inflammatory drugs to minimize host response
during initial delivery phase. The first part of this aim will be achieved by a simply
repeat of the animal protocol in Aim#3, however this time with a more potent double
stranded or self complementary scAAV9.S100A1 vector. The second part explores a
theoretical drug/gene combination approach with controlled release formulations in vitro.

3.2 Overview of Research and Impact
The motivation for advancing the topic of improving direct delivery of AAV
mediated gene products is an important research discipline, especially since enrollment
in cardiac gene therapy trials have been and are expected to increase in the near future.
Despite significant advancements in the field overall, most of the attention in gene
therapy is geared toward vector engineering and target identification but not delivery.
Chapter 1 outlined all of the key therapeutic mechanisms, targets, and rationale for AAV
mediated gene therapy, whereby S100A1 presents with significant potential to translate
in future clinical trials. Chapter 2 provides a thorough review and key insightful
conclusions on state of the art cardiac gene transfer systems and concepts within the
context of clinical applications.
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This research seeks to provide a clear, yet comprehensive approach to
designing, building and testing a new direct cardiac injection technique as well as
identify key delivery variables with existing systems in its evaluation. Chapter 4
summarizes the rationale and technical development phase of the needleless liquid jet
injection concept. Chapter 5 is the heart of this work, which characterizes the refined
concept in both an acute retention and AAV mediated marker gene expression model. It
is here where the technology is evaluated against existing methods with key insights
offered for both future development of cardiac gene delivery applications. Chapter 6
presents a comparative head to head assessment of liquid jet injection against standard
IM delivery in a chronic ischemic myocardial infarction model featuring the
ssAAV9.S100A1 therapy. The translational aspects of direct cardiac delivery are
thoroughly evaluated in terms of outcome, whereby cardiac performance, transduction
efficiencies and host response endpoints are paramount.
From there, two novel therapeutic concepts are explored to improve direct
cardiac delivery: (1) The use of self-complementary (scAAV9.S100A1) and (2) Codelivery of anti-inflammatory drugs with AAV products to increase efficacy. Chapter 7
provides a complete pilot study assessment with the same methodology in Chapter 6 to
explore whether or not a different vector with S100A1 may result in an improved
outcome. Chapter 8 conceptualizes a forward thinking, theoretical concept of a
controlled release drug/gene combination approach with a feasibility test in vitro. Finally,
Chapter 9 capstones key points for future cardiac gene therapy applications with respect
to delivery science. The work ultimately advances the body of knowledge with the aim to
improve outcomes in cardiac gene therapy, specifically when using direct administration
routes.
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CHAPTER 4

Needleless Liquid Jet Injection for Cardiac Gene Therapy:
From Concept to Application

4.1 Introduction
The previous chapters provided a solid foundation describing the rationale for a
new direct injection cardiac gene delivery method. In this chapter, we briefly review the
core science of ballistic delivery, its track record in similar applications, and the executed
development path in this dissertation. Needleless liquid jet injection is characterized as
a ballistic delivery based approach. The technology was originally developed in the
early 1960’s and applied for these simple medical applications: mass routine
vaccinations, administration of local anesthetics, tuberculin testing and dermatology
treatments of minor skin lesions. Closely related, the “gene gun” concept has a solid
foundation in molecular biology. In this chapter, the literature highlighting key results is
briefly discussed in Section 4.1.1 below for the gene gun, while section 4.1.2 delves into
the related, but fundamentally different liquid jet application. Finally beta testing and
modification of the concept for translation into the cardiac anatomy for a gene therapy
application is detailed in sections 4.3 and 4.4, respectively.
4.1.1 Gene Gun Ballistic Delivery Principles
Particle bombardment (also called Gene gun or ballistic DNA transfer) utilizes
heavy metal particles introduced with a high velocity pressurized inert gas into the target
cell (Figure 4.1).

62

Figure 4.1 Gene gun delivery is demonstrated featuring gold
particles coated with vector DNA being accelerated and dispersed
at the target tissues

Naked DNA can deposit onto these particles, and after entering the cell they are
gradually released. Acceleration can be achieved by a high-voltage electric spark or a
helium pressure gun. For optimal gene expression the following parameters have been
taken into account: (1) the properties, density and sizes of gold particles for
bombardment; (2) the DNA doses, and (3) the discharge voltage for optimal gold
particles penetration. Using a sub-microgram amount of DNA per bombardment, 1000 to
10,000 copies of DNA can be delivered to each target cell [1,2].
The fundamental principal of the gene gun is the transfer of DNA-coated particles
into the cell through the holes in the plasma membrane resulting from the initial injection.
Some authors believe that it may be possible to employ a gene gun to transfect cells that
are relatively resistant to other delivery systems [3]. In this method DNA or RNA adhere
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to metal particles (gold or tungsten) then the DNA-particle complex is accelerated and
shot into the target tissue. Uncoated metal particles could also be delivered through a
solution containing DNA surrounding the cell thus picking up the genetic material and
proceeding into the living cell.
Despite some interest in translation, the primary problem with the gene gun is the
technical maintenance cost in addition to complexing vectors to relatively large metallic
particles. Given the stability and formulation advantages of modern viral vectors,
ballistic delivery of active therapeutic is more cost effective through liquid jet delivery.
4.1.2 Liquid Jet Delivery Principles
A ballistic method jet injection is performed using a high-speed pressurized gas,
usually CO2 but the driving gas can be changed per application. The injection is
comprised of piercing center and surrounding microjets, whose effects create pores in
cellular membranes to facilitate intracellular gene transfer (Figure 4.2).
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Figure 4.2 Liquid delivery is demonstrated featuring DNA vector
suspended in a liquid formulation being accelerated and dispersed
at the target tissues
The penetration power depends on three factors: the applied pressure of the gas,
the dispersion factor of the jet as a function of the nozzle bore and the tissue‘s
mechanical properties [4]. Levels of gene expression by jet injection were found to be
50-fold higher than by conventional needle injection in one preliminary study [5]. The jet
injection gene transfer is usually well tolerated without side effects provided that the
settings are optimized. This method is described only for non-viral based techniques of
gene transfer and uses a high pressure.
Macromolecules of varying chemistries and properties can be delivered ranging
from stable active compounds, DNA and to a lesser degree proteins. Pressure used is
typically less than 3-4 bars with resultant velocity profile of the droplets ranging from 100
m•s-1 to 300 m•s-1. The velocity of the fluid in the jet injection contributes to the
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distribution in the tissues, whereas the diameter of the jet and the injected volume limit
the penetration depth [6]. The efficiency of this method depends on nozzle diameter
(150-300 µm), velocity of the liquid jet and distance between the nozzle and surface of
the tissue [7].
The penetration of the injected molecules inside the cells subsequently results in
direct uptake, maximizes bioavailability in the tissue environment for additional
molecules, and worst case inadvertently reaches off target organs via systemic
circulatory penetration. The high pressure of the jet creates a hole in the tissue surface;
the depth of this hole is increased due to the accumulation of fluid. The use of
intramuscular jet injection of DNA combined with electroporation was demonstrated to
be feasible in a mouse model [8]. We and others could not find publications on the
applications of this method for cardiac gene therapy [9].

4.2 Device Description & Specifications
The handheld needleless liquid jet (DERMOJetTM) was purchased from Robbins
Instruments (Chatham, NJ). The device itself was invented by Dr. A. Krantz in France
with the medical device manufacturer Akra DermoJet (Pau, France). The device (Figure
4.3) is comprised of a stainless steel design with polycarbonate reservoir with
dimensions: 8 ounces (weight), 6.5 inches (length), and 11/16th inches (Diameter)
injector head. The exit orifice is 0.0079" (32 gauge; 235µm) diameter in a jewel shape
design. The size transmission limit is crystalline particles up to 200 microns.
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Figure 4.3 The DermoJet Needleless Liquid Jet Device
The device is actuated by an internal spring mechanism which drives a piston
that subsequently accelerates a fixed volume fluid load. Injection is executed by a
loading lever mechanism which sets the spring lock element, while the push button
trigger releases for the acceleration of drug through the orifice. The ejection orifice
features an internal jewel shaped configuration for a dispersive effect. The ejection
volume is fixed at 100µL at the ideal retention limit of most tissues. Various mechanical
components in the device are tunable, most notably the spring and orifice
characteristics.

4.3 Beta Testing
4.3.1 Manual Injection
My first experience testing the device after priming was to assess both the level
of penetration and inflammatory response first hand. At the manufacturer’s settings, I
injected sterile saline into my palm approximately 0.5cm above the skin surface. An
immediate, sharp burst provided transfer beneath the dermal layer with a small pinhole
entrance site marked by spot bleeding. The inflammation and pain from the injection
peaked at 24 hours, and diminished after 48 hours. It was determined that if left at this
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current setting transfer would not be ideal since the piercing jet did not provide adequate
distribution but only a deep penetrating bolus in a locale. Subsequent manual tests at
greater distances revealed much less piercing, but it was interesting to note significant
fluid retention under the surface of the skin with seemingly no pain from the injection was
observed. This transfer distance whereby retention was achieved at the lowest level
was about 24 inches from the nozzle.
4.3.2 Explanted Rodent Hearts
Methylene blue dye was loaded into the device and fired directly on the surface
of explanted rodent myocardium samples, which are generally 1-2 cm thick transmurally
across the left ventricle. A clear “jet track” line was noted, with less than 1mm
distribution from it. It was noted that retracting the device at 2 inch increments resulted
in more surface coverage and in some cases complete penetration. At greater distances
this effect was erratic and a “spray” behavior was noted indicating only superficial layer
penetration. Given that the cardiac gene therapy application requires both maximal
transfer without damage and consistency, several modifications to the device were
needed for application.

4.4 Device Modifications for the Cardiac Gene Therapy Application
Following the very early experiments described previously, it was readily
determined that optimizing both the pressure and distance settings would permit ideal
transfer within safety limits. Very early acute model rats suffered severe cardiac
bleeding events and or arrest with distances less than 8 inches at the manufacturer
settings. Safety limits were defined as tolerance of at least 6 consecutive 100µL
injections without significant EKG changes or morbidity.
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4.4.1 Pressure and Velocity Optimization
The original experiments indicated that the device as is would not be suitable for
any cardiac application since the potent jet was piercing with high force and
simultaneously providing limited distribution. Advancing to distances greater than 24
inches from the target organ were required to remotely obtain anything of value in terms
of dye transfer, thus it was imperative to modify the settings. Since the device was
actuated by a spring, we worked with the manufacturer to cut the constant down by 80%
of the original length. The original jet velocity was measured and confirmed by the
factory at just over 330 m/s out of the nozzle. The modified device yielded roughly 110
m/s exit velocity with a 100-200kPa driving pressure range. As a means to control the
distance between the exit nozzle and the target, the device was mounted to an arm
apparatus as shown in (Figure 4.4).

Figure 4.4 Mounted Device to Control and Optimize Delivery
Distance
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CHAPTER 5
Needleless Liquid Jet Injection: Validation Studies in Normal Hearts
Adapted From: Fargnoli AS, Katz MG, Williams RD, Margulies KB, Bridges CR. A Needleless
Liquid Jet Injection Delivery Method for Cardiac Gene Therapy: A Comparative Evaluation of the
Novel Approach Versus Standard Routes Demonstrates Enhanced Therapeutic Retention and
th
Extensive Cardiac Specific Gene Expression. Submitted to Human Gene Therapy Jun 10 2014.

5.1 Introduction:
Heart failure (HF) remains a significant burden to the global healthcare system
with annual costs exceeding $32 billion [1]. Besides the limited number of donor organs
available for transplantation, current medical and device therapies have not significantly
reduced disease burden. Through careful scientific investigation and clinical
development, gene therapy has emerged as a potential strategy to directly treat myocyte
dysfunction at the molecular level. A number of genes have been identified to impact
these critical disease pathways - which if expressed robustly in the myocardium enhance contractility, promote survival, and in some cases completely reverse chronic
HF [2-4]. Adding to this momentum, novel microRNA and angiogenesis targets
promoting genetically induced regeneration are accelerating through various
developmental stages [5,6]. Therefore, the recent basic scientific progress has
bolstered an already thriving pipeline of viral mediated gene therapeutics and it is
expected that new clinical trials will be forthcoming.
A pivotal milestone for the cardiovascular gene therapy field was the successful
launch of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in
Cardiac Disease (CUPID) trial featuring adeno-associated viral vector (AAV) encoding
the contractility enhancing sarcoplasmic endoreticulum ATPase (SERCA2a) gene [7].
This key trial has provided reason for cautious encouragement as favorable results were
achieved in the high dose group versus placebo [7,8]. Despite these encouraging results
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in the high dose group, achieving efficacy with lower doses remains a concern given that
no improvement was found in patients receiving less than the maximum 1 x 1013
DNAase resistant viral particles (vp) [8]. Delivery efficiency is the main concern,
whereby higher doses are needed to achieve sufficient expression levels, which
inherently increases the risk for adverse events. Therefore, more efficient delivery
systems would most likely improve clinical outcomes.
The administration route currently in clinical trials is antegrade intracoronary
infusion, given its safe and effective implementation in clinical practice [9]. From a
therapeutic AAV transfer perspective however, standard infusion approaches are
critically limited by these factors: (1) Prohibitive physical barriers (e.g. pre-capillary
sphincters and endothelial barriers) preventing viral vector diffusion into the interstitial
compartment [10] (2) Plaques and inflammatory elements in primary vessels, which are
common in HF patients with advanced coronary disease (3) neutralizing antibodies and
blood components which limit viral particle bioavailability [11] (4) Inadvertent systemic
exposure via general circulation and finally (5) Exclusion of many patients seropositive
for AAV. Sophisticated modifications to percutaneous catheter infusion (e.g. single or
concomitant retrograde/antegrade balloon occlusion systems [12] and even surgical
closed loop recirculation systems [13]) have been advanced recently to increase
efficiency at the cost of complexity. Some of these systems may be implemented in
future trials, however most would either exclude high risk patients or impose additional
safety concerns.
An alternative to infusion methods in an effort improve efficiency in terms of
cardiac specificity is direct myocardial delivery. Direct injection methods circumvent the
blood and anatomical barriers by directly administering product into the myocardium,
which additionally offers the advantage of precise site selection. For this reason direct
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intramuscular (IM) injections were attempted with adenovirus in the very first series of
angiogenesis trials [14], but yielded poor results. Cited problems with this route are
limited distribution per site and inflammatory responses [15,16]. There has been little
work to date to improve direct myocardial delivery applications despites these concerns
and limitations.
In this study we present a novel approach to improve direct cardiac gene delivery
using a needleless liquid jet methodology. Similar ballistic delivery methods were
utilized in very early DNA transfection studies via gene gun [17,18], but to date none
have attempted delivery of AAV therapeutics as a potential clinical strategy. The liquid
jet application is essentially a device concept that accelerates and disperses the
therapeutic at a targeted myocardial site. The core hypothesis offered is that this
approach with optimized settings could result in: increased therapeutic retention in the
initial delivery phase, achieve significantly more total myocardial expression per dose ,
and in addition yield a more homogenous profile around the injection site. Overall, this
would increase efficiency in terms of transduced muscle per delivery site unit and
decrease the likelihood of an immune response.
This proof of principle study optimizes the needleless liquid jet strategy for
cardiac applications and evaluates the method in a series of rodent experiments. In each
set of experiments, the liquid jet method is compared with three existing methods:
Intramuscular injection (IM), Single pass LV intracavitary infusion (LVIC) infusion, and
LV intracavitary infusion with aortic and pulmonary artery occlusion (LVIC-OCCL). In the
first series of experiments we evaluate each methodology’s immediate myocardial
retention profile in an acute model. In the second series we utilize a highly cardiotrophic
AAV9.EGFP marker gene construct to simulate a more realistic long term gene
expression scenario. Finally, a preview of the needleless liquid jet method’s translational
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potential in the large animal setting is performed with post-harvest specimens. Key
translational aspects for direct injection and infusion approaches are then discussed for
future directions to improve cardiac gene delivery technologies.

5.2 Materials and Methods:
Animal Care and Handling
40 rats were procured from Charles River Laboratories and handled in accordance with
IACUC guidelines at the Cannon Research Center at Carolinas Healthcare System.
Normal Sprague Dawley rats (males, weight 300 g) were obtained for all experiments.
Needleless Liquid Jet Injection Device Optimization & Specifications
A DermoJetTM liquid jet device (Robbins Instruments, Chatham NJ) was acquired and
modified for cardiac delivery applications. The spring actuator length was reduced by
80% to 1.9 cm, which resulted in a significant driving power reduction. A super speed
camera (Zeiss International, Thornwood NY) at the University of Pennsylvania Complex
Fluids Laboratory was used in a custom analysis suite to quantify jet fluid exit velocity
and to compute estimated driving pressure. The nozzle jet velocity was measured at
110 m/s based on a 30,000 images per second capture rate. The driving pressure
ranged from 150 – 250 kilopascals (kPa). Prior to the modification, the factory setting
results were 330 m/s velocity at greater than 550 kPa.
The next key parameter to optimize for a surgical application was the injector head
distance normal to the target cardiac plane. To execute, the pen configuration injector
was mounted to a stainless steel arm apparatus secured to a solid base. For alignment
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with the cardiac targeted surface plane, an optical system consisting of a field laser and
digital level were utilized in conjunction to ensure accuracy between injections.
The safe liquid jet delivery distance range was determined by performing a limited
number of acute studies with methylene blue dye injection. Safety criteria were defined
as tolerance of 6 consecutive projected needleless injections without visible bleeding
and EGC changes. Confirmation of hits was validated via marks by surface retention of
dye. The optimal distance range was determined between 8-10 inches (i.e. nozzle tip to
heart surface). This range was found effective where sufficient dye was retained
transmurally, but no incidence of major cardiac damage was observed.
Rhodamin B Dye Preparation for Acute Studies
Rhodamin B Dye (Sigma Aldrich, St. Louis MO) was prepared in (50 µg/mL) working
aliquot concentration. Rhodamin B dye was selected based on easy formulation and
high performance in muscle tissue types for the acute retention purpose.
AAV9.EGFP Viral Vector Production for Survival Studies
All Recombinant AAV9.EGFP was sourced from the University of Pennsylvania Vector
Core (Philadelphia, PA). Briefly, vector production, harvest, purification and testing were
done from cell lysates by the Penn Vector Core. The recombinant vector used in this
study contains an AAV serotype-9 viral capsid and a single strand: ~4.5-kb DNA
containing the EGFP marker gene driven by a cytomegalovirus immediate-early
promoter/enhancer, a hybrid intron, and a bovine growth hormone polyadenylation
signal. Manufacturing process details can be found
(http://www.med.upenn.edu/gtp/vectorcore/). Following production, viral preps were

75

pooled from individual lots and aliquoted in sterile vials each containing a dose of 2 x
1011 vp in 500µL volume.
Acute Model Protocol: Retention of Rhodamin Dye
The endpoint selected for retention in the cardiac cross sections was % myocardial area
positive for Rhodamin B dye level shortly after cardiac delivery. Since global,
homogenous distribution is the ideal outcome for contractility genes, this measure
essentially determines what areas of myocardium are accessed per route.
All rats were anesthetized with ketamine IM, intubated and placed on a Harvard
Apparatus ventilator and maintained with isoflourane 1-3%. A left thoracotomy was
performed and the pericardium excised to expose the beating heart. Each animal was
then assigned to 1 of 4 acute delivery groups (n=6 each) [IM Injection, Needleless Liquid
Jet, LVIC-OCCL, LVIC)] to receive a single 500µL fixed dose Rhodamin B Dye. A 10
minute waiting period commenced after delivery. The heart was then harvested and
sectioned immediately following.
Delivery Route Descriptions
(Figure 5.1) provides a conceptualized illustration of all 4 cardiac delivery approaches of
IM Injection, Needleless Liquid Jet injection, Left ventricular single pass infusion (LVIC)
and Left ventricular infusion with concomitant occlusion of the aorta and pulmonary
vessels (LVIC-OCCL) applied in the model studies.
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Figure 5.1. Cardiac Gene Delivery Methods (A) IM Injection (B) Liquid Jet
Injection Concept (C) Intra left ventricular cavitary Infusion [LVIC] (D) LVICOCCL Infusion featuring dual occlusion of aortic and pulmonary vessels
The technical delivery details for execution were as follows:
IM Injection
A 1 mL 30 gauge syringe was loaded with the 500µL of volume. Injection sites on the
left ventricular apex, anterior wall, and lateral wall were marked with a surgical pen. Two
injections were performed in the mid-ventricular plane for each of the anterior and lateral
walls, with a single injection in the apex for 5 total injections. Injections were spaced
about 5 mm.
Needleless Liquid Jet Injection
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500µL delivery volume was loaded into the chamber with a residual capacity of at least
200µL additional to ensure the 5th shot maintained the same kinetics as per DermoJetTM
manufacturer instructions. A digital level and laser was used to ensure adequate
degree and plane alignment with the middle left ventricular plane. Five separate shots,
each containing 100µL, were fired perpendicular to the LV surface. Hits were confirmed
by detection of pinhole piercing on the epicardial surface with surrounding coloration
changes.
LVIC-OCCL Infusion
Silk suture was placed in two locations, the proximal aortic arch and the left pulmonary
artery. Following, a 16 gauge needle introducer was used to catheterize the left ventricle
from the apex. A catheter was secured in place with a syringe containing the 500µL of
therapeutic. Just prior to infusion, concomitant occlusion of both snares with slow
infusion was conducted over a 10 second period. The occluding sutures were then
released after the 10 second period.
LVIC Infusion
A 16 gauge needle introducer was used to catheterize the left ventricle from the apex. A
catheter was secured in place with a syringe containing the 500µL of therapeutic. Slow
infusion in the left ventricle over 10 seconds was performed without interruption.
Survival Model Protocol: Expression Profile Following Delivery of AAV9.EGFP
All rats were anesthetized with ketamine IM, intubated and placed on a Harvard
Apparatus ventilator and maintained with isoflourane 1-3%. A left thoracotomy was
performed and the pericardium excised to expose the beating heart under aseptic
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conditions. Each animal was then assigned to 1 of 4 delivery groups (n=4 each)
following the same delivery protocol for [IM Injection, Needleless Liquid Jet, LVIC-OCCL,
LVIC)] groups. The therapeutic was a single 500µL fixed dose 2 x 1011 (vp) of single
stranded adeno-associated virus encoding green fluorescent protein (ssAAV9.EGFP).
Following delivery, the incision was closed and each animal was recovered and
monitored to 6 weeks. At the 6 week peak expression endpoint, the harvest
commenced.
Tissue Harvest and Cross Section Preparation
For each Rhodamin Dye animal, middle and basal left ventricular cardiac sections and a
single liver cross section was acquired. Similarly, for each AAV9.EGFP therapy animal,
the left ventricle was sectioned in 2 plane regions: Middle and Basal regions to assess
the degree of AAV mediated EGFP dispersion per route. A single liver section was also
acquired. All cross sections were snap frozen in OCT. Ten micron sections were cut on
a cryostat and mounted on glass slides for further analysis.
Immunohistochemistry Staining for EGFP Detection
Tissue from rats receiving the ssAAV9.EGFP was stained with a rabbit polyclonal AntiGFP antibody (Abcam ab-290). Bound antibody was detected with an ImmPRESS antiRabbit kit (Vector Labs MP-7401) and visualized with ImmPACT VIP chromagen (SK4605). Cells were counter stained with methyl green.
Cross Section Image Capture
Images of the entire cross section were obtained using an Olympus BX40 microscope
with a DP72 camera and CellSens software with fixed acquisition settings at 4 x
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magnification. Multiple images at 4x were stitched to reconstruct a complete 2D cross
section for heart and liver per animal per region. Slides of unstained cross section tissue
from rats receiving Rhodamin B were imaged under 540nm fluorescence. Basic light
microscopy was used with the same approach as described above for the EGFP
sections, however without fluorescence as positive GFP detection was indicated by
brown-purple stain hues.
Imaging Analysis Protocol
Following acquisition, all myocardial and liver cross section images were standardized
with a custom Java programmed macro in ImageJ software to apply uniform brightness,
contrast and sharpness settings. Quality control checks of pixel density, resolution, and
image size were done prior to analysis. All images were saved into Grayscale 16 bit
format and blinded for analysis.
Cardiac Cross Section Analysis
Each cross section was loaded into ImageJ. For the Rhodamin B fluorescent images
only, each cross section was first subtracted from saline control templates to minimize
the background effect. The Iterative self-organizing data analysis technique (ISODATA)
algorithm was utilized to determine the threshold for positive therapeutic (Rhodamin B or
EGFP positive pixels). Briefly, the algorithm mathematically derives the statistically
validated threshold based on the normal distribution sampling of all pixel intensity values
and arrives at an optimal detection value [19].
Following ISODATA identification, the 16 bit Grayscale images were converted into
binary, whereby all pixel values above the computed threshold were scored positive.
Two myocardial contours were drawn, one for the outer epicardial border and another for
80

the inner endocardial surface. The percentage positive therapeutic area was defined as
follows for the cross sectional myocardium:

% Score =

# Postive Therapeutic Pixels
× 100
# Pixels in Outer Area − # Pixels in Inner Area

Liver Cross Section Analysis

The cross sectional images were handled the same as described above, however
scoring was focused on therapeutic intensities in the liver to gauge systemic uptake.
First, as in above the percentage positive liver area was determined. Second, the
grayscale Integrated density was determined by multiplying the gray value (1-255) for
each pixel:
Total (+) Pixels

�
1

Gray Value x Pixel Unit

The final exposure score was computed as the mean gray value of all positive pixels
determined from the algorithm (Integrated Density/Total Positive Pixels) X % affected
area.
Both the Rhodamin and EGFP populations were evaluated in two separate left
ventricular planes, middle and basal respectively. For simplicity, an overall score
combining both planes was used to characterize the Rhodamin model. Similarly, an
overall score was compiled for the EGFP groups by combining both LV sections for a
total cardiac score, but presently separately to assess total myocardial coverage.
Needleless Liquid Jet Evaluation in Explanted Ovine Myocardium
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To obtain a basic translational perspective on the optimized device, a basic methylene
blue injection experiment was executed with post-harvest ovine left ventricle. 15 liquid
jet injections each containing 100µL were fired from the device setup at a 4 inch distance
to account for the greater thickness. Qualitative epicardial and endocardial wall
penetration as well as coverage were observed.
Data Analysis and Statistics
All data are reported as mean ± SEM, per delivery group in each respective study.
Single way ANOVA was used to determine difference across all 4 delivery groups. Ttesting with Bonferroni correction was used for comparison between multiple groups.

5.3 Results:
Rhodamin B Dye Acute Model Analysis
(Figure 5.2) illustrates the typical distribution profile per method from the Rhodamin B
retention analysis. The images demonstrate both the degree of myocardial coverage
and regional cross section peak intensities (e.g. mild red to hot yellow) as a function of
delivery route. These results were consistent between subjects per group; supporting
the claim that delivery route had a major influence on retention profile.
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Figure 5.2. Acute Study Results Per Group (Left to Right) IM Injection, Liquid
Jet Delivery, LVIC-OCCL and LVIC Infusion. Rhodamin B dye retention
demonstrated in myocardial cross sections (top) and systemic exposure in the
liver sections (bottom)

IM injection resulted in highly focal, heterogeneous cardiac delivery with a moderate
degree of systemic exposure. By comparison, the liquid jet group demonstrated a more
disperse, yet homogeneous pattern with higher intensities along the epicardial surface,
but none has high as in the IM sections.
Conversely, the infusion groups demonstrated that increased retention is driven by
induced pressure and residence time as there was a dramatic difference between the
LVIC-OCCL and LVIC groups.
Quantitatively, the Liquid Jet [52±6] % (+) myocardial area group performed in a similar
range with the LVIC-OCCL group [58±5] % (+). Both the Liquid Jet and LVIC-OCCL
methods resulted higher distribution levels (p<0.01) compared with the IM [31±8] % (+)
and LVIC [35±5] % (+) (Figure 5.3A). All groups presented with varying degrees of
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systemic liver exposure, (Figure 5.3B) IM [37±7] arbitrary Rhodamin Units (AU), Liquid
Jet [26±5] (AU), LVIC-OCCL [45±7] AU and LVIC [46±7] AU. The Liquid Jet group was
the most cardiac specific.
When comparing direct (i.e. combined IM/Liquid Jet) versus infusion (i.e. combined
LVIC/LVIC-OCCL), higher systemic liver exposure (Figure 5.3C) [46±5] AU as
compared with direct injection methods [31±4] AU was found p<0.05.

Figure 5.3. Acute Model Results: (A) Liquid Jet and LVIC-OCCL demonstrate
significantly greater retention versus both IM and LVIC groups p<0.05 (B) All
groups result in systemic exposure (C) Direct methods, IM and Liquid Jet
combined demonstrate lower overall exposure versus Infusion methods or LVICOCCL and LVIC combined
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AAV9 Mediated EGFP Expression Analysis at 6 Weeks Post Delivery
Despite the profound size (Rhodamin dye 20-50Da; AAV 4 x 106Da), , diffusive
properties and functional differences between dye and AAV, it was found that the overall
distribution patterns for each delivery group nearly matched those results found in the
acute study.
A key number of findings were determined, specifically with respect to the EGFP
distribution throughout the LV anatomy, indicative of methodology characteristics.
(Figure 5.4) depicts representative whole left ventricular cross sections per group (i.e.
higher basal and lower middle LV plane regions), whereby GFP detection is indicated
with (brown/purple) stain while white/blue regions are devoid of any detectable
expression. The results are summarized by group as follows:
IM Injection Group
The GFP distribution was localized around the primary injection sites, but in comparison
to dye results the size and bioactivity of AAV permitted greater myocardial coverage in
the middle region. The middle left ventricular region score was significantly higher
[46±2] % (+) than the basal region [13±12] % (+) p<0.05. This difference was most
likely attributable to the consistent application of AAV into the middle left ventricular
zone. Based on this difference, it is likely that not much product diffuses into regional
distances beyond the site of injection. The GFP systemic liver exposure score was
relatively high at [71±10] AU.
Liquid Jet Injection Group
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The needleless jet offered a robust, yet homogenous pattern of GFP expression with
nearly equal levels in the basal and middle left ventricular sections indicating the jet
profile’s dispersive effects per shot. The scores were [54±8] % (+) in the middle and
basal [56±9] % (+) regions. The intensity was generally greatest in the epicardial
regions of site impact, although significant expression was found in the remote posterior
wall regions indicating complete myocardial penetration. Moreover, the systemic liver
score was low at [27±3] AU.
LVIC-OCCL Infusion
This route offered the highest degree of expression in terms of both intensity and
distribution of cross sectional GFP coverage. The score in the middle left ventricular
was the highest at [71±6] % (+). The basal region also scored high [50±14] % (+) and
presented with a homogenous pattern. These model results recapitulate the importance
of driving local pressure and residence time to maximize delivery through the coronary
anatomy.
LVIC
The difference between expression levels between the anatomical regions was the most
dramatic here, with the middle region scoring [41±6] % (+) while the basal region [5±3]
% (+), p<0.05. These results suggest that very little retention in remote areas is
achieved without increased pressure and residence time.
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Figure 5.4. Left Ventricular Cross Section GFP Expression Distribution Per
Delivery Method. Top to Bottom, IM Injection, Liquid Jet, LVIC-OCCL and LVIC
AAV9 groups. Expression profiles presented in the Middle and Basal LV
sections (left to right) per group with composite % area transfected with GFP.
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Overall when combining both the middle and basal regions, AAV mediated GFP delivery
in the heart was more effective with the Liquid Jet [54±5] % (+) and LVIC-OCCL [60±8]
% (+) methods, both p<0.05 as compared with IM [30±9] % (+) and LVIC [23±9] % (+)
(Figure 5.5A). The Liquid Jet group was the most cardiac specific resulting in a lower
liver score versus the other 3 groups, p<0.05 (Figure 5.5B).

Figure 5.5. AAV9.GFP Survival Model Study Results. (A) Liquid Jet and LVICOCCL groups demonstrating greater overall expression versus IM and LVIC
groups, p<0.05. (B) Liquid jet group presented with a much lower GFP liver
exposure score compared with the other groups, p<0.05

Ex Vivo Ovine Myocardial Liquid Jet Injections
The selected epicardial injection distance for the proposed clinical equivalent was
determined at 4 inches. This strike distance was found optimal since maximum
myocardial coverage and retention transmurally, but not through the endocardium
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surface (i.e. complete LV wall retention). The figure below depicts primary impact sites
shown on the epicardial surface (Figure 5.6A) and transmural retention shown from the
reverse endocardial surface (Figure 5.6B). As expected the greater scale size factor
imposes concerns for direct delivery.

Figure 5.6. Ex Vivo Ovine Methylene Blue Results for translational potential of
needleless liquid jet injection (A) Injection points located on the epicardial surface
demonstrate the jet’s local, yet dispersive profile along the adjacent surface contours
and (B) robust transmural delivery retained per injection site within the endocardial
surface.

5.4 Discussion:
Achieving sufficient myocardial expression through any selected vector, dose
and delivery route configuration is balanced by the clinical implementation risks [20,21].
As demonstrated in this study, the choice of delivery method alone can significantly
impact the type of cardiac distribution and collateral organ expression profiles realized
over time. The ideal cardiac gene delivery method would facilitate sufficient transduction
levels in as much myocardium possible effectively achieving global rescue with the
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minimum required dose. The resultant expression profile would also have to be
sustainable over time and not induce host responses. Fundamentally this study
demonstrates that route efficiency is paramount in achieving maximum myocardial
expression, but also offers insight into distribution profiles. The initial delivery is largely
influenced by physical transport principles (i.e. pressure, residence time, dispersion
trafficking, mechanical resistance) that are independent of AAV characteristics and
therefore must be considered with any given delivery strategy. AAV serotype and capsid
engineering must also be considered within these limits in obtaining desired expression
patterns.
Two unresolved problems with direct delivery wherein the needleless liquid jet
approach may be beneficial are to improve initial therapeutic retention and diminish
subsequent host responses associated with highly focal expression. With regard to the
first problem, other studies have confirmed that a significant portion of the IM injection
volume is either lost into the systemic circulation or back through the injection site itself
[22-24]. This finding likely explains the variable results achieved between patients, since
the beating heart represents a challenging dynamic target featuring accentuated
changes in the structural wall thickness during injection [25]. Our results in this study
demonstrated that the IM method consistently had a higher degree of systemic delivery
as exemplified in the liver versus the liquid jet method. Our application of liquid jet
technology demonstrates that a tunable pressure/dispersion profile can promote
maximally retained therapeutic per unit volume across a wider surface area within a
range of given thickness. With a more sophisticated instrumentation setup, it would be
possible to actively adjust driving parameters with real time system feedback and or
image guidance.
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The second and more challenging problem to resolve for direct delivery methods
is the risk for adaptive immune responses. Large animal studies utilizing IM injection
have reported high incidence of myocarditis and T cell mediated immune responses [26].
In addition to the inflammation generated from multiple needle sticks, comprehensive
studies have raised key concerns regarding the highly localized gene expression profile
in muscle [26,27]. It has been postulated that both inflammation resulting from injury at
the time of delivery as well as the highly focal expression profile are interrelated in
triggering subsequent immune responses long after the initial delivery period [28]. Both
innate and adaptive immune responses are major concerns especially since advanced
heart failure patients present with moderate to severe degrees of chronic inflammation
and fibrosis [29]. This study did not evaluate levels of induced inflammation, but it is
hypothesized that the jet’s impact should be less inflammatory versus repeated needle
sticks in the same area. Expounding upon this point, other reports confirm that
pharmacodynamic effects with IM injections saturate to a biological limit [30,31],
whereby expression levels beyond the therapeutic threshold provide no clinical benefit
and actually increase risks.
Although intriguing, the liquid jet injection approach would need extensive
modification to be positioned in the clinic as a standalone intervention. Certainly our
results are very limited to effectively targeting 1 gram of transmural myocardial mass in
the rodent. In on our development course, we have identified optimized settings for a
thickness level (e.g. transmural rodent cross section at 0.5cm). The settings in this
particular application are most likely not optimal for larger animals.. Our basic explanted
heart dye application demonstrated this point and underscored the problem of scale.
Given that 1 g of mass was covered with 5 injections, it is very likely that >250-500 sites
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would be needed to achieve the same level of coverage in a human left ventricle. This is
certainly not feasible with the existing setup. Future model studies will be needed to
determine if further optimization is possible to reduce the number of sites as well as
establish safety limits with a more sophisticated prototype.
Infusion approaches will remain on the forefront in trials but must address the
problem of increasing driving pressure and navigating anatomical/disease barriers while
remaining within safe limits. In the future there could be a gradual shift to direct methods,
since >50% of the general population has pre-existing immunity to one or more AAV
serotypes, preventing enrollment [32]. Therefore, improved direct delivery methods
would most likely be a better choice for these patients. It is conceivable that future
applications could include modifying the various driving parameters with a single injector
for angiogenesis products that require local delivery and a multiple injector array
adapted to supporting instrumentation for global delivery for heart failure applications.
Either approach could be further developed as an adjunctive or primary minimally
invasive surgical procedure, or along with microinjection devices with minimally invasive
endocardial delivery applications.
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CHAPTER 6
A Comparative Evaluation of Direct Injection Methodology: Liquid Jet Injection
Increases the Efficacy of Therapeutic S100A1 Expression in Limiting Ischemic
Myocardial Infarction

6.1 Introduction
Chapters 4 & 5 established the core bioengineering concepts and physical limits
for needleless liquid jet injection delivery of AAV therapeutics to the myocardium. Given
that the injections were well tolerated with excellent results in normal subjects, the
research focus then shifted to determine if whether or not the delivery profile could
rescue from ischemic myocardial infarction. The therapeutic selected for the study was
serotype 9 single stranded AAV S100A1 (ssAAV9.S100A1), which has been established
as a potent therapeutic in driving contractility and restoring cardiac function. As
discussed in previous chapters, AAV is the primary vector of choice in clinical trials
where long term therapeutic expression is desired. Therefore it was logical to evaluate
the direct injection methodology in an ischemic infarction setting with a gene that could
rescue from acute MI and restore contractility. This chapter describes a very thorough
evaluation of direct delivery methods and their outcomes with a potent transgene
encoded with a high quality vector. A key focus is placed on the quantitative aspects of
gene therapy, which are seldom explored in detail including genome copy number,
therapeutic induced protein levels, and finally a careful look into the immunological
aspects of direct delivery of AAV to the myocardium.

6.2 The S100A1 Target: Molecular Actions & Previous Studies
6.2.1 The multi-potent effects of S100A1
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The lead candidate in clinical trials at present is the AAV1.SERCA2a therapeutic,
which seeks to restore calcium handling through long term SERCA2a expression to
drive calcium handling in the sarcoplasmic reticulum in failing myocytes. As described in
Chapter 1, SERCA2a is further along the regulatory pathway; however the S100A1
target has certainly provided very intriguing results to date and is well positioned for
clinical trials. The S100A1 target is multi-faceted in aim, improving not only calcium
handling, but also shown to accentuate function in these areas: anti-apoptotic
mechanisms, mitochondrial energetics, structural protein binding enhancements and is
also hypothesized to have a role in directing regeneration [1].
S100A1 is a member of the S100 protein family, which represents the largest
group among EF-had Ca2+ binding proteins prevalent in vertebrates [2,3]. In addition to
vigorous effects on calcium handling, these S100 proteins have a variety of key
biological functions including but not limited to: cell proliferation, differentiation, survival,
motility, cytoskeletal dynamics, nitrous oxide homeostasis [4-6]. S100A1 expression is
the highest in the myocardium, with moderate levels found in the skeletal muscle,
kidneys and nervous tissues. Within myocardium, S100A1’s presence is only in
myocytes and not fibroblasts or endothelial cells, suggesting a prime role in contractility.
It has a role in both diastolic and systolic function through influencing both SERCA2a
and secondary calcium gating ryanodine receptor 2 (RyR2) as shown in (Figure 6.1) [710].
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Figure 6.1 Multi-target effects of S100A1 Protein
From detailed pre-clinical studies, it is evident that S100A1 has multiple binding
sites within the cytoplasmic domain featuring separate effector mechanisms in both
energetics and structural integrity of myocytes. With regard to energetics, S100A1 in
cardiac mitochondria enhances the effects of the enzyme mitochondrial ATP synthase,
which is the most important enzyme for ATP production. In addition to synergistic
activity with the synthase, S100A1 also works on the adenosine nucleotide translocator,
mediating exchange of ADP and ATP between the mitochondrial matrix and the
cytoplasm, thus increasing the availability of ATP for use [11-13]. Thirdly, S100A1’s
effects on myocyte viability via structural integrity have been documented through
activity on microfilaments. S100A1 has been detected and found to play a significant
role in the sarcomere unit. Periodically, it appears at the Z and the M line as well as
within the I and A bands [14-16]. The key function is within the I band, whereby S100A1
interacts with a very large integral structure protein titin. Titin has a key role in cardiac
mechanics, specifically with the preservation of passive tension in myocytes [16].
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6.2.2 Previous Results from Animal Studies
The first attempts with S100A1 overexpression were with an adenovirus vector in
a rodent heart failure model via coronary infusion at 12 weeks. The study reported
reversal of post ischemic deterioration and preservation cardiac function [17]. Serial
studies in swine led by Dr. Patrick Most revealed S100A1’s clinical potential both with
AAV6 and AAV9 serotypes, demonstrating high expression levels and rescue from post
MI [18,19]. Summarizing, it is anticipated that S100A1 gene therapy for ischemic
cardiomyopathy will gain significant traction moving toward a Phase I trial in the next 1-3
years.

6.3 Methods & Materials
Protocol Summary
32 rats received a baseline echo and infarct creation via left anterior descending
artery (LAD) ligation and were divided into 4 separate groups (n=8 ea.): 2 Control
consisting of, Needle injection (IM) and Liquid Jet Injection (LJ), both receiving equal
amount of saline and 2 Experimental consisting of, IM and LJ each receiving 1.2x1011
vg of ssAAV9.S100A1. IM injections were performed with three separate 100uL in the
left ventricle with a 30G needle, while the LJ device fired three separate 100 µL
injections projected at the exposed left ventricle from 25 cm above the thoracotomy.
Following 10 weeks, the rats were evaluated with echocardiography for LV function,
Masson’s Trichrome staining for infarct area, QPCR for AAV9.S100A1 genome
detection, and IHC staining for S100A1 protein. In addition to function and therapeutic
endpoints, host response assessment was conducted on 10 week blood and cardiac
tissue specimens via cytokine panel and the CD38 immune marker.
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6.3.1 Echocardiography Procedures
All rats were subjected to baseline and follow up 10 week post myocardial
infarction echocardiography as follows. Rats were induced and maintained with 1-5%
isoflourance and placed supine on a surgical table. The VisualSonics Vevo5000
Echocardiography small animal unit was utilized to capture all images. Briefly, 1.7 – 2.2
cm depth, 15-20MHz frequency, 60-70% Gain, and other visual parameters were
adjusted for optimal view. Long axis and M-mode views to assess ventricular wall
motion score were obtained for each animal. 3 individual data sets were acquired and
averaged for 1 overall score set reported for each animal. This ensured minimal
variability per run, an example is shown in (Figure 6.2).

Figure 6.2 Echocardiography of Left Ventricular Function
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6.3.2 Surgical Procedures & AAV Delivery
An SP02, Harvard Apparatus Ventilator, and ECG devices were calibrated prior to
surgery. Following induction and intubation, all rodents were placed in the left decubitus
position and prepared for a mini left thoracotomy while under complete monitoring of
heart rate, ECG, SPO2 and respiratory parameters. The heart was exposed and the left
anterior descending artery was identified. The mid line of the artery was marked with a
surgical pen, then 7.0 prolene sutures were used to ligate the artery. Infarct creation
was confirmed by both discoloration and ECG changes. Following infarction, each
animal received 3 separate 100µL injections of either saline or ssAAV9.S100A1
therapeutic by either IM injection or the Liquid Jet. All animals were recovered and
monitored until the 10 week endpoint. The heart was harvested, with myocardial cross
sections and individual samples prepared for assay testing.
6.3.3 Quantitative Real Time Poly Chain Reaction (QPCR) of ssAAV9.S1001
Genome
All servicing was performed blinded by the Molecular Profiling Core at the
Cannon Research Center. Three separate cardiac zones were harvested from each
animal: Anterior Wall, Borderzone, and the Lateral Wall. The liver organ was selected
as the primary endpoint target to quantify systemic exposure and was also collected for
each animal. Once samples were transferred to the facility a routine protocol with
robotic instrumentation was used for processing. Briefly, whole DNA was isolated from 3
left ventricular and 1 collateral organ liver specimens using the Chemagen MSM1 kits to
set up the QPCR assays for viral AAV9.CMV.S100A1 DNA. To examine the expression
of S100A1, customized kits designed by Abiomed Systems generated the S100A1
primers and then laboratory equipment was prepared to execute the experiment. The
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level of ovine GAPDH DNA was used to calculate normalized expression with the ΔΔCt
method to obtain QPCR values. Absolute genomic copies of S100A1 DNA were
quantified with the standard normal curve built from serial dilutions. Data was reported
as number of viral genome copies (GC) per 100 ng of whole DNA. Data analysis was
performed for each delivery group combining data from all 3 cardiac zones, with the liver
scored separately. All samples reported out of range, either undetectable at the limit of
transfer or those >100,000 GC per 100 ng DNA were removed from the analysis.
6.3.4 Histology Protocols: Quantitative S100A1 Protein Analysis in Myocardial
Cross Sections via Immunohistochemistry with Confocal Microscopy & Masson’s
Trichrome Staining for Infarction Area
6.3.4.1 Quantitative S100A1 therapeutic protein levels in myocardium
Samples of Rat Heart Tissue
Sections were prepared from formalin fixed and paraffin embedded heart tissue blocks.
All Immunofluorescence staining, image processing, and quantification were performed
by the CaresBio Resources Inc. (Shelton, CT) service provider in a blinded manner.
Immunofluorescence (IF)
Immunofluorescence staining was performed on tissue samples. Briefly, slides
were subjected to heat induced antigen retrieval in citrate buffer (pH 6.0) and or in
proteinase. Slides were incubated for 1 hour/ overnight with primary antibodies CD38,
S100A1), after blocking with nonspecific antigenicity blocker. Corresponding fluorescent
conjugated secondary antibodies were applied for 1 hour at room temperature. 4, 6 Diamidino-2-phenylindole (DAPI) were included with the secondary antibodies to
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visualize nuclei. The staining, imaging and image analysis were performed by CaresBio
Laboratory, LLC (Shelton, CT, USA).
Image Acquisition and Analysis
Briefly, slides were scanned using a customized, computer-controlled
microscope (with xy-stage and z controller) a Zeiss LSM780 confocal microscope (Carl
Zeiss GMBh, Jena, Germany) with ×40 and X20 objective. Every case had 32 images
including 16 images per section. Images were analyzed using an image analysis
software based on MATLAB (R2011b, MathWorks), developed by CaresBio Laboratory.
The final result is the average of 32 images per case what was compared with average
baseline to calculate times of increase. Image analysis algorithms were applied to the
images generated from microscopic slides of tissues stained with secondary antibody
and isotype controls to generate the background score. Control/Baseline was used to
generate the algorithm to differentiate between the signals and signal to noise ratio. The
same algorithm has been applied to all the images. This provided the option for
separation of single stained only areas-and double/triple-stained areas from secondary
only and or- isotype only stained areas by means of subject specific thresholding. A
good separation of single- and double-stained pixels from secondary antibody only and
or isotype control (background) stained pixels was achieved. Automatic background
subtraction was performed. Significant differences in relative areas stained and mean
specific intensity for the stains between control and treatment groups in rat tissue were
calculated.
Quantitative analysis of the IHC cross sections stained for S100A1 was
performed with confocal microscopy detection and normalization to untreated controls to
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remove the effect of endogenous levels. A 32 array grid, featuring 8 randomn but
separate zones defined in the anterior, lateral, posterior and septal wall regions were
obtained for analysis at 20x magnification. (Figure 6.3) best characterizes the method,
whereby the yellow squares represent individual regions of interests zoomed out at 4x
magnification. A composite overall expression score normalized to control (i.e. 1.0
background endogenous S100A1) was computed for each animal.

Figure 6.3 Quantitative Proteomic S100A1 Methodology Featuring IHC &
Confocal Microscopy; 32 individual zones (YELLOW) throughout the
myocardium were analyzed

6.3.4.2 Masson’s Trichrome Staining for Infarct Size Characterization
Formalin fixed paraffin embedded tissues were sectioned at 4 microns on a Leica
RM2125 microtome, picked up on Plus slides and air dried overnight. Slides were then
baked in a 60 degree oven for 20 minutes to remove excess paraffin before being
deparaffinized and with xylene and rehydrated with several changes of graded alcohol to
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distilled water. H&E sections were stained with Mayer’s hematoxylin for 20 minutes,
rinsed with running tap water and stained with Eosin Y for 5 seconds followed by several
rinses in 95% alcohol. Masson’s Trichrome slides were stained with Weigert’s Iron
Hematoxylin for 10 minutes followed by a rinse in tap water. The rest of the staining was
done with a Masson’s Trichrome kit purchased from Polyscientific (Bay Shore, NY cat#
k037 ). The slides were then dehydrated with several changes of graded alcohol and
cleared with xylene before being coverslipped with Permount.
6.3.5 Host Response to S100A1 Gene Therapy
The IM route has documented evidence of inducing both inflammatory and
adaptive immune responses that can dramatically reduce efficacy and lead to poor
outcomes. As described in the previous chapters a significant aim of the dissertation
presented was to investigate these both in the myocardial tissue and global response via
blood testing. The analysis was divided into two subparts, cardiac tissue and whole
blood.
Cardiac Tissue Immunohistochemistry for CD38 Expression
The CD38 protein is a marker of cell immune activation, specifically described at
the crossroad of innate and immune activation [18]. The same preparation of tissue and
quantitative methodologies described in section 6.3.4 were utilized, except with an antiCD38 antibody obtained from AbCam Scientific.
Whole Blood Cytokine Panel
This analysis was utilized to obtain a clear picture of the host’s global
inflammatory profile at 10 weeks post myocardial infarction and gene delivery. Analyte
concentrations were measured and quantitated using a Bio-Plex Suspension Array
System (Bio-Rad, Hercules, CA, USA). A Bio-plex multiplex premixed rat cytokine,
chemokine and growth factor panel was used. Analytes including EPO, G-CSF, GLP-1,
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GM-CSF, GRO KC, IFN-ɣ, IL-1 α, IL-1ß, , MCP-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL12p70, IL-13, IL-17A, IL-18, M-CSF, MIP-3α, RANTES, TNF-α, and VEGF were
examined. These assays use color-coded bead sets, each of which is conjugated with
analyte-specific antibodies and designed in a capture sandwich immunoassay format.
The samples were diluted using with the supplied diluent as directed. The antibodycoupled beads were mixed and incubated with diluted plasma samples, or with the
standards. Thereafter, unbound proteins were removed by washing in the Bio-Plex Pro
wash station (Bio-Rad) and a biotinylated detection antibody was added to the beads.
Each captured analyte was detected by the addition of a reporter molecule, streptavidinphycoerythrin. The contents of each well were drawn into the Bio-plex array reader (BioRad) where precision fluidics align the beads and lasers excite them in order to
quantitate the captured analytes. Analyte concentrations were automatically calculated
with Bio-Plex Manager software by using a standard curve derived from the recombinant
standard provided with the assays. A key focus was placed on these markers which
were more relevant for the particular analysis of innate and adaptive immune response
following gene therapy: IFN-ɣ, IL-1α, IL-4, IL-6, IL-10, IL-17, RANTES, TNF-α.

6.4 Results
6.4.1 Operative & Delivery Results
The overall survival rate from induction to 10 weeks endpoint was 93%. A limited
number of animals (n=3) were lost during infarct creation and replaced such that each
group tallied at least (n=8). The IM injections were tolerated without major incidence, but
minor bleeding events were noted and managed appropriately. The liquid jet injections
were also tolerated without any major incidence, although some minor bleeding and
discoloration in the impacted area was noted as in previous studies with this method.
6.4.2 Echocardiography Measures of Cardiac Performance
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(Table 6.1) below summarizes all major data obtained to determine left ventricular
function in addition to global left ventricular remodeling parameters associated with the
progression following ischemic myocardial infarction.
Table 6.1 Echocardiography and Outcome Data for ssAAV9.S100A1

Single way ANOVA revealed no significant difference in any data point at baseline.
However, as expected the effects of both the infarction and potential therapeutic action
of S100A1 led to a number of differences observed at the terminal 10 week post MI
point. First confirming model behavior, all 4 groups exhibited an increase in LV
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remodeling points, all * p<0.05 for: End Diastolic and End Systolic Indices, Ejection
Fraction, 2D Epicardial Area and a decline in LV wall thickness suggestive that the
ischemic MI induced these changes. These are consistent results and provide solid
evidence that the infarction promoted the typical dysfunction and compensatory changes
following the initial myocardial insult at time zero. Second, as compared in order with
the [IM Saline] ; [Liquid Jet Saline] and [Liquid Jet-S100A1] groups, the IM-S100A1 had
a more progressive remodeling course suggestive of more severe LV dysfunction with
End Systolic Volume Index at [1.0±0.2 µL/cm2] vs. [0.7±0.2 µL/cm2] ; [0.7±0.1 µL/cm2]
and [0.5±0.1 µL/cm2] respectively and greater End Diastolic Index at [1.7±0.2 µL/cm2] vs.
[1.2±0.2 µL/cm2] ; [1.3±0.1 µL/cm2] and [1.3±0.2 µL/cm2] respectively. These data points
did not pass the single way ANOVA, however two key points did, Ejection Fraction and
Global Myocardial LV thickness.
The Liquid Jet-S100A1 preserved the most baseline function at [60±3]% and was
greater p<0.01 than the other 3 groups in terms of overall performance; IM Saline
[47±3]%, Liquid Jet [46±3]% and IM-S100A1 [43±4]%. There was a much greater
degree of structural integrity in the treated Liquid Jet S100A1 group with a greater
overall wall thickness p<0.05 [1.5±0.1 mm] versus all 3 other groups.
The infarct sizing characterization yielded very striking results. In support of the
functional data, The IM-S100A1 exhibited extremely profound deterioration in the left
ventricular cross sections. The infarct size in this group revealed a much greater
affected zone [40±4] %, p<0.05 area versus the IM Saline [33±6]%, Liquid Jet Saline
[20±6]% and Liquid Jet S100A1 [17±5]%. (Figure 6.4) depicts the extreme, featuring a
typical IM S100A1 (A) compared with a typical Liquid jet S100A1 (B).
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Figure 6.4 Masson’s Trichrome Staining for Infarct scar at 10 Weeks: (A) Typical
IM gene therapy animal with large (blue) infarct zone while the Liquid Jet therapy
group (B) demonstrated much lower scar and thicker myocardium
The Liquid jet S100A1 group overall had the lowest scar size, which was not expected
but intriguing. Overall, there was a clear difference between the delivery groups with the
same therapeutic dosing/gene strategy thus confirming the method was the difference in
outcome both in terms of function and LV integrity.
6.4.2 Quantitative PCR Detection of AAV9.S100A1 Therapeutic DNA
The analysis was divided into two major anatomical zones. The first was the
Cardiac zone comprised of 3 harvested sites per animal (Anterior Wall, Borderzone,
Lateral Wall) to determine the degree of therapeutic transfer (i.e. 8 animals by group x 3
specimens = 24 Cardiac). The second collateral liver (i.e. 8 animals by group x 1 liver
specimen = 8 Liver).
The IM S100A1 group demonstrated robust detection in all 32 cardiac and liver
specimens, however 10 were greater than 100,000. This suggests that there was very
high focal expression in the myocardium and a high degree of systemic exposure in the
liver as found in the Chapter 5 marker study. After the removal of these outliers, the
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overall cardiac zone score for the IM group was [13128±2774] GC per 100 ng DNA,
while the systemic liver score was significantly higher p<0.05 at [65051±15836] GC per
100 ng DNA.
The Liquid Jet S100A1 group on the other hand demonstrated an overall lower
score in terms of focal expression as 14/32 specimens did not have detection, however
those that did scored in the range (n=10), but lower than the IM group at [10147±3572]
GC per 100 ng DNA. The collateral liver analysis revealed minimal detection [40±40],
with two samples with readings near zero. (Figure 6.5) summarizes the data by delivery
method. For assay validity, non-therapy controls were run and yielded undetectable
readings (data not shown).

Figure 6.5 Quantitative PCR Results: IM-S100A1 Group (Red) Demonstrated
significantly higher detection in the Liver, while the Liquid Jet-S100A1 group
(Green) was more cardiac specific with higher detection in the heart.

These results confirm what was found in the Chapter 5 marker study: (1) IM
delivery results in highly focal levels of viral mediated expression (2) Inadvertent infusion
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and or in combination with poor myocardial retention occurred resulting in lower cardiac
specificity. The greater cardiac specificity of the liquid jet is most likely attributable to the
tuning of the jet properties, whereby microjet penetration is sufficient enough to
perforate, but remain in the myocardium with reduced volume entry into the left
ventricular cavity. Although not confirmed with additional biodistribution testing, there is
most likely collateral residual expression in the thoracic and adjacent lung tissues with
the liquid jet’s dispersion and impact effects.
6.4.3 Quantitative Myocardial S100A1 Proteomic Levels & Confocal Microscopy
The overall proteomic S100A1 detection assay utilizing advanced confocal
microscopy applications featuring immunofluorescent detection yielded more detailed
findings beyond viral mediated detection. Two key findings were overall fold higher
expression and a difference in distribution per method.
In terms of overall S100A1 expression as measured by normalization to saline
controls [1.0±.05], both the IM [5.0±0.1] and Liquid Jet [4.3±0.1] gene therapy groups
yielded dramatically higher fold S100A1 in S100A1 Fluorescence Intensity Fold Ratios.
As expected, AAV9 mediated viral vector transfer of S100A1 raised baseline levels and
or restored depleted S100A1 reserves lost in ischemic MI. Another key finding inline
with QPCR data was that the IM had roughly 1 fold greater overall S100A1 gene
expression (Figure 6.6).
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Figure 6.6 Quantitative Proteomic Analysis: Both IM-S100A1 and Liquid Jet
S100A1 groups yielded significantly higher fold overall S100A1 in the
myocardial cross sections at 10 Weeks. IM scored higher as compared with
Liquid Jet, all p<0.05.

Due to the variability inherent with both delivery and the ischemic model, a logical
fixed 32 zone sequences was utilized to determine overall expression, but the overall
score does not address the problem of heterogeneous expression as found previously
with the IM group.
In an effort to characterize the degree of S100A1 expression per zone, the
standard deviations derived per animal resulting from the 32 individual zones were
analyzed. It was found, as expected, that the Liquid Jet had a more homogenous
S100A1 as measured by a lower variability score in the S100A1 expression profile
[13.5±1.5] versus the IM group [20.1±0.5], p<0.05. (Figure 6.7)
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Figure 6.7 S100A1 Expression Variability. IM Injection results in a higher
degree of variation in the myocardium following after analyzing the standard
deviation in the 32 zones per animal.

The confocal microscopy images verified these findings with vibrant images indicating
the degree and distribution pattern of S100A1 expression typically found by route
(Figure 6.8). These are depicted in the figure below.

Figure 6.8 Confocal Microscopy Images: Cross sectional myocardial S100A1
expression (maroon) with labeled nuclei (blue) by route: (A) IM Injection (B)
Liquid Jet Delivery. Liquid Jet has a less intense, more disperse pattern of
expression as compared with IM.
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6.4.4 Host Responses to Direct ssAAV9.S100A1 Expression
Given the dramatic difference in outcome between the delivery groups, as
asserted in this dissertation as well as compelling evidence suggests that highly focal
cardiac expression may contribute to triggering maladaptive immune responses. The
host response was approached from both a local tissue inflammatory CD38 marker in
part A, and a complete physiologic cytokine panel B. Part A seeked to determine local
risk profile for an adaptive T cell mediated immune response via CD38 activation, while
B sought to determine if the immune system was activated via evidence of elevated
cytokines.
6.3.4A The CD38 Inflammatory Marker
Given the difference in both LV performance and cardiac structure, it was
anticipated that the IM-S100A1 group suffered from the compounded effects of
myocardial infarction in addition to a host response. Both groups experienced a
significant level of CD38 expression throughout the myocardial cross section against
Control specimens [1.0±0.03]. The IM-S100A1group [7.2±0.8] was nearly twice as high
as the Liquid Jet-S100A1 group [3.8±0.2] in CD38 Fluorescence Intensity Fold Ratio
(Figure 6.9).
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Figure 6.9 Pro-Inflammatory CD38 Marker Expression reveals significant fold
higher presence
bothGlobal
the Liquid
jet and IM groups
*p<0.05.
6.3.4B
The WholeinBlood
Pro-Inflammatory
Cyotkine
Panel The magnitude
was nearly 2 fold higher in the IM group †p<0.05 suggesting a higher degree of
The
cytokine
results are clearly summarized in (Table 2) with a number of key findings.
immune
activation.
Table 6.2 Pro-Inflammatory Blood Cytokine Data at 10 Weeks Post MI

CYTOKINE:
IL-1α
CCL5 (RANTES)
TNFα
IFNγ
IL-4
IL-6
IL-12

BLOOD LEVELS [picograms/mL]
Controls
IM - S100A1 Liquid Jet - S100A1
113±29
156±22
124±26
79±15

319±127*
262±55*
256±50*
242±77*

197±21
211±29
189±94
54±11

37±8
46±11
54±14

67±22
136±65
105±49

28±4
109±95
39±13

* p<0.05; AAV.S100A1 Delivery Group vs. Saline Controls
The IM-S100A1 group exhibited a significantly higher amount of a variety of key
circulating pro-inflammatory cytokines involved in innate and adaptive immune
responses. These were IL-α, CCL5 (RANTES), TNFα, and IFNγ. Higher trends were
also noted with IL-4, IL-6 and IL-12.
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Thus, both inflammatory signals were found in the cardiac zones and the
peripheral blood system indicating the AAV mediated gene therapy via direct injection
induces a number of responses. It is clear that these responses, inline with the poor
outcome data, were more profound in the IM group.

6.5 Discussion
The results from this study solidify key points identified in the Chapter 5 marker
study. Major novel contributions include revealing some key risk factors for direct AAV
mediated gene therapy post myocardial infarction. First, all of the major principles of
liquid jet injection were re-affirmed in this study with a bona fide AAV9.S100A1
transgene vector platform, namely:
•

Liquid jet can achieve a disperse, long term gene expression profile in the disease
setting of acute myocardial infarction

•

S100A1 is a robust transgene that promotes long term rescue of myocytes in the
ischemic MI setting.

•

A homogenous expression profile similar to infusion approaches is possible

•

Liquid Jet Injection more cardiac specific than IM since optimized settings control the
degree of penetration into higher risk areas (i.e. left ventricular cavity)

•

Synergistically, a cardiac specific, homogenous gene expression profile and minimal
collateral organ expression is at much less risk for host responses
Reflecting these key points above in the context of this rodent study, Liquid Jet

injection results achieved a disperse, cardiac specific S100A1 profile compared with the
heterogeneous profile of the IM route. The conclusion that delivery with
ssAAV9.S100A1 therapy is more efficacious with the liquid jet route is more than justified
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given the compiled data sets. The difference in ventricular function, geometry, and
disease burden were dramatically different between the treatment groups. The IM
S100A1 group suffered deleterious effects in the left ventricle leading to poor outcome,
most likely attributable to an adaptive immune response that exacerbated left ventricular
remodeling, despite seemingly adequate levels of S100A1 overexpression. In particular
the infarct size measurements were striking, whereby nearly double affected zone was
found between groups. The non-homogenous expression profile as found in the
proteomic analysis in combination with much higher levels of systemic exposure via
QPCR data are more than likely the causes.
In essence, there were 3 main stimuli events in this model that factored into the
clinical outcome and host responses found at 10 weeks: A. Induced Myocardial
Infarction B. Injury from Delivery C. AAV mediated S100A1 expression and D.
Inflammatory risk factors. The interaction of all 4 of these determined the outcome per
group. A goal of this dissertation was to determine the relationships. With respect to
infarction it is understood that there is inherent variability in any given ischemic model,
however it is very unlikely that variation alone in this category factored in the outcome
based on robust numbers in each group.
With respect to injury, it was beyond the means of this particular study to determine
the level of injury at the cellular level per route, especially in the context of acute MI.
However despite this key limitation, a few points can be introduced for future discussion.
It has been challenged by this dissertation that one of the advantages of Liquid Jet
injection is that it is safer than the IM route. This was visually evident in the surgeries,
whereby less bleeding was noted with the jet injections which only left visible welts on
the epicardial surface. As asserted previously, any given delivery method results in a
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level of injury, but the degree of injury is paramount to consider in the actual delivery
application.
Numerous studies have made the case that host inflammation resulting from delivery
itself can result in aggressive adaptive immune responses against AAV mediated
transgenes [19]. While the immunological possibilities are complex, it is logical to
conclude there is a synergistic role of delivery in an already inflammatory post MI
environment. Although not supported with additional data, it was very intriguing to find
that the Liquid Jet Groups (treated and untreated) had smaller infarct zones overall.
This observation would counter an argument that the system is more deleterious alone
versus IM injection.
Additional insight for future studies with S100A1 or AAV mediated products is the
degree of overexpression. The CD38 inflammatory expression data indicates that
greater expression levels increase the risk for maladaptive immune responses. In this
case study, it appears that delivery route, more than the vector/transgene with direct
injection contributed to the poor outcome in the IM group, but these factors may have
different relative significance with other vector/transgene systems. In general, numerous
gene therapy studies selecting the IM route have confirmed that very little successful
transfer and or reactions occur in damaged muscle [20]. Similar problems, but to a
lesser extent, have been found in Hemophilia trials, whereby infusion of the same AAV
dose in the liver was much more efficacious than IM delivery [21,22]. Thus, the case for
liquid jet injection for cardiac gene therapy applications with AAV product is solidified.
Expanding on the discussion of adequate expression levels, optimal gene therapy
treatment would utilize the minimum amount of vector such to achieve therapeutic
expression in the myocardium. From the standpoint of adequate expression levels, it
was interesting to note that despite very high S100A1 expression as measured by both
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QPCR and proteomic analysis, the IM S100A1 was spiraling down the path of chronic
heart failure. The Liquid jet group on the other hand despite a fold lower, was
efficacious. It is asserted by this dissertation that the difference can be found with the
host response, in that once the responses drive beyond a threshold to complete
systemic activation the therapy itself becomes toxic.
Summarizing, these results communicate an important concept that there is most
likely a delicate balance between successful therapy (i.e. tolerance) with AAV mediated
products versus complete immune activation. The conclusions in this study assert that
outcome can most definitely be mitigated with route, vector and dose selection. The
next two Chapters 7 and 8 are dedicated to exploring additional options in navigating this
balance. Chapter 7 repeats the study design as presented in this chapter, except with a
double stranded AAV9 vector.
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CHAPTER 7
Alternative Strategies for Enhancing Direct Myocardial Gene Delivery in Ischemic
Myocardial Infarction: A Case Study Featuring Self Complementary Vector

7.1 Introduction
The previous chapter revealed some key findings with the use of
ssAAV9.S100A1 therapy through two different direct routes of administration. Despite
the strong compelling case for Liquid Jet Injection as the superior route and the
confirmation of multiple host responses in the IM group, there was no conclusion on
whether or not it was the intensity of the expression profile, vector capsid interactions, or
high systemic exposure that caused the aggressive host responses in the IM group.
Given that both groups had a high expression profile in terms of cross sectional area and
intensity, it would appear less likely that S100A1 was the problem given the discrepancy
in outcome at 10 weeks. As described in previous chapters, AAV infection imposes risks
to the system that have been acknowledged in the field for decades, but more recent
studies have elucidated the means [1].
In particular with AAV in muscle, a diagram model of the host response is
presented below in (Figure 7.1). Numerous studies have unraveled more detailed
information on the risks of AAV mediated gene therapy in terms of host response. In
order to improve clinical outcomes, one major goal the field is focusing upon is
correlating the upfront risks of delivery with systemic priming, whereby ultimately the
immune system tips into therapeutic tolerance or mounts a response. It is believed that
understanding these interactions throughout the process of therapy can mitigate the
risks.
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Figure 7.1 Host Response model depicting the difference between tolerance
and immunity. Multiple signaling events contribute to adaptive immune
response through antigen recognition (Signal 1), Co-stimulation (Signal 2) and
the production of systemic inflammatory markers (Signal 3).
AAV is less immunogenic than adenovirus because it avoids directly interacting
with and transducing antigen presenting cells. However, in the presence of inflammation
or when systemic exposure penetrates a threshold, these key cells can be activated
against both AAV and transgene antigens and or signals derived from the cells that
contain them [2].
In our case study example presented in Chapter 6, it is very likely the IM S100A1
group with single stranded vector suffered a deleterious TH1 adaptive immune response
since the risk factors were present, recapitulating: (1) High levels of IFNγ, TNFα in the
blood (2) CD38 markers all present in higher proportion versus the other 3 groups (3)
Inflammation from both infarct and delivery events were present at time zero and
beyond. Not shown in the diagram is the contribution of early inflammation, dubbed
Signal 0, which has a role in determining whether or not Signal 2 occurs.
Given that ischemic myocardial infarction and subsequent therapeutic target areas are
very high risk, this Chapter describes an alternative vector strategy, the self123

complementary AAV9 vector or double stranded DNA vector which has several
advantages over the single stranded version.
One of the key advantages of S100A1 besides its potent effects is its transgene
cassette size at only 330 base pairs (bp). The cloning capacity of AAV cassette is only
4,440 bp total, however much of the space is designated for the inverted terminal
repeats, promoter and other elements, thus limiting transgene packaging to around 3100
base pairs. Therefore other transgenes over a certain size such as SERCA2a could
never be packaged into a double stranded vector. The double stranded vector has two
key advantages that might increase performance in higher risk myocardium.
The first advantage is leveraging the key molecular biological advantage double has
over single stranded versions that is skipping the DNA template conversion step.
Described briefly here since vector engineering is beyond the scope of this
research, all AAV viruses package single stranded DNA sequence cassettes that must
first convert to double stranded DNA. This step precedes which precedes therapeutic
expression and if conversion fails so does the therapy. Self-complementary vector was
developed to address the key rate limiting step of single stranded DNA to double
stranded after the virus successfully transfects a cell. This process of template
synthesis was which was once thought highly efficient, however key studies and
applications in clinical scenarios prove otherwise [3,4]. Furthermore, even after
successful template synthesis conversion, studies have reported instability events
whereby the newly converted strand is degraded rapidly in vivo, negating any
therapeutic potential of the original transfection [5].
The second hypothesized advantage, although controversial and one point this
research seeks to determine is whether or not double stranded vector with the same
dose/transgene should be less inflammatory. Single stranded DNA infections have a
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long established research track record with vaccinations, or induced immune responses
[6]. The following logic is that within inflammatory environments and or high
concentrations of product (i.e. vaccination delivery), this would increase the risk of an
adaptive response.
Supported by a solid body of evidence, the double stranded vectors because of
these cited reasons leads to both faster and higher levels of gene expression in muscle
[7]. One study in rodent hearts reported 10 to 15 fold higher copy number vector
transfer along with a more robust marker gene expression profile [8]. This study cited
the concept of a saturation point, whereby maximum possible copy number increased
with local injection but reached an upper limit in terms of actual cellular transduction
Therefore, this Chapter 7 was dedicated to exploring the concept of using the
same gene therapeutic intervention, however constructed with a self-complementary
vector. The central hypothesis challenged is twofold:
(1) That for one or both routes of direct injection, self-complementary vector would offer
increased expression levels and similar or better outcome at 10 weeks post MI
(2) Due to eliminating the conversion step risk factor, the therapy overall would be less
inflammatory

7.2 Methods & Materials
7.2.1 Protocol Summary
20 rats received a baseline echo and infarct creation via left anterior descending
artery (LAD) ligation and were divided into 2 separate groups (n=10 ea.): 2
Experimental consisting of, IM and LJ each receiving 1.2x1011 vg of scAAV9.S100A1.
IM injections were performed with three separate 100uL in the left ventricle with a 30G
needle, while the LJ device fired three separate 100 uL injections projected at the
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exposed left ventricle from 25 cm above the thoracotomy. Following 10 weeks, the rats
were evaluated with echocardiography for LV function, Masson’s Trichrome staining for
infarct area, QPCR for AAV9.S100A1 genome detection, and IHC staining for S100A1
protein. In addition to function and therapeutic endpoints, host response assessment
was conducted on 10 week blood and cardiac tissue specimens via cytokine panel and
the CD38 immune marker.
Essentially this study is a repeat of the previous Chapter 6, however featuring
delivery of only scAAV9.S100A1 vector. All echocardiography, surgical, animal
handling, and tissue harvest/analysis were as is the previous.
7.2.2 Grouping & Data Analysis
Previous data from the 2 control groups [IM Saline, Liquid Jet Saline] and 2
ssAAV9.S100A1 treatment groups [IM S100A1, Liquid Jet S100A1] were used to assess
various endpoints in comparison to the results presented in Chapter 5. Specifically, the
control groups were not repeated and used for reference to evaluate: LV mechanics,
S100A1 and CD38 proteomic expression normalization, and cytokine panels. The
genome copy detection via QPCR is however completely original.

7.3 Results
7.3.1 Operative & Delivery Results
One animal in each the IM group and Liquid Jet group was excluded due to
complications with either the MI or delivery, thus grouping IM scS100A1 (n=9) and Liquid
Jet scS100A1 (n=9) for the analysis. Delivery parameters were executed as in the
previous study without major incidence.
7.3.2 Echocardiography Results
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The key hemodynamic data from this follow up study are presented in (Table 7.1).
Table 7.1 Echocardiography and Outcome Data: scAAV9 Pilot Study

Data Point:
Weight [g]
Heart Rate [bpm]
End Diastoic Volume Index
End Systolic Volume Index
Ejection Fraction [%]
Epicardial 2D Area [cm2]
LV Wall Thickness [mm]

Data Point:
Weight [g]
Heart Rate [bpm]
[mL/cm2 ]
[mL/cm2 ]
Ejection Fraction [%]
Epicardial 2D Area [cm2]
LV Wall Thickness [mm]
Infarct Size [% LV Area]

IM - Sa.
409±21
355±12
0.6±0.1
0.2±0.03
71±2
0.7±0.1
1.5±0.06

BASELINE
Liquid Jet-Sa.IM - SC S100A1
406±32
373±14
346±9
343±13
0.7±0.1
0.5±0.1
0.2±0.05
0.1±0.02
68±2
72±1
0.8±0.1
0.6±0.1
1.4±0.05
1.4±0.04

IM - Sa.
587±16*
306±31
1.2±0.2*
0.7±0.2*
47±3*
1.4±0.1*
1.2±0.1*
33±6

10 WEEKS POST MI
Liquid Jet-Sa.IM - SC S100A1 Liquid Jet - SC S100A1
610±22*
581±13*
573±8*
317±9*
314±15*
309±13
1.3±0.1*
0.8±0.1*
1.3±0.2*
0.7±0.1*
0.3±0.1*
0.8±0.2*
60±2* †
57±4* †
46±3*
1.5±0.1*
1.1±0.1* † §
1.5±0.1*
1.2±0.1*
1.4±0.04* †
1.5±0.1 †
20±6
30±13
32±9

Liquid Jet - SC S100A1
336±24
318±13
0.7±0.1
0.2±0.02
70±1
0.8±0.1
1.5±0.06

* p<0.05; Baseline to 10 Weeks
† p <0.01; vs. Control Saline Groups
§ p<0.01; vs All Other Groups
There was no difference between the groups at baseline. At 10 weeks however,
the most striking results were found in the IM SCS100A1 group, whereby dramatic LV
functional improvement was found as compared to the single stranded data as found in
Chapter 5 Table 1. This group unlike the analogous with the single stranded, preserved
significant baseline function at [60±2]% and was found superior to both IM Saline [47±3]
and Liquid Jet Saline [46±3]%. This group also demonstrated the lowest degree of
global geometric LV remodeling changes with: (1) Lower 2D Epicardial Area [1.1±0.1]
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cm2 p<0.05, versus all other groups IM Saline [1.4±0.1] cm2, Liquid Jet Saline [1.4±0.1]
cm2, and the Liquid Jet SCS100A1 group [1.5±0.1] cm2. (2) Trending lower End diastolic
and End systolic dimensions. It is important to note however that this particular group
also started with lower indices, but the point is the difference in direction from the single
stranded group which dramatically worsened in the direction of chronic heart failure.
On the other hand, the Liquid Jet SCS100A1 group basically confirmed similar results
found in the previous study, with a significantly retention of LV functionl [EF+57±4%],
p<0.05 versus IM Saline and Liquid Jet Saline.
Structure wise, both treatment groups featured severe MI zones with IM
SCS100A1 [30±13]% and the Liquid Jet SCS100A1 [32±9]% LV affected area. Despite
these affected zones however, both treatment groups had greater average LV wall
thickness (IM SCS100A1 [1.4±0.04] mm; Liquid Jet SCS100A1 [1.5±0.1] than both IM
Saline [1.2±0.1] and Liquid Jet Saline [1.2±0.1], suggestive of rescue.
Summarizing, both the IM and Liquid Jet herapy groups in this pilot study evaluating
scAAV9.S100A1 were efficacious within study limits.
7.3.3 Quantitative PCR Detection of scAAV9.S100A1 DNA
The same methodology for analysis were that were used in Chapter 5 were also
applied here. The fold expression with the self-complementary vector was much higher
compared with the single stranded results in Chapter 5 (Figure 7.2). In comparison to
the single stranded vector results, there are a number of key points that can be drawn.
First, the large change in the magnitude of copy number in both groups was profound,
more so in the IM group as expected with the focal expression profile. The IM
SCS100A1 group presented with [304276±36753] GC per 100 ng DNA in the cardiac
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regions, but also had a distinctly higher presence in the liver that superseded all group
specimens tested at [665279±39818] GC per 100 ng DNA, p<0.01.

Figure 7.2 QPCR analysis revealed significantly higher transfer levels in both
the cardiac regions and collateral liver. The IM Group demonstrated
significantly higher expression * p<0.05 for both regions, with the liver
superseding † p<0.01 other tissues.

By comparison, the Liquid Jet (i.e. compared with IM SCS100A1) cardiac regions
had nearly 10 times less copy number, with [36753±5844] GC per 100 ng DNA.
However unlike the previous single stranded set, a sizeable amount was found in the
Liver at [39818±3246] GC per 100ng DNA.
Fold detection wise, the IM group experienced a roughly 23 fold increase in the
cardiac zones comparing double to single stranded vector transduction. The Liquid jet
likewise was 3.6 fold higher in the cardiac but ever more so in the liver at nearly 1000
fold. Recall there was minimal detection in the liver with the single stranded vector with
this route previously.
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Summarizing, double stranded vector in terms of transduction performed higher than the
reported target of 10-15 times fold in comparison to single stranded vector, but
particularly with the IM group the cardiac specificity is an issue.
7.3.4 Quantitative Cross Sectional S100A1 Proteomic Expression
Given the accentuated increase in copy number it was expected protein amount
would also increase with the self-complementary vector. This was true for both the IM
and Liquid Jet groups. The IM SCS100A1 group scored very high levels of
overexpressed S100A1 protein [8.8±0.3] S100A1 Fluorescent Units, in fact significantly
p<0.05 higher than the other 3 delivery/vector combinations (Figure 7.3).

Figure 7.3 The second iteration of S100A1 proteomic analysis revealed
significantly higher overexpression in all treatment groups * p<0.05.
Comparatively, both Self Complementary vector treatment groups scored
higher † p<0.05 than corresponding Single stranded groups. The IM-SC group
scored much higher overall than all others § p<0.05.
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The Liquid Jet SCS100A1 group reached [6.1±0.3] levels, higher than both single
stranded IM [5.0±0.1] and Liquid Jet [4.3±0.1].
Confocal microscopy images revealed what was found in the analysis at 20 times
magnification. (Figure 7.4) demonstrates the typical intensity in S100A1 expression
found when comparing single versus self-complementary vector results.

Figure 7.4 Representative image comparing single stranded versus selfcomplementary S100A1 expression (A) IM single stranded Group (B) IM selfcomplementary Group demonstrates higher S100A1 expression

7.3.5 Host Response to scAAV9.S100A1 Therapy
In line with both an increase in copy number and S100A1 protein detection,
CD38 marker also increased. As found in Chapter 5, the Liquid Jet SCS100A1 [8.0±0.3]
CD38 Fluorescent Intensity Units was significantly p<0.05 lower than the IM SCS100A1
which scored the highest at [10.7±0.5]. (Figure 7.5) plots the results.
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Figure 7.5 CD38 Expression trends higher inline with overall viral mediated
S100A1 expression. As found previously, overexpression of S100A1
increases immune signaling * p<0.05. The IM group as compared with Liquid
Jet was significantly higher † p<0.05.

Blood Cytokine Panel Results
(Table 7.2) summarizes the cytokine analysis determining the global immune effects of
self-complementary vector driven overexpression.
Table 7.2 Pro-Inflammatory Blood Cytokine Data at 10 Weeks Post MI: scAAV9.S100A1

CYTOKINE:
IL-1α
CCL5 (RANTES)
TNFα
IFNγ
IL-4
IL-6
IL-12

BLOOD LEVELS [picograms/mL]
Controls
IM - S100A1 Liquid Jet - S100A1
113±29
156±22
124±26
79±15

282±94*
257±34*
158±54
100±30

353±157*
325±86*
183±51
133±72

37±8
46±11
54±14

65±17
80±37
137±44*

42±9
92±62
209±88*

* p<0.05; AAV.S100A1 Delivery Group vs. Saline Controls
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Elevated profiles of IL-1α and CCL5 (RANTES) were found in both the IM and
Liquid Jet groups. There was however no major increase in TNFα or IFNγ as found in
the IM single stranded group that experienced an increase in all 4. Another unique
finding was that the double stranded results yielded an increase in IL-12, which was not
found previously. Based on these results, overall, it appears the double stranded vector,
despite much higher fold S100A1 expression, is less inflammatory for IM Injection. For
Liquid Jet Injection on the other hand, it appears more inflammatory but does not result
in poor outcome at 10 weeks.
In terms of outcome based on cardiac mechanics and host response, a penultimate
outcome overview is described in (Table 7.3).
Table 7.3 Compiled Outcome Results: ssAAV9 vs. scAAV9 Per Group

p

y

CARIAC FUNCTION PROFILE
GROUP

p

THERAPEUTIC PROFILE

HOST RESPONSE PROFILE

Function EF% Integrity LV WT LV Scar % S100A1 Fold Expression Myocardium CD38

Blood Cytokines

Liquid Jet S100A1

60±3%

1.5±0.1

17±5%

4.3±0.1

3.8±0.2 None

IM S100A1

43±4%

1.1±0.1

40±4%

5.0±0.1

7.2±0.8 IL-1α, CCL5, IFNγ, TNFα, IL-12

Liquid Jet SC-S100A1 57±4%

1.5±0.1

32±9%

6.1±0.3

8.0±0.3 IL-1α, CCL5, IL-12

IM SC-S100A1

1.4±0.04

30±13%

8.8±0.3

10.7±0.5 IL-1a, CCL5, IL-12

60±2%

7.4 Discussion
The two major limitations of this study are the single dose of 1.2 x 1011 viral
particles and the lone 10 week follow up timepoint. We will review the compiled data
within the context of these two limitations. Despite these constraints, the compiled
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studies do offer some very interesting concepts that can be explored for future direct
myocardial delivery studies featuring AAV mediated overexpression for ischemic MI.
Several key topics for discussion will be: the pharmacodynamic effects of viral mediated
S100A1 therapy by vector/route selection, saturation limits with the IM route regardless
of dose, and factors that elevate host response risk profiles.
As argued by this dissertation, the ideal direct delivery mediated gene treatment
paradigm for ischemic MI would do the following: (1) Transfect a sufficient % of
myocardium to rescue failing myocardium and simultaneously reduce disease burdened
cells in affected fibrosis area (2) Tip the host response in favor of tolerance rather than a
deleterious adaptive immune response (3) Minimize collateral overexpression in nontarget organs with an optimized direct route of administration. (4) As a function of (1), (2)
and (3) selection of the correct vector/dose that would achieve the objective within safety
limits. Essentially we argue that a solution is not likely an optimized vector construct or
the perfect device arrangement, but a systematic approach exploring the interactions
between them.
One key element of a systematic approach includes an understanding of the
pharmacodynamics of AAV mediated cardiac gene therapy. This has become a
significant area of interest, with a number of studies designed to elucidate the ideal copy
number required for an efficacious delivery profile or exploring relationships between
exposure and downstream expression levels [9]. In this study as in previous studies
[10], self-complementary vector at the same dose level and route results in dramatic
differences in: therapeutic viral DNA transfer, mRNA expression levels, and
subsequently therapeutic protein production. For IM delivery, our results demonstrated
a 23 fold difference with the same dose. For Liquid Jet, less dramatic, but still significant
elevated at roughly 4 fold. Thus, it is a reasonable conclusion that the same therapeutic
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benefit in our study could have been achieved with a lower dose of self-complementary
AAV given that only a 4 fold overall increase in S100A1 expression was found to be
efficacious in the ssAAV9.S100A1 Liquid Jet S100A1. Therefore, future dose response
studies including both vectors would reveal more important findings on kinetics.
These observations on the performance differences between the vector
constructs leads our discussion into two key directions with regard to dose/vector
selection when targeting failing myocardium. First, after breaching an inherent biological
capacity threshold, additional copy numbers may not provide benefit in terms of
additional therapeutic protein production and should be considered carefully. Secondly,
direct routes (i.e. whether IM, needleless microinjections) a cardiac muscle region via
saturation limit prior to inducing host response risks. This upper limit is analogous to
those that are sought with routine vaccinations, whereby a successful cardiac gene
therapy administration is the antithesis.
Expanding on the first point above, it was found that the overall fold protein
S100A1 ratio in the IM Groups (i.e. increase from 5.0 to 8.3 fold) did not correlate with
the 23 fold increase in DNA copy number, the basis for expression. This suggests
internally either the cells can only generate so much S100A1 protein from mRNA or
additional regulators exist. From a clinical perspective, this indicates an important
concept on a per gram myocyte basis scaled up to larger organisms. Therefore, it is
plausible that there is a suitable effective range of vector which in effect reaches the
biological upper limit, but does not provide benefit beyond that with increased copy
number. This range may depend on the health of the area, since diseased muscle areas
are more difficult to transfect [11], but ultimately an upper limit is reached readily with
direct injection methods since there are minimal barriers to circumvent as opposed to
transvascular delivery [12]. This study demonstrates that at least 2,000 – 10,000 copies
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per 100 ng DNA of encoded S100A1 DNA in rodent myocardium seemed to be sufficient
in rescuing from acute myocardial infarction with raising basal expression levels 4 fold.
Expanding upon the second major point, we and others assert that the same therapy
providing benefit beyond the window can dramatically increase the risk of host
responses. In our case studies this concept may have been realized even though two
groups were efficacious, but immunologically activated.
This concept was exemplified in this study with two very different vector
transduction efficiencies at the same dose level. The group with the highest cardiac
specificity was the single stranded Liquid Jet, the only group (Table 7.3) with both a
positive cardiac and host tolerance outcome measures. This group featured the lowest
overall fold S100A1 protein level by comparison with the other 3, but also had the least
host response as measured by CD38 and the systemic cytokines. It is very likely that
very minimal off target exposure in the liver reduced these risks given that delivery,
vector and dose variables were controlled.

However it is important to note when

switching to self-complementary vector this level in the Liquid Jet group increased nearly
1000 fold. Although striking and not in proportion with the IM group changes, this is
likely explained by the difference in single stranded genome conversion between in the
liver. In other AAV mediated gene studies it was found that liver cells have much more
difficulty with single strand synthesis likely explaining the results in our studies [5-7].
Therefore, collateral exposure is a function of both delivery and vector selection and
must be considered in risk assessment.
The most striking outcome discrepancy in the compiled results is clearly with the IM
route when comparing single versus self-complementary vector. It appears one
plausible conclusion is that the difference in outcome when comparing transduction and
protein levels with IM are: (1) the single strand to double strand conversion step is very
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inflammatory with a robust, heterogeneous IM expression profile and (2) Self
complementary vector has a significant time advantage in establishing vital expression in
the early post MI period.
As described previously, strong evidence supports the claim that the single
stranded genome conversion process in vivo after the viral nuclear docking step is not
without risk and can trigger immune activation. The difference between the IM and liquid
jet expression profiles established in Chapter 5 is spatial myocardial distribution. It is
reasonable to assert that the highly heterogeneous, overexpressed regions in muscle
containing unconverted viral origin single stranded DNA triggered the difference. The
liquid jet methodology essentially disperses this risk under a theorized immunological
threshold. The second intriguing explanation may be timing, whereby selfcomplementary has a key advantage in the early stage of acute MI. This is due to the
fact that self-complementary vector as designed delivers fully capable therapeutic DNA
that immediately generates S100A1 protein. Therefore, is very likely that in addition to
being less inflammatory, the scAAV9 vector generated efficacious levels much faster.
Due to the 10 week timepoint limitation, no conclusion can be made as to whether or not
any of the 2 efficacious groups with elevated risk profiles (Liquid Jet SCS100A1 or the
IM SCS100A1) would be remain so over time.
There are many studies that demonstrate efficacy for periods up to 3 months,
then show rapid losses of both therapeutic expression and outcome measures due to
aggressive immune responses. For this reason, a number of gene therapy trials have
actively acknowledged the risks of systemic exposure and inflammation by incorporating
immunosuppression in an effort to keep the host under the critical threshold of immune
activation [13].
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Summarizing, outcome is a function of the efficacious target expression balanced
by the risk of delivering the sufficient vector payload to reach a stable range, yet not
breach tolerance. Host response problems are clearly identifiable when doses are
dramatically increased beyond a range such that therapeutic outcome has saturated or
systemic exposure becomes too high.
This study illustrated these concepts and support further temporal experiments
with additional vector configurations, whether self-complementary or those with different
promoters/transgenes etc. Chapter 8 explores a means to reduce the host response
risks upfront with a combination drug/gene therapy concept. It is anticipated that the first
critical post AAV delivery window has a major role in determining therapeutic benefit.
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CHAPTER 8
A drug/gene combination strategy to enhance direct myocardial AAV delivery
Adapted from: Fargnoli AS, Mu A, Katz MG, Williams RD, Margulies KB, Weiner DB, Yang S,
Bridges CR. Anti-inflammatory Loaded Poly-Lactic Glycolic Acid Nanoparticle Formulations to
Enhance Myocardial Gene Transfer: An In-Vitro Assessment of a Drug/Gene Combination
Therapeutic Approach for Direct Injection. J Transl Med. 2014 Jun 16; 12(1):171

8.1 Introduction
Acquired heart disease from myocardial infarction (i.e. heart attack) remains the
leading cause of mortality and morbidity worldwide, with 22 million new patients
diagnosed annually. Essentially, all approved pharmacologic and device systems
impose significant cost burden to the health system, yet fail to increase survival rates. [13] Cardiac transplantation, which is the gold standard for patients, will never meet the
clinical demand due to the chronic shortage of viable donors [4,5]. Therefore, new
therapeutic approaches to manage the disease burden represent a significant unmet
need. Recently, sophisticated molecular profiling tools combined with a deeper
knowledge base derived from disease models have ushered in a new era of
biopharmaceutical development for heart disease. This has resulted in the development
of a more potent class of therapies designed to act at the myocyte level, whereby
therapeutic action is achieved primarily through DNA, RNA and or microRNA genetic
reprogramming. [6]
Various gene therapy concepts have been applied successfully in animal models
demonstrating increased contractility, repaired myocardium, and or regenerated new
vessels to reduce myocardial infarction reoccurrence. [7-10] Independent of the
targeted gene mechanism, the most common means to achieve these aims are with
either bioengineered viral or non-viral vector biologics, since the uptake and success
rates of naked molecular therapies is very poor in vivo. [11,12] The most effective gene
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products today have shown remarkable promise, but at the same time have also
presented more risks and complicated translational issues, especially when compared
with traditional pharmaceutical compounds.
Despite the availability of effective transgene-vector systems, one major rate
limiting problem is with achieving safe and efficient myocardial gene transfer in the clinic.
[13,14] Due to size scale and more complex membrane barriers, these issues do not
emerge in smaller animal studies yet are a major challenge in larger organisms. [15,16]
Although the preferred route of administration in clinical trials, it remains controversial
whether or not minimally invasive catheter infusion approaches can yield sufficient
therapeutic expression levels that significantly improve outcomes in the clinic. [17]
Another major problem with these systems is restricting therapeutic expression to the
heart and minimizing off target effects. In fact, published large animal data has
demonstrated a greater than 2000 fold higher presence in collateral organs versus the
heart [18-20]. Alternatively, direct myocardial delivery methods can largely restrict
therapeutics to the heart if safely administered.
Direct myocardial delivery methods (e.g. needle injection, sonoporation) can offer
greater cardiac specificity of gene therapeutics compared to percutaneous infusion
approaches. The key unresolved problem is with the limited distribution of gene
therapeutic per delivery site requiring many injections. [21] Increasing the number of
injections has the adverse effect of triggering inflammation in the myocardium, thus
limiting the availability of additional injection sites and jeopardizing the retained therapy.
The immune response to gene therapy products, especially notorious with the viral
mediated products, is complex but several key studies have demonstrated a clearer
relationship between inflammation and the increased risk of an adaptive immune
response. [22,23] Therefore it is postulated the use of an anti-inflammatory drug co141

delivered with the gene therapy product could: (1) Address the inflammation to minimize
the adaptive immune response and promote therapeutic tolerance (2) increase
trafficking and uptake in a more favorable microenvironment and (3) potentially permit
more injection sites.
This concept of a direct injection drug/gene approach has yet to be translated
into the heart, whereby problems exist with increasing uptake and extending the half-life
of anti-inflammatory drugs at the site of injection beyond the peak acute inflammatory
window of 48 hours. In addition to the timing issue, the anti-inflammatory load must not
interfere with vector trafficking or the subsequent gene expression efficiency. Numerous
studies have explored of advanced non-viral vectors to increase in vivo performance by
means of transfection alone. [24,25] However, none have attempted to use antiinflammatories at the injection site co-delivered with a higher risk, but optimal gene
transfer vector to provide a more promising clinical strategy.
This study summarizes the development and parameter testing of a reliable
nanoscale anti-inflammatory formulation production process for co-delivery with gene
products. The development phase features aspirin and prednisolone, two widely utilized
anti-inflammatories and incorporates them into two common FDA approved poly lactic
glycolic acid (PLGA) polymers. [26] Complete nanoparticle characterization, process
tolerance limits and an in vitro feasibility assessment in harvested myocytes are offered
to evaluate the concept of a drug/gene combination therapy.

8.2 Methods and Materials:
Poly-Lactic Glycolic Acid Nanoparticle Production Process
Pre-Processing Steps:
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A water oil water (w/o/w) double emulsion process outlined in (Figure 8.1) was
executed to generate aspirin (99% pure, Sigma Aldrich USA) and prednisolone (99%
pure, Sigma Aldrich USA) loaded poly- lactic glycolic acid (PLGA) nanoparticles (NPs).

Figure 8.1. The water oil water double emulsion nanoparticle production
process work flow sequence to generate high quality anti-inflammatory
formulations
First, initial drug load water phase stocks of 1-3 mg/mL aspirin and 0.1-0.4
mg/mL prednisolone were created by dissolving in 1% poly vinyl alcohol (PVA) solution.
In the case of prednisolone due to its poor water solubility, a 10% Ethanol (w/w%) was
added. These doses were selected based on body weight and pharmacokinetic data for
the rodent species. The second step or oil phase was generated in a separate vial, with
PLGA, input mass range (20-120 mg) of one of either types (50:50, 65:35 i.e. % of lactic:
glycolic acid chains) dissolved in 2.5 mL of Dichloromethane. For the in vitro study only,
production runs were carried out as described in the methods above except 100

g of


Rhodamin B dye powder was added to the first drug water phase.
Process Steps:
The first emulsion was created by adding 1 mL of aspirin or prednisolone drug
PVA 1% solution dropwise to the oil phase polymer in a 5 mL glass vial under probe
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sonication. After 3 minutes, this resultant emulsion was then added dropwise to a larger
outer water phase containing 15 mL of PVA 1% to create the double emulsion. The
double emulsion was then placed in a fume hood and stirred gently for at least 24 hours
to facilitate solvent evaporation and particle formation. Separation was achieved with via
ultra-centrifugation at 30,000g for 35 min at 10C. The resultant particle pellets were
washed to remove residual drug/polymer, then freeze dried overnight. Four nanoparticle
compositions were generated with the reaction: PLGA (50:50 Aspirin), PLGA (65:35
Aspirin), PLGA (50:50 Prednisolone) and PLGA (65:35 Prednisolone).
Post-Processing:
All yields were weighed then stored in sterile cryovial containers at -20C.
Scanning Electron Microscopy (SEM) Analysis & Characterization
Approximately 5 mg of each freeze dried NP sample was prepared for SEM with
gold sputter coating, and then imaged on a JEOL SEM unit at 1.00 kV between 1020,000 x. Multiple images were taken from separate locations on the field with focus in
the range of 1 um to 500 nm.
Stability Testing
24 Hour Formulation Stability Test
Saline stability re-constituted particles tests were also conducted. Ten mg of
freeze dried nanoparticles were dissolved and probe sonicated in sterile 0.9% saline
water and allowed to settle over a 24 hour period. Repeat droplets were first dried and
sputter coated for loading into the SEM.
Zeta Potential Colloidal Stability Measurements
A sample of each particle composition was prepared in water and added to
testing cuvettes per manufacturer instructions of the Zetasizer Nano ZS instrument
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(Malvern Instruments, UK). Triplicate runs were averaged to represent a single data
point for multiple samples from the same production lot.
Controlled Release & Loading Efficiency Analysis
A UV-vis spectrophotometer (NanoDrop, National Instruments) was used to
generate two separate standard curves for serial dilutions of known drug concentrations.
The wavelength consistent with aspirin detection was 275 nm and 235 nm for
prednisolone.
Drug loading efficiency calculations
To compute loading efficiency, the amount of either aspirin or prednisolone
encapsulated in the nanoparticle formulations was determined by measuring the residual
amount in the supernatant following centrifugation relative to the initial load in the water
phase. Percentage was derived as the mass amount of drug remaining in the
supernatant following separation.
Controlled Release Analysis
High quality yields were selected based on the most potent drug formulation of 5
wt.% PLGA aspirin and 1.5% PLGA prednisolone were manufactured per process
specifications. Each particle formulation was prepared for controlled release studies as
follows: (1) 20 mg of particle was dissolved into 10 mL of 42C (2) Samples for
spectrophotometry analysis were removed with a syringe 450nm filter at 12 hours, 1, 2,
3, 4, 5 days (3) The sample volume was replaced and the process repeated for each
interval up until the final point (4) Triplicate UV-vis spectrophotometry measurements
against the standard curve for each drug were performed on each sample to determine
the percentage released for each run.
In Vitro Testing Protocol
Neo-natal Rat Cardiac-myocyte harvesting
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Day 0 to 3 neonatal pups are used and the pups were euthanatized by
decapitation and the heart was immediately removed with forceps. The atria and great
vessels were removed and the left ventricular tissue was minced and subjected to a
trypsin-based disaggregation procedure in a 6 well plate with ethanol cleaned scissor,
rinsed with HBSS with1% P/S/G, and place in a 50ml conical tube containing 10ml of
Trypsin solution for shaking (200rpm) at 37C for 15 min. Cells were then centrifuged at
660rpm at 4c for 5 minutes. The supernatant was discarded and the cells were resuspended in 20 ml of media and pre-plate for 1-3 hours in the incubator. Harvested
cells were collected with centrifuge spin at 660rpm for 5 min at room temperature. Cell
pellets for experiments were then placed in the culture media and counted using 0.4%
Trypsin blue.
Plasmid GFP DNA & Tagged Nanoparticle Preparation
A 10 mg master aliquot of eGFP plasmid DNA was obtained from Invitrogen and
handled according to manufacturer’s instructions. Under sterile conditions working
yields for each well was created with, 6µg of DNA was diluted into 100 µL of RNAase
free water. Separately 10 mg of each of the process output 4 resultant particle systems
[PLGA50:50-Aspirin, PLGA50:50-Prednisolone, PLGA65:35-Aspirin, PLGA65:35
Prednisolone] tagged with Rhodamin B was finely crushed and mixed into 20 mL of
phosphate buffer saline. To remove residual dye not bound within the particle structure,
the particle solution was placed into a dialysis membrane submerged in an outer bath of
PBS at 37. Prior to well transfection, 10 µg of each nanoparticle solution in 500µL was
placed in individual aliquots.
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DNA and Nanoparticle Well Transfection
On the day before transfection, cells were placed in 12 well plates with each well
seeded at a density of 500,000 myocytes in 1mL of DMEM (GIBCO) media without
antibiotics. The transfection complexes were then prepared:
Complex 1 – One 6µg of DNA aliquot was diluted into 100µL of media in an individual
eppendorf vial. Complex 2- 8µL of Lipofectamine (Invitrogen) was diluted into 100µL of
media. Then, complexes 1 and 2 were mixed together and permitted to incubate at
room temperature for at least 20 minutes. After 20 minutes the contents of the individual
eppendorf yields were then transferred into each well. The plate was gently rocked then
placed back in the incubator until the first 24 hour imaging time point.
For the nanoparticle treatment wells as designated, the 500µL filtered sterile solution
was added via syringe to each well with a 450nm to prevent aggregates from
transferring.
Follow up Fluorescent Microscopy
The first set of images was taken at 24 hours post transfection. Media was
removed from each well prior to imaging and replaced prior to returning to the incubator.
The remaining set of images was taken at the 48 hour time point.
Fluorescence images were acquired using a Nikon Eclipse TE2000-U fluorescence
microscope equipped with a Plan Fluor ×20/0.50 objective (Nikon, Tokyo, Japan.
Microscope controlling and image processing were carried out using Image-Pro Plus
4.5.1.27 (Media Cybernetics, Bethesda, MD, USA).
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Statistical Analysis
All SEM and nanoparticle characterization data was loaded into GraphPrism
software suite for statistical testing. Single way ANOVA was utilized to determine
differences in nanoparticle subtypes. Individual paired t-tests were used to compare
across individual groups. Bonferroni corrections were applied for significance testing.

8.3 Results
8.3.1 Process Capability
Over 45 nanoparticle production yields were obtained over the development
course with the optimal ranges. The process volumes were held in a fixed ratio,
featuring water phase #1 at 1mL, the oil phase at 3mL, and the outer water phase #2 at
15 mLs. Pilot runs in greater amount adhering to this proportion scale yielded the same
quality particles. Briefly, basic guidelines for each process phase:
Water Phase: Aspirin 1-3 mg dissolved in PVA 1% or Prednisolone 0.02-1 mg in 10%
ethanol PVA1%. It was noted that adding additional solvents to increase drug load in
this phase resulted in failure to maintain particle integrity and stability.
Oil Phase: The process was very flexible in terms of changing the amount of polymer
added to the system and was stable in the range of 20 – 120 mg of either PLGA type.
Outer Water Phase: The PVA in the system acts as a vital stabilizer that can be readily
increased. Increases beyond 2% tended to inhibit the amount but not the quality of
generated nanoparticles. Thus, a working range of 0.5-2% of PVA stabilizer in the outer
water phase is suitable for accommodating various drug/polymer complexes with good
stability.
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8.3.2 Particle Characterization
The results presented here summarize the characterization for each of the 4
resultant nanoparticle types acquired from 5 consecutive runs. Polymer load was fixed
at 60 mg, aspirin 3 mg and prednisolone at 1mg respectively.
SEM images from the various runs for each nanoparticle type were loaded into ImageJ
software for analysis. The process consistently yields uniform, spherically shaped
formulations (Figure 8.2AB). The size distribution was very narrow, of high quality and
was as follows: PLGA50:50 Prednisolone [234±9 nm], PLGA65:35 Prednisolone [228±7
nm], PLGA50:50 Aspirin [323±13 nm] and PLGA65:35 Aspirin [302±7 nm]. ANOVA
indicated significance between the groups, specifically it was determined that aspirin
contributed to larger particles as both PLGA50:50 and PLGA 65:35 types were
significantly larger than their matched prednisolone counterparts. (Figure 8.2C) This
difference in size was most likely attributable to both higher aspirin mass content and
charge of the first water phase in the reaction since size was unaffected by the addition
of more polymer (data not shown).
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Figure 8.2. SEM Characterization Sizing Results. A. Narrow size distribution
and high quality spherical shaped yield example in A at 2µm scaling. B. Close
up 500 nm scaling image indicates narrow size distribution in the 200-350 nm
range consistently for all manufactured yields. Nanoparticle average size by
drug and polymer combination. C. Aspirin nanoparticles of either 50:50 or
65:35 type had greater size (p<0.05) versus prednisolone.
Yields were very consistent and proportional to polymer mass input in the range
of 75-80% recovery upon final harvest. The average yields per polymer/drug type based
on 60 mg input were: PLGA50:50 Prednisolone [46±1 mg], PLGA65:35 Prednisolone
[45±2 mg], PLGA50:50 Aspirin [48±1 mg] and PLGA65:35 Aspirin [47±2 mg].
Production yields with increased or decreased polymer loading revealed the same
results (data not shown).
Loading Efficiency results were uniform for all 4 nanoparticle types, independent
of drug or polymer and were: PLGA50:50 Prednisolone [88.9±0.01 %], PLGA65:35

150

Prednisolone [88.2±0.01 %], PLGA50:50 Aspirin [89.0±0.01 %] and PLGA65:35 Aspirin
[88.8±0.01 %].
Stability Analysis
Positive nanoparticle visualization was realized on the SEM 24 hours after reconstituting freeze dried product in saline for all 4 polymer configurations. The particle
shape and size was retained. The stability of the nanoparticles in suspension was
moderate to good in the range of -30 to -53 mV. A score much less than -30 indicates a
stability issue with a pharmaceutical dispersion, while any score higher than -60
indicates maximum. The potential scores by nanoparticle type shown in (Figure 8.3)
were as follows: PLGA50:50 Prednisolone [-47±5 mV], PLGA65:35 Prednisolone [-31±1
mV], PLGA50:50 Aspirin [-45±0.5 mV] and PLGA65:35 Aspirin [-32±0.9 mV]. Statistical
tests revealed that the PLGA50:50, independent of drug load was superior compared
with the 65:35 type.

Figure 8.3. Nanoparticle Zeta Potential Colloidal Stability Testing Results
indicate that the PLGA50:50 nanoparticles are more stable in solution versus
the PLGA65:35 types.
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Controlled Release of the Nanoparticle Formulations
(Figure 8.4) shows a graphical depiction of the release over the span of 5 days. It was
evident that the aspirin released faster overall as compared with prednisolone. This is
most likely due to a combination of factors including size, stability and charge. The
PLGA50:50 Aspirin type had the fastest release profile.

Figure 8.4. Controlled release study results demonstrate that aspirin particles
overall release faster than prednisolone types.

8.3.4 Process Limitations
The high quality in terms of particle shape uniformity, yield, surface charge and
release properties were critically limited by a number of key variables. Therefore,
production with major deviations with the water phase I input (data not shown) resulted
in lower quality profiles featuring aggregation and wider size ranges. The first major
critical variable was the concentration of the loading drug in the first water phase, which
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was largely limited by the inherent solubility at room temperature. In the case of aspirin,
without solvents added, the maximum concentration was 3 mg/mL directly at the
solubility limit. Runs at the 5-10 mg/mL range resulted in aggregation and lower quality.
In the case of prednisolone, it was anticipated that on a per gram basis at least 1 mg/mL
would be required to achieve high quality in addition to a realistic dosing paradigm for a
rodent heart with target of 1 gram mass. This was achieved suitably with 10% Ethanol,
however concentrations greater than 25% in an attempt to load more drug distorted the
process (data not shown). The PLGA and PVA stabilizer system as presented here is
therefore open to excipient manipulation provided that solubility and other attributes of
the selected drug are addressed such to prevent deviations in overall quality which may
or may not be desired depending on the application. We anticipate this platform would
be open for further experimentation by professional formulation scientists tailored to
each specific PLGA/drug selection for the intended direct injection application.

8.3.5 In-Vitro Myocyte Transfection
All wells were checked for viability and it was determined that none indicated any
major media discoloration or visual evidence of contamination. The following 5 groups
all had positive detection of GFP (green) in at least 2/3 replicate wells at both 24 and 48
hours, with a greater degree of cells positive as expected at 48 hours. Figure 5 depicts
independent uptake of both GFP plasmid and nanoparticle co-signal. The absorption
clusters were confirmed in the center of myocytes. The multiple DNA and nanoparticle
infection groups yielded nanoparticle presence (red) or both (yellow) at the 24 and 48
post transfection: I. Control GFP DNA only (data not shown) II. GFP and PLGA65:35
Aspirin (Figure 8.5A) III. GFP and PLGA50:50 Aspirin (Figure 8.5B) IV. GFP and
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PLGA50:50 Prednisolone (Figure 8.5C) V. GFP and PLGA65:35 Prednisolone (Figure
8.5D).

Figure 8.5. In Vitro Fluorescent Imaging at 48 hours post transfection. All 4
particle systems exhibited safe and robust uptake in myocytes while not
interfering with plasmid uptake and subsequent GFP expression. Yellow
signal indicates co-existence of GFP and nanoparticle in: A. PLGA65:35
Aspirin B. PLGA50:50 Aspirin C. PLGA50:50 Prednisolone D. PLGA65:35
Prednisolone.
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8.4 Discussion
This study presents two key findings that have broad implications for the
advancement of cardiac gene therapies. First a reproducible, simple to use lab scale
process was developed to generate anti-inflammatory nanoparticles of very high quality
for co-administration with gene products in a - regulatory friendly - PLGA platform.
Although only two anti-inflammatory drugs were utilized in this feasibility assessment, it
is anticipated that any other drug indicated for injection into muscle could be introduced
by modification of the first drug water phase. Also the process offers an easy means to
adjust the polymer content in the oil phase for the desired degradation/release profile,
along with increasing the amount of stabilizer. Therefore this system can provide a
platform to guide future pre-clinical studies to investigate reliable clinical interventions to
address the role of inflammation on the relative performance of gene products in muscle
tissue.
The potential role of inflammation should not be overlooked, particularly in
myocardial tissue where the most common delivery scenario is in ischemic regions,
which are characterized by a high degree of inflammation and fibrosis. The second key
finding in the final test was that PLGA uptake and release of anti-inflammatory agents in
myocytes does not interfere with the absorption and trafficking of the GFP plasmid.
Muscle tissue has a high risk of developing an adaptive immune response to gene
products. Wilson et al described in detail the host response after AAV delivery by route
of administration and more specifically the role of inflammation. [27] A key finding with
AAV mediated gene transfer was that the host either induces tolerance or an adaptive
immune reaction through a series of complex interactions. [28-30] A prime risk factor in
these interactions that was found to trigger adaptive immune responses were
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inflammatory cytokines and signals either already present in tissue or induced at the
time of delivery. [31] It has been postulated that with attenuation of innate inflammatory
response signals, the immune system has a much lower risk for mounting maladaptive T
cell responses.
Using the example of AAV, once vector capsid antigens are cleared from the
system, typically 12-16 weeks after delivery, there is a good chance for therapeutic
tolerance. The risk is that an adaptive immune response will destroy those cells
expressing the transgene of interest well before these antigens are cleared. Use of antiinflammatory agents to mitigate the innate response to injury is likely to result in
enhanced long term gene expression. Intravenous delivery approaches are associated
with a lower level of induced inflammation but are also very inefficient. In contrast, the
IM route in the heart remains attractive because greater cardiac specificity can be
achieved, especially for angiogenesis or regenerative therapies that require a more local
delivery profile. Yet IM delivery is associated with a more robust innate immune
response due to associated tissue injury.
Direct injection into healthy or ischemic myocardial regions introduces the gene
product into a highly inflammatory region, which likely explains the poor cardiac gene
therapy results with IM interventions. Early studies by Snyder [32] et al reported that
very little successful transfer occurs in damaged muscle in the inflammatory
environment. Numerous examples have validated these observations in gene therapy
trials. In hemophilia trials for example it was found that IM injection into skeletal muscle
resulted in transient therapeutic gene expression and an adaptive CD4+ immune
response. [33,34] However, delivery of the same product infused into the liver has
resulted in better outcomes and limited reactions. Muscular dystrophy trials have
encountered similar difficulties and have attempted to utilize immunosuppressant drugs
156

and other agents to limit responses after multiple IM injections compromising patient
safety. [35]

8.5 Conclusions and Future Direction
In this proof of concept study, GFP plasmid was utilized to simulate a therapeutic
construct understanding that naked DNA is likely to be at the lower end in terms of
transduction efficiency. For more practical gene therapy applications, it is anticipated
that viral vectors encoding the gene of interest could readily be combined with particles
containing potent anti-inflammatory drugs. The hypothesis offered is that with the right
formulation, the anti-inflammatory agent would be released at the sufficient level over the
critical post-delivery inflammatory period to provide an optimal viral vector trafficking
microenvironment. There would be a predicted increase in transduction efficiency,
minimize the innate and adaptive immune response to the vector and/or transgene and
promote long term gene expression in the target tissues..
This strategy of course would not be without its own limitations and would require
much more experimentation to determine the best matched drug and release profile for
co-administration into the heart. More complex approaches in managing the host
response following therapy have been applied, however it may turn out that simply
addressing the innate immune response at the time of delivery may be a meritorious
approach to advance successful clinical translation.
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CHAPTER 9
Summary, Limitations and Future Direction for Needleless Liquid Jet Delivery for
Cardiac Gene Therapy Applications

9.1 Summary
Recurrent or a single major acute myocardial infarction (MI) event results in a
significant decline in cardiac function in the early stages, progressive decline through left
ventricular remodeling and maladaptive physiology changes in the mid stage, then
ultimately in end stage heart failure whereby high cost/low reward (i.e. excluding
transplants) options still fail to extend survival. The burden this problem presents to the
healthcare industry as whole does not need more awareness, but more effective
solutions.
Cardiac gene therapy applications are expected to meet or exceed growth
projections and will remain a strong research area in an effort to develop new targets,
engineered vectors to encode them and finally as argued by this dissertation their
optimal delivery route for the given dose required. Demand is the main reason cardiac
gene therapy will be a stronghold in modern medicine for years to come. This demand
is driven by 3 primary factors: (1) The chronic shortage of donor hearts will never meet
demand for 22 million end stage patients (2) State of the art surgeries and the latest line
of drugs are palliative and are no longer cost efficient for government and managed care
payers (3) The incidence of heart disease, specifically from coronary artery disease, is
expected to increase significantly with aging populations in the United States, Europe,
Asia and other developing nations whom adopt western habits.
Chapter 1 describes the overall advantage of cardiac gene therapies as compared with
the standard of care. Regardless of the specific mechanism, the goal is to treat the
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myocardial disease permanently at its root cause by administering therapeutic molecular
biologics as the medicine. These strategies either restore function and or attenuate
maladaptive cellular regulation with a sustainable encoded fix. The excitation
contraction coupling, angiogenesis, and other related survival mechanisms are well
established. With the continual growth of computation power, microarrays and
bioinformatics the number of targets for myocardial dysfunction will also likely increase
over the next 10-15 years as massive genetic databases are being built [1]. On the
basic science front, more detail knowledge is being developed with microRNA
regulation, therefore new strategies to induce cell directed repair/regeneration have
already found some early success [2].
In addition to the explosion of new strategies, Chapter 1 also illustrates that viral
mediated genome transfer can result in safe, long term outcomes as evidenced by a
longer track record of other AAV gene therapy trials. The field has simply learned much
more with a more prudent scientific approach, whereby human trial data and a growing
network of investigators have blossomed. Bioproduction engineers and scientists
therefore will continue to be motivated to develop, safer, more effective transfer vehicles
engineered for the intended cardiovascular disease now that safety and efficacy can be
realized with careful administration [3].
Given the availability of targets and improved transfer vehicles, Chapter 2 introduces the
key problem of efficient myocardial gene delivery. This dissertation and a growing body
of evidence argues that this is the rate limiting problem that must be solved in the clinic
[4]. Overall, cardiac gene delivery systems have lagged in terms of development as
compared with targets and vector engineering. As presented in our detailed
development of a liquid jet concept, it is clear there are major discrepancies between
animal model and actual clinical applications. The first major difference is anatomy, not
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only in terms of size scale but additional transport barriers that exist in humans such as
pre-capillary sphincters [6]. The second are co-morbidities common to heart disease
patients, such as chronic inflammation in the targeted area compounded by diseased
transport vessels necessary for AAV trafficking into the myocardial compartment. These
are never captured in large animal models that claim to resolve the scale issue and must
be considered.
Delivery strategies as reviewed in Chapter 2 fall into two major categories: (1)
Transvascular or those that seek to leverage the capacity of the patient’s cardiac vessels
for transfer (2) Direct methods which apply physical means of fluid, pressure, electrical
current etc. to drive AAV directly into beating myocardium. The primary goal is to
transfect the highest % of myocytes possible with the least degree of systemic exposure
that would raise risk profiles. The majority of gene therapy trials because of safety and
an established preference with interventional cardiologists, select the percutaneous
antegrade catheter infusion system.
As leaders in the cardiovascular gene delivery space for the last 10 years, our
group has demonstrated that the route of administration is the prime factor that will
determine outcome, since transfecting a high % of myocytes is an absolute requirement
for demonstrable efficacy in terms of cardiac rescue with AAV mediated excitation
contraction coupling genes. The CUPID Phase II trial results featuring AAV1.SERCA2a
do not show a statistically significant improvement in echocardiography and other
improvement metrics are trivial at best [6,7]. Based on analogous large animal and a
limited number of post mortem clinical specimens, evidence suggests that antegrade
single pass “slow” intracoronary infusion transduces only 1-3% of myocytes [7,8].
Moreover, the distribution is limited to the axis of the primary infusion vessel. Other
published large animal data with the same construct resulted in a much higher % of liver
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transfection versus the heart, even with attempts to recapture vector leaving the cardiac
system with a perfusion circuit (i.e. V-Focus device) [9, 10]. It is important to note that
these ovine subjects did not have either the transport or disease barrier conditions,
suggesting that intracoronary infusion without modification may never be a viable route
despite its safety.
Given the shortcomings of single pass antegrade, the field has employed
extensive bioengineering means to develop a variety of catheter modifications such as
different lumen and or balloon occlusion configurations that have resulted in a slight
increase in efficacy.
For upcoming AAV1.SERCA2a trials, a shift has occurred toward favoring
retrograde systems that leverage more favorable dimensions and less restrictive
transport barriers on the venous side cardiac anatomy. Our laboratory designed an ideal
system leveraging the venous side at the most extreme level, surgically isolating the
heart in situ with cardiopulmonary bypass, featuring a high pressure retrograde
recirculation of AAV vector throughout the Molecular Cardiac Surgery with Recirculating
Delivery (MCARD) system [11]. The MCARD system with AAV1.SERCA2a
demonstrated the highest reported cardiac specificity (i.e. up to 2000 fold more cardiac
expression versus liver) and rescued in later stage ovine ischemic cardiomyopathy [12].
The obvious limitation of MCARD is its relative complexity and available use in a limited
number of patients already undergoing adjunctive surgical therapy.
Given the state of cardiac gene delivery systems, it is clear that there is a major
bias toward transvascular systems and this research sought to contribute to the less
visited, but increasing important direct injection routes [13]. As described in Chapters 2
and 3, this bias is primarily due to the poor performance of other direct methods in terms
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of distribution and resultant induced inflammation, which is known to trigger immune
responses [14].
Chapter 3 describes the complete aims in this dissertation to develop a
translatable direct myocardial injection methodology leveraging liquid jet device
technology. The challenge was adapting the DERMOJetTM device for both a rodent and
ovine application. The hypothesized advantages of liquid jet delivery were: (1) increase
myocardial retention (2) limited collateral spillover provided tuned device settings (3)
wider coverage of myocardial tissue mass per injected unit volume (4) Less
inflammatory; both in terms of the initial punctures and subsequently generated
homogenous expression profile and (5) Would potentially provide a solution for 50-60%
patients excluded from AAV therapy trials due pre-existing antibody titer. Ideal delivery
with this proposed route as stated was to project and disperse AAV through myocardium
in a powerful, yet safe jet stream that would be retained.
Liquid jet injection technology as discussed in Chapter 4 is not at all novel and
had previously been utilized in both scientific and basic medical applications including
vaccination [15]. Within the realm of gene therapy, there was no prior literature
describing the concept for AAV mediated therapy with contractility transgenes, thus the
inspiration for this work.
Preliminary experiments with the DERMOJetTM revealed the need for
optimization. As described in Chapter 4, ex vivo muscle and mock demo testing of
various materials characterizing the jet profile revealed a potent laser like injection track
with minimal dispersion from close range (i.e. 1-3 inches from the surface). The nozzle
velocity was roughly 330 m/s with a 500KPa driving pressure inside the chamber. These
factory ratings were tuned for deep skin/muscle penetration, which of course serve
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vaccination applications well. It was determined that if this approach would work,
optimization was required.
The device settings were altered through working the engineering team of the
manufacturer to reduce the power rating via actuator spring size reduction. Then,
through a series of optimization experiments in beating heart non survival models, it was
determined that 110 m/s velocity and a driving pressure of 100-250KPa would provide
the proper dispersion. Another key variable was identifying optimum target distance
range to achieve safety and maximum myocardial dispersion simultaneously. This
range was determined with simple methylene blue studies. The ideal range was
between 7.5 to 9 inches from the thoracotomy open heart for the rodent application, and
2-4 inches for the ex vivo ovine heart application. Once optimization was achieved,
several key rodent model experiments were executed in Chapters 5 to both validate the
system and compare with other delivery approaches.
Chapter 5 was the heart of this work, essentially validating the liquid jet
methodology and simultaneously exploring key variables in the new approach against
others in practice. As described, important clinical translation aspects were described in
the experimental series. The first was retention, whereby needle injection and especially
transvascular methods were not well characterized from a quantitative basis. We
selected a simple fluorescent dye, much smaller than AAV, to assess retention after 10
minutes post-delivery in an acute model. The Liquid jet performed well in terms of
retention with limited uptake in the live and a disperse, homogenous myocardial
coverage profile. As expected, the IM group had a very robust retention around the
injection track, but resulted in inadvertent systemic infusion. Comparing the left
ventricular infusion with versus without occlusion, two key points were validated as
argued previously in this dissertation. The transvascular systems must increase
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residence time and driving pressure variables in order to both increase cardiac
specificity and limiting systemic exposure. The cost is the level of invasiveness, but the
concepts were demonstrable.
The follow up live AAV9.GFP survival model largely revealed the same
expression profiles as found with the acute retention series. This permits conclusion that
the initial delivery event largely determines the expression profile that will be achieved in
the future. It was here that a number of key points were determined for the overall aims
with liquid jet injection for cardiac gene therapy, namely: (1) Liquid jet injection with
optimized settings can achieve roughly the same, but not as intense, level of the best
available transvascular approach (2) Limit the degree of systemic exposure (3) Achieve
more myocardial coverage per injection. Point #3 is arguably the most important, since
limiting the number of injections is key for direct myocardial gene delivery. This topic will
be expanded upon in the next section discussing the limitations.
Although the validation experiments revealed positive concept testing results, the
next series of experiments described in Chapters 6 and 7 tested the methodology’s
validity in an ischemic myocardial infarction model. It cannot be underscored that the
differences between normal and ischemic myocardium are immense. The induced
model insult analogous to the clinic has a significant impact on subsequent cardiac
performance and host responses. Separately from intervention, the ischemic myocardial
insult promotes a complex myocardial degeneration process marked by inflammatory
events, limited repair mechanisms [16]. Due to the limited capacity of cardiac repair, a
number of compensatory mechanisms locally in the myocardium and neurohormonal
physiology commence. These temporal changes from initial insult to chronic failure must
be considered when optimizing any delivery strategy. This was a prime challenge for the
liquid jet injection method, but certainly attainable with careful design.
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Essentially for Chapter 6, the focus of the liquid jet injection’s applicability was to
test whether or not it would be efficacious with an AAV therapeutic encoding a bona fide
transgene within the clinically relevant maladaptive post MI environment. We selected a
high cardiotrophic AAV9 vector and arguably the most promising S100A1 transgene,
which is rapidly approaching clinical trial. The four groups were 2 Control saline and 2
single dose 1.2 x 1011 vp ssAAV9.S100A1 treatment. The head to head delivery
assessment featured liquid jet against traditional IM injection. This chapter ultimately did
not incorporate a comparative infusion group since these results translate poorly to the
clinical problem as argued in the discussion of Chapter 5.
The results in Chapter 6 were striking featuring a major discrepancy in outcome
across delivery groups. The IM S100A1 group performed considerably worse in terms of
overall LV function and presented with a degraded LV structure. The affected infarcted
area was double, with full blown heart failure in nearly all 8 group subjects. The Liquid
Jet group achieved a 4.3 fold higher S100A1 expression profile, greater than control
(1.0) but slightly less than the IM group at 5.0 overall. Despite an overall score of 5, the
proteomic analysis variability in the cross section indicated that some regions likely
increased this average due to intensity, but the overall degree of expression as in % of
transfected myocardium may have been lower. In addition, the results indicated that the
pattern of expression and the degree of systemic exposure contributed to the major
declines found in the IM animals. The host response testing revealed that the IM group
most likely suffered a deleterious immune response as hypothesized based on much
higher CD38 tissue marker and systemic inflammatory cytokine profile.
Following the results of the first major efficacy study, Chapter 7 explored a new
approach with S100A1 gene therapy with the use of the double stranded DNA or selfcomplementary vector scAAV9.S100A1. Since a vector control group was not utilized,
168

the same dose was selected for this study based on the hypothesis that a selective in
vivo dose response would be elucidated with higher copy number. The use of double
stranded vector is intriguing with several advantages. The first main advantage is
conversion efficiency, whereby DNA is ready to drive gene expression just after nuclear
transfection, whereas with single stranded vector a key conversion step is needed. The
second key advantage, as argued by this dissertation, was that in highly focal muscular
expression patterns the single stranded step might be inflammatory.
The efficacy results to support these claims and is valid given that the IM
SCS100A1 performed dramatically better than the single stranded group. It therefore
can be concluded within the limits of this study that on a per dose basis selfcomplementary vector should be used for direct injection applications since they achieve
the desired level of therapeutic copy number more efficiently. A major limitation of the
efficacy studies presented is the imprecise cause of the adaptive inflammatory immune
responses in rank order IM S100A1, IM SCS100A1, and Liquid Jet SCS100A1. The
host immune response is a complex interaction of induced innate inflammation caused
by delivery route, biological state of target tissues (i.e. healthy vs. remodeling from acute
MI), AAV viral vector antigen payload risk, S100A1 expression profile/distribution, and
collateral organ (i.e. liver) expression. It is acknowledged that the specific root cause of
the immunological host response was beyond the limits of this study; however Chapter 8
explored an often overlooked aspect of these risks, the initial delivery event.
Cardiac gene therapy methods, especially direct injection techniques, cause mild
to moderate levels of inflammation that can increase the risk for the host response.
Chapter 8 explores the concept of a drug/gene therapy approach, whereby gene therapy
product would be co-delivered with an anti-inflammatory drug at the time of delivery to:
(1) Promote a more favorable AAV trafficking environment (2) Reduce stress on cells
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that need to generate therapeutic expression in the microenvironment (3) Induce
tolerance by ensuring the host immune response up to 1 week post delivery (i.e. vector
clearance rate is high by this point) is beyond the window of co-stimulation, which is
critical for adaptive host responses. For this theoretical application, a poly lactic glycolic
acid polymer nanoparticle production process was developed. The rationale was that a
nanoformulation would: (1) increase local drug uptake in the myocardium due to size
advantage (2) Not interfere with vector trafficking and expression mechanisms (3)
Extended release of anti-inflammatory over the innate immune response period through
6 days. Much of the work entailed the anti-inflammatory process development aspects,
whereby a robust set of operating parameters were identified to engineering 200-300 nm
particles encapsulating a variety of anti-inflammatory drugs. Aspirin, prednisolone and
solumedrol have been tested in the system and the in vitro work illustrated the potential
for this combination approach.
The remaining sections discuss the key limitations and future studies for each
specific aim, followed by on overall conclusion on the body of work.

9.2 Limitations and Future Direction
9.2.1 Specific Aim#1 - Define and optimize engineering parameters for the liquid
jet injection device for the cardiac application in an acute rodent model and ex
vivo large animal setting to define a safe, yet effective operating transfer range.
9.2.1.1 Limitations
Adapting the liquid jet injection approach for cardiac gene delivery required
detailed experiments and select modifications of key driving device parameters. A
problem is that these same pressure settings that performance well in one given
myocardial region can also permanently injure another with a more advanced disease
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stage. In a controlled, consistent rodent model application however it was possible to
obtain excellent results due to this level of precision. This of course would not be in the
clinic, whereby populations of patients with a diverse set of co-morbidities will have
different levels of affected areas and geometry. Therefore settings would need to be
flexible enough over an acceptable range to remain safe. Given these findings, the key
limitation of the current results is that this development process would have to be done
at a much higher level of sophistication for a clinical application.
First as presented, the size scale factor is a major problem as it is very unlikely
that a single pen injector design would be suitable for an AAV mediated therapy. This is
especially true for cardiac contractility genes, whereby global myocardial expression
over roughly 150 – 300 mg of myocardial mass is needed in the left ventricular zone.
Our rodent model demonstrated efficacy, but the target was only 1 mg reached with 3
injections. Therefore, scaling estimates with this primitive system would require at least
300 injections to reach the same efficacy level, which would not be feasible with a single
device.
It is also likely that primate and human host responses are more aggressive than
the rodent model, therefore inflammatory events would have to managed even more
carefully with a selective pressure system approach.
9.2.1.2 Future Direction
A second generation device configuration would most likely go in two directions:
(1) A multi array port of injections with selective control over pressure settings featuring
real time feedback or (2) A hybrid microneedle array concept for direct injection that
would penetrate then slightly pulse pressurize for maximal distribution. Concept #1
would ideally leverage an imaged guidance setup, whether it be echocardiography or
high fidelity MRI to use structural data to map desired target areas. The
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conceptualization is that ischemic areas are typically much thinner than remote healthy
zones, therefore different injection ports would require the correct programmed
pressurized settings. These settings could be optimized with a series of engineering
modeling and cadaver harvests over a range of cardiac mechanical properties (i.e.
optimize pressure settings for levels of thickness, disease vs. non-diseased structures).
Another key concept not explored in this dissertation due to cost was the use of a
more optimal driving gas. Many of these liquid jet systems are pressurized by carbon
dioxide gases instead of room air/oxygen [17]. Although minimal, there is a risk of air
penetration into the system warranting the use of C02. The selected gas, may or may
not alter transfection rates but would be interesting to explore. For safety reasons, C02
gas would be the obvious option that is readily available in the clinic. In the future,, if
warranted, it is also conceivable that the liquid approach could be adapted to a minimally
invasive catheter system that would delivery from the endocardial surface.
Exploring Concept #2 of a microneedle system, these have been tried with different
transdermal systems with various adjunctive configurations but have not been translated
into the heart [18]. It is conceivable that the liquid jet concept could be engineered to
perform more consistently with an image guidance capability but this would be difficult to
execute. If engineered correctly however this system would have the advantage of more
precision in select zones at the cost of complexity.
9.2.2 Perform a two phase therapeutic delivery study to the beating heart in an
acute rodent model to evaluate the liquid jet approach against traditional methods
in practice. The methods to evaluate against are: A. Standard IM Injection B.
Non-selective Intracavitary Infusion C. Intracoronary Infusion
9.2.2.1 Limitations
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As concluded in Chapter 5, the sequential validation rodent studies evaluating
the liquid jet strategy revealed a number of key considerations for myocardial delivery
overall; with a keen focus on animal model to translational perspectives. A number of
key points were highlighted for each delivery class when analyzing model results. The
first is scale, and was demonstrated effectively with the Liquid Jet concept. The targeted
myocardial LV mass is roughly between 1-2 mg in the healthy condition. Our results
demonstrate that with optimal settings, 300 microliters of volume was sufficient to cover
the entire cross sectional space with Liquid Jet or Infusion with occlusions.
The ovine (i.e. more resembling the human application) mass target is at least
150-200 mg, but much less coverage is achieved with a single injection. This result in
the demand for 100-350 injections and this reaches the higher risk range for both injury
and priming for immune responses. IM delivery on the other hand is worse in that the
highly focal expression profiles achieved would not promote an overall increase in
contractility at the larger scale that is needed and surprisingly results in higher systemic
exposure than expected due to poor retention [19].
The conclusion with the infusion approaches (e.g. primary infusion with or without
anatomical occlusions) was that a means to increase the driving pressure and residence
time of vector in the cardiac anatomy is required to increase expression levels. This
concept clearly demonstrates the problem of the endothelial barriers, which prevent viral
vector trafficking into the interstitial. Although recognized, implementing this at much
larger scale is very difficult and requires complex methodology. Banding the pulmonary
artery and aorta would never be clinically feasible. Our laboratory to date has presented
the only competent means to achieve higher residence time and pressure, which can
only be done safely under cardiopulmonary bypass conditions [20].
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The concept of increasing pressure locally around a peripheral artery or vein
however, is attainable with balloon occlusion catheters. Despite their success in large
animal models, the disease vessel integrity breach and other complications that would
result (i.e. especially on the arterial side) would not be justified with the benefits. Balloon
occlusion on the venous side with primary infusion through the greater cardiac vein the
most applicable strategy. Groups have shown increased AAV uptake with retrograde
balloon infusion with various pressure and occlusion settings versus antegrade. These
approaches are likely to have a higher translational impact. This is due to the fact that
venous side anatomy has both increased dimension and less disease factors [21].
9.2.2.2 Future Direction
Marker gene delivery studies featuring multiple approaches most definitely would
be strengthened by incorporating a wider dose range and using different settings for said
approaches. For example altering injection volumes, pressure, occlusion times, device
design may increase therapeutic AAV transfer. Elucidating these mechanisms in more
detail requires multiple level designations for each method, this study only featured one
dose with one set of delivery parameters for each.
9.2.3 Perform a chronic ischemic infarction 10 week model study to evaluate
delivery of a single dose 1.2 x 1011 GC of ssAAV9.S100A1 vector featuring a head
to head format comparing liquid jet vs. IM injection.
9.2.3.1 Limitations
Although very striking differences were found between the IM injection and Liquid
Jet groups versus controls, there were major limitations in this well executed efficacy
study. The first was using a single fixed dose and at one time (i.e just after infarct).
Given the many inherent variability factors that can be different between animal subjects,
having one or ideally two more dose arms would have complemented the data sets
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tremendously. Moreover, analyzing how the transgene rescues at different stage of
disease would be more clinically relevant. The analogous clinical situation in this model
was just after MI, but more than likely AAV.S100A1 therapy would be for advanced
disease stages. This is true especially in the context of evaluating why the IM injection
group performed so poorly which can only be postulated was due to an inflammatory
response caused by too much collateral expression and or single stranded vector
conversion signals. It is anticipated this response might be different after the remodeling
and after inflammatory courses secondary to MI reach more of a steady state condition
in the later disease stages.
Another major limitation in this study beyond its scope was the lack of precision
with regard to the immunology assays. Typically, gene therapy studies incorporate the
use of two key assays that were not used due to cost. The first is the neutralizing
antibody titer, which determines the circulating levels of antibody specific to the AAV9
capsid antigens. The second is the T cell mediated response precisely determined by
ELISPOT, whereby a determination can be made on whether responses were generated
to the capsid antigens or viral mediated S100A1 protein. The protein encoded in this
case was human and overexpression of foreign transgenes in different hosts is more
likely to cause responses than the antigens, although this was not confirmed. It was
assumed that the immune reactions would be complex and the focus was more on
outcome in terms of cardiac function with an associated overall response regardless of
source.
Last but not least, the single 10 week timepoint was the most impactful limitation
in that all conclusions can only be made at 10 weeks. This concern is twofold given that:
(1) LV remodeling and cardiac dysfunction changes over greater time periods from initial
MI (2) Expression profiles, although less likely to change with AAV mediated therapies
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are still variable (3) Immune response are unpredictable (i.e. the 3 efficacious groups
might have suffered a response with a reversal in cardiac preservation at 2, 4 or 6
months later).
Item #3 is of particular concern since it is backed by findings in many studies that
show efficacy in the 1-2 month timeframe, then a steep drop off and reversal. These
studies would typically show a decrease in gene expression levels accompanied by a
deleterious CD8 T cell mediated response. Therefore, the delivery conclusions were
more valid in this time frame, however long term impact can only be evaluated with
successive timepoints.
9.2.3.2 Future Direction
Multiple dose levels at different points of intervention (i.e. baseline, 3 weeks post
MI 12 weeks post MI), more precise immune response assays, and longer term
timepoints (i.e. 3 months, 6 months post MI) would provide a more clear means to
evaluate aims in greater detail.
9.2.4 Specific Aim #4 - Two key testing parameters that may significantly alter host
responses are offered: A. Using double stranded vector equivalent B. Co-delivery
of anti-inflammatory drugs to minimize host response during initial delivery
phase.
9.2.4.1 Limitations
Given that the only difference in the follow up pilot study with the selfcomplementary double stranded scAAV9.S100A1 vector was molecular, the already
compiled limitations as stated in 9.2.3.1 hold for part A of this aim as well. The
performance of self-complementary vector may or may not be different if applied beyond
the baseline/Post MI period. This pilot study only tested whether or not it would perform
better in terms of transduction and cardiac efficacy. Despite significant changes in
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efficacy found in the IM injection group between the two vectors constructs, there was no
means to determine if these events would be maintained with elevated cytokine profiles.
With respect to the Part B aim of co-delivery of anti-inflammatories with AAV product, the
concept was largely limited to a primitive proof of concept in vivo application. Much
more detailed in vivo work would have to be performed to determine the correct drug,
drug and tuned PLGA release profile that would maximize AAV therapy. The case study
only featured DNA plasmid in neonatal myocytes which have different properties.
9.2.4.2 Future Direction
There are numerous parameters independent of delivery that can alter the host
response profile in vivo. Follow up studies changing dose levels, promoters in the AAV
constructs, co-expression of regulatory elements, and changing serotype might yield
more useful in myocardial muscle in the early to late post MI periods. AAV1, AAV6 and
AAV9 all have high functional reported efficacy in cardiac muscle but there have not
been comparative studies assessing outcome in terms of the host response. Given that
the serotype affects efficiency independent of method on a per dose basis, it is
conceivable that the more efficient vector would be less inflammatory given that dose
can be lowered to reach the same target expression level. Counter to that argument, it
might also be that one set of antigens of the capsid is more responsive versus others,
this would be measured with ELISPOT assays at a fixed dose with the same construct.
Despite the best efforts to engineer the AAV delivery vehicle to minimize expression,
there is no way to stop innate immune activation following direct myocardial delivery
whether it be with a needle, liquid jet or other physical method. An anti-inflammatory coformulation strategy is novel from the sense of it being locally directed to the
myocardium rather than systemically. Numerous gene therapy trials incorporate
systemic use of steroids and or immunosuppression to knockdown inflammatory host
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responses. This dissertation argues that a local blockage may actually be more effective
and better for the patient’s overall health given the side effects of the current means.
However, identifying the correct drug with the precise release profile must be determined
to thoroughly test this strategy in future in vivo rodent study.

9.3 Conclusions
Improving clinical outcomes in present and future AAV mediated gene therapy
trials for post myocardial infarction induced heart failure patients will require a systematic
approach. Delivery as shown in the study series in this dissertation was proven to be a
prime factor that can determine outcome along with proper dose, vector and gene
selection. Delivery considerations in terms of safety and efficacy may be defined patient
to patient, whereby the goal is to rescue the sufficient percentage of cells that would
reach desired expression levels indicative of improved measurable outcomes. These
measures must be defined within safety limits that promote host tolerance, or the cardiac
gene therapy will fail. Gene therapy as a whole field is a risky enterprise due to this
risk/reward complex. In the case studies where therapy fails it is most certain that there
was not enough therapeutic expression or maladaptive responses mounted negating
any therapeutic effect.
The inspiration of this dissertation was to advance the seemingly dead end direct
delivery arm of cardiac gene delivery technology with a novel concept. The liquid jet
concept was reduced to practice in a rodent model, but as stated many more technical
challenges would need to be surmounted in order for it to become a viable therapeutic
strategy.
In terms of market need the liquid jet technology would at minimum be suitable
as an adjunctive surgical therapy with a controlled device, or perhaps a minimally
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invasive application where the transgene expression need to be localized (i.e.
angiogenesis genes). Therapeutic formulation manipulation with either altering vector
molecular biology (i.e. as in our case example with double stranded vector) and coadministration with working pharmacologic compounds to address secondary problems
offer solutions to manage these risks clinically. Since the goal is to treat diseased and
healthy at risk myocardial areas with the least possible dose resulting in an efficacious
expression profile, it is argued that delivery studies will remain a key research area to
improve outcomes.
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